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Abstract 
This Birmingham Prostatic Neoplasms Association Study (BiPAS) was initiated to investigate 
determinants of prostate cancer. The study recruited 314 prostate cancer patients, 381 active 
surveillance patients, 201 hospital controls and 175 population controls. By comparing groups 
of varying risk, the aetiology of the disease was investigated. 
 
Within the BiPAS dataset, sun exposure, physical activity and obesity were analysed. The 
association with occupation was assessed by performing a meta analysis of 7, 762 cases and 
20, 634 controls. Finally, a replication study on genetic polymorphisms on 8q24 using 277 
cases and 282 controls from the Netherlands Cohort Study (NLCS) is presented. 
 
A protective effect was observed for high sun exposure in early adulthood and high intensity 
exercise. An increased risk was observed for low intensity exercise and men classed as obese 
at age 20. The meta analysis suggested moderately increased and decreased risks associated 
with a number of job titles, however none were statistically significant. The results for allele A 
on the single nucleotide polymorphism rs1447295 were replicated; however a decreased risk 
was detected for allele -8 on the microsatellite DG8S737. No significant difference was 
detected for analysis comparing prostate cancer or high PSA cases. 
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1.1 The Prostate 
1.1.1 Anatomy 
The prostate is the male sexual accessory gland. It is located on the floor of the pelvis and 
surrounds the neck of the bladder and urethra (see Figure 1.1). In men, the urethra serves two 
purposes; urination and ejaculation. It runs from the bladder through the prostate and to the tip 
of the penis. The section of the urethra running through the prostate is known as the prostatic 
urethra. After being produced in the testicles, sperm moves into a coiled mass, known as the 
epididymis for maturation. It then goes into two muscular tubes known as the vas deferens, 
which coil around the bladder and seminal vesicles. The seminal vesicle can house the sperm 
for several days until ejaculation. During ejaculation, the prostate muscles contract and expel 
the sperm into the prostatic urethra towards the tip of the penis.  
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Figure 1.1 The Prostate Gland 
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The average weight of a healthy prostate is approximately 11grams, ranging between 7 and 
16grams (1). It is encapsulated by a fibroelastic tissue layer, leading to septa extending 
inwards and dividing the prostate into different lobes. The lobes accommodate nearly 50 
irregularly branched saccular glands, excretory ducts, stroma (connective tissue cells), blood 
vessels and nerves. The glands are lined with two epithelial cell layers, the outer layer is 
composed of cuboidal epithelia (simple cube shaped) and the inner layer is composed of tall 
columnar epithelia. This transitional epithelium or urothelium has the ability to contract and 
expand according to the volume of fluid within.  
 
The main male hormone is testosterone and is produced in the testicles. The prostate is 
regulated by dihydrotestosterone. Dihydrotestosterone is synthesized from testosterone in the 
peripheral tissue. 
 
1.1.2 Prostate Function 
The primary function of the prostate gland is to store part of seminal fluid and assist 
ejaculation during sexual activity. The smooth muscles in the prostate help to expel semen 
during ejaculation. The slightly alkaline fluid produced by the prostate makes up 25% of 
seminal fluid and allows sperm motility and viability. The vaginal tract is acidic therefore the 
alkalinity of the semen neutralizes the environment to allow the sperm to stay viable. A major 
constituent of prostatic secretion is prostate specific antigen (PSA), along with citrate (18.7 
mg/ml), zinc (488 µg/ml), spermine (243 mg/ml) and cholesterol (78 mg/ml) (2). 
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1.1.3 Prostate Structure 
The prostate can be classified by two different systems; zones or lobes. The zonal 
classification is used more in pathology; classifying the prostate into four different regions. 
The peripheral zone (PZ) forms about 70% of the prostate and surrounds the urethra. Nearly 
80% of prostatic cancers develop in the PZ. The central zone (CZ) surrounds the ejaculatory 
ducts and forms 25% of the prostate. Only 2.5% of prostatic cancers arise in this region, 
however the cancers that do develop here are more aggressive (3). The transition zone (TZ) 
accounts for around 20% of prostatic cancers and surrounds the proximal urethra. The TZ 
grows larger over time; benign prostatic enlargement originates in this region. The final 
region, the anterior fibro-muscular zone consists of muscle and fibrous tissue only.  
 
The lobe classification system also divides the prostate into four different regions, the anterior 
lobe (roughly the same as the TZ), posterior lobe (comparable to the PZ), lateral lobes (spans 
all zones) and the median or middle lobe (CZ). This classification is usually used when 
describing the anatomy of the prostate. 
 
1.2 Prostate Carcinogenesis 
Cancers are described as unregulated growth and consequent spread of cells to other parts of 
the body (4). All types of cells can undergo such malignant changes and become cancers, 
however only epithelial cells can become carcinomas. The normal cell cycle is disrupted and 
the new “tumour” cells overgrow in a localised region at first, then spread to surrounding 
tissue and finally to other parts of the body via the lymphatic system and vascular system (5-
6).  
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In the process of carcinogenesis, normal cells are transformed into cancer cells due to an 
uncontrolled cell division. Normal cell division maintains a balance between proliferation and 
cell death with tightly regulated processes. Mutations in DNA can disturb these processes, 
leading to the cell to rapidly divide and therefore proliferate at a much higher rate. The 
resulting mass can either be benign, which does not spread to other parts of the body, or be 
malignant which can invade other organs and spread to distant locations.  
 
A possible precursor of prostatic carcinoma is prostatic intraepithelial neoplasia (PIN). PIN 
involves the abnormal development of the epithelial cells which line the prostate glands. Low 
grade PIN is characterized by crowded and irregularly spaced epithelial cells where the nuclei 
are hyperchromatic (with elevated chromatin) and pleomorphic (where there is variation in 
size and shape). In high grade PIN, a higher level of hyperchromatisms and pleomorphism 
exists. PIN is distinguished from adenocarcinoma by the involvement of a cluster of rounded 
cells, resembling a raspberry shape, known as acini (7). Presence of PIN suggests an increased 
risk for adenocarcinoma however it can be up to 10 years before prostate carcinoma presents 
(8). 
 
Adenocarcinoma is a type of cancer arising from epithelial cells of the secretary glands lining 
the prostatic ducts. The cytological features include enlarged hyperchromatic nuclei, as in PIN 
(9). 
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1.2.1 Molecular changes 
Most of the human genome is non-coding DNA; therefore the majority of genetic changes are 
harmless. The coding DNA makes up approximately 3% of the genome and genes are also 
split into introns (non-coding) and exons (coding). Only mutations in the exon regions of the 
genome are subject to harmful changes which may affect protein composition (4).  
 
Although the genetics of prostate cancer are poorly understood, we know cancers almost 
always arise from a single somatic cell, that undergoes a number of genetic changes which 
cause a change in gene activity and therefore phenotype (10). Cancer causing mutations 
usually arise in genes involved in the regulation of cellular growth or death (11). Since there 
are over 100 types of cancers and each tumour has a number of different subtypes, the 
complexity makes it difficult to pinpoint origin of disease. The past two decades have seen 
extensive research in the molecular, biochemical and cellular processes involved in the 
transformation of normal cells to malignant cancer cells. The vast majority of cancer cells 
have six different capabilities; self sufficiency in growth signals, insensitivity to anti growth 
signals, evasion of apoptosis, infinite replication ability, sustained angiogenesis and ability to 
invade tissue and metastasise (12). Normal cells monitor their external environment and 
stimulate cell division when necessary. Cancer cells, however, produce their own signals 
which liberate them from the growth limitations of normal cells. The second capability is 
insensitivity of anti-growth signals, which works in the same way as the previous stage, as 
cancer cells do not receive signals to inhibit growth. The third feature is the acquired 
capability of sustained growth. A normal cell usually stops replicating after 60 or 70 times, 
which is controlled by the telomeres. These segments of DNA are shortened by each round of 
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DNA replication, and eventually, when they are too short for another round of the cycle, the 
cell undergoes apoptosis (cell death). Cancer cells are able to maintain the length of their 
telomeres, allowing them replicate infinitely. The next feature is evasion of apoptosis, which 
is usually exerted by p53. In cancer cells, the p53 gene is often mutated and therefore 
apoptosis does not occur as normal. Angiogenesis is the formation of new blood vessels. 
These are essential for supplying the tumour with oxygen and nutrients. And the final 
capability is tissue invasion and metastasis, where cancer cells attach themselves to other cells 
and move around the body (13).  
 
Cancer genes can be classified into three main categories; oncogenes, tumour suppressor 
genes and cells involved in DNA repair. Oncogenes were the first cancer causing genes 
identified and lead to unregulated cell growth (10). Most arise from genes known as proto 
oncogenes responsible for normal cell growth. They are generally dominant and common 
mutations include an increase in protein activity or loss of regulation, increase in protein 
concentration or chromosomal translocation causing gene expression of the different cell type. 
Examples of oncogenes include ras (mutated in about 15% of cancers), myc and abl (14-15). 
Tumour suppressor genes are also known as anti-oncogenes and are usually inactivated by 
loss of function mutations. In 1971, Knudson studied sporadic and familial retinoblastoma and 
formulated the two hit model of carcinogenesis which demonstrates the loss of function 
changes. In familial retinoblastoma, there is a 50% chance of a child inheriting the condition 
from an affected parent and in sporadic there is no additional risk (16). The inherited form is 
not known to cause a predisposition of tumour development due to germline mutations in one 
copy of the tumour suppressor gene (17). A somatic mutation of the second copy will cause 
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tumour progression. In sporadic retinoblastoma, two different “hits” are required within the 
same cell to develop a tumour. The p53 gene TP53 is one of the most important tumour 
suppressor genes involved in key cancer control pathways, such as cell cycle control, 
apoptosis, angiogenesis and genetic stability. And the final category is genes responsible for 
DNA repair mechanisms, which allow normal DNA replication. Mutations in this process 
often result in genetic instability leading to abnormal chromosome numbers or breaks (18). 
 
A mutation specific for prostate cancer is yet to be identified. Also, common mutations in 
oncogenes and tumour suppression genes for various other cancers are surprisingly rare in 
primary prostate cancer (13).  
 
1.2.2 Prostate Specific Antigen  
Prostate specific antigen (PSA) is a glycoprotein produced by the prostate acinar cells and is 
unique to the prostate gland (19). The function of PSA is to dissolve the seminal clot after 
ejaculation in order to facilitate the transport of spermatozoa along the female reproductary 
tract. PSA may be complexed to serum proteins, when it is known as “complexed PSA” or it 
can be free, known as “free PSA”. Both complexed PSA and free PSA are combined to give a 
measure of total PSA. Although PSA is present in high concentrations in seminal fluid (0.5 to 
2.0 mg/mL) it has a much lower concentration in the blood, almost 1000 times lower. 
Although the variations in concentration are independent of other proteins, it is sensitive to 
changes in serum testosterone levels (20). Age specific normal ranges are used to identify 
elevated levels; however these vary according to the assay used.  
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PSA was first described as a prostate cancer marker in 1982 and the first reports of its use as a 
screening test were in 1991 (21-22). The incidence of prostate cancer has had a gradual 
increase in most Western countries over the last 30 years, however the use of PSA testing 
caused a spike in new diagnoses in the USA in the early 1990s (23). A good screening test 
should be sensitive, safe, cheap and should be used for diseases in which early detection 
improves prognosis. There has been some debate over the last criterion for PSA testing, 
although it has been developed extensively in order to increase specificity and sensitivity (24-
26). As benign prostatic enlargement can also be responsible for increasing PSA, an adjusted 
value called PSA density, is often used. For this measure, the serum PSA value is divided by 
prostate volume. The main advantage of this test is that it guides decision making for prostate 
biopsies. However, as a transrectal ultrasound (TRUS) is required for the measurement of 
prostate volume, it increases the discomfort for the patient and it is costly (27). Free PSA can 
be measured by a blood test and is usually lower in prostate cancer patients, however the 
reasons for this are unclear (23). Men with a free PSA of less than 15% have a higher risk of 
prostate cancer, yet in men with 25% or higher free PSA, the risk is significantly reduced (28).  
 
As PSA increases with age, cut off values are age dependent (see Table 1.1). There are also 
different reference ranges for different ethnicities (29). Although these reference ranges are 
easy to use, they can fail to detect high grade prostate cancer in older men (30). 
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Table 1.1 PSA Reference ranges for Caucasian men, using the Roche E170 assay 
 
 
 
 
 
 
Taken from Oesterling JE et al, Serum prostate-specific antigen in a community-based 
population of healthy men. Establishment of age-specific reference ranges JAMA. 1993 
270(7): p. 860-4. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Age 
(years) 
Reference Ranges 
(ng/mL) 
50-59 0-3.5 
60-69 0-4.5 
70-79 0-6.5 
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1.2.3 Symptoms and Diagnosis 
Prostate tumours are usually slow growing and symptoms may not occur for many years. In 
the early stages of prostate cancer, there are often no symptoms. However, due to its location 
surrounding the urethra, symptoms for the disease most commonly affect urination. Prostate 
cancer symptoms include frequent urination, increased urination during the night, (nocturia), 
difficulty in maintaining a steady stream of urine, blood in the urine (hematuria) and painful 
urination (dysuria). It can also affect sexual function, for example difficulty in achieving 
erection or painful ejaculation. If the cancer is advanced, it can spread to other organs, causing 
bone pain in the pelvis or ribs. Many of the urinary symptoms also occur in other prostate 
diseases, such as benign prostate hyperplasia, along with an enlargement of the prostate. 
Prostate tumours are only felt in a small percentage of cases during a digital rectal 
examination (DRE). Diagnosis of prostate cancer must be confirmed by a needle biopsy. The 
International Classification of Diseases version 10 (ICD10) classifies malignant neoplasm of 
the prostate as code C61 (31).  
 
1.2.4 Tumour staging  
Once a patient has been diagnosed with a prostate tumour, the cancer must be staged to 
determine if it has spread beyond the prostate. Staging also provides a better insight into the 
risk of the disease spreading further so the correct treatment option is selected. The TNM 
stage was developed by the American Joint Committee on Cancer/International Union Against 
Cancer (AJCC/UICC) (32). It is used to evaluate the extent of the primary tumour (T), the 
affected regional lymph nodes (N) and if it has spread or metastasized (M). There are four 
stages; in stage I only a small part of the prostate is cancerous, most of the cells are normal 
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and the gland feels normal. In stage II, a lump can be felt in the prostate to the examining 
finger and a larger part of the prostate is affected. In stage III, the tumour has spread beyond 
the prostate and in stage IV; it has spread to lymph nodes or nearby organs. A more detailed 
view can be found in Table 1.2. 
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Table 1.2 Staging of Prostate Cancer 
Primary Tumour 
(T) TX Primary tumour cannot be assessed 
  T0 No evidence of primary tumour 
  Ta Non invasive papillary carcinoma 
  Tis Carcinoma in situ: "flat tumour" 
  T1 Tumour invades sub epithelial cells 
  T2 Tumour invades muscle 
    T2a Tumour invades superficial muscle (inner half) 
    T2b Tumour invades deep muscle (outer half) 
  T3 Tumour invades perivesical tissue 
    T3a Microscopically 
    T3b Macroscopically 
  T4 Tumour invades prostate 
    T4a Tumour invades prostate 
    T4b Tumour invades pelvic wall or abdominal wall 
      
Regional Lymph 
Nodes (N) NX Regional lymph nodes cannot be assessed 
  N0 No regional lymph node metastasis 
  N1 
Metastasis in a single lymph node 2cm or less in greatest 
dimension 
  N2 
Metastasis in a single lymph node 2cm but no more than 
5cm in greatest dimension 
    
Multiple lymph nodes, none more than 5cm in greatest 
dimension 
  N3 
Metastasis in a lymph node no more than 5cm in 
greatest dimension 
      
Distant Metastasis 
(M) MX Distant metastatic cannot be assessed 
  M0 No distant metastatic 
  M1 Distant metastatic  
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1.2.5 Tumour Grading 
Tumours are graded to allow better predictions for prognosis. The Gleason Grading System is 
the most commonly used system, where cancers are scored according to their appearance 
under a microscope. During biopsy, a sample of the prostate tissue is obtained and prepared on 
microscope slides. Two grade scores are assigned for the two most common tumour patterns, 
and these scores added together for a final Gleason sum. Gleason scores range from 1 to 5, 
where 5 has the poorest prognosis and Gleason sums range from 2 to 10. The Gleason patterns 
are detailed Table 1.3. For the primary grade, pathologists identify which pattern corresponds 
with at least 50% of the tumour and the secondary grade represents the minority of the 
tumour. 
 
The prognosis for prostate cancer can be variable. More aggressive tumours, with Gleason 
sum 8, 9 or 10, can lead to death in a short space of time, however lower grades, with Gleason 
sum of 6 or lower, may not see any clinical consequences (23). Albertsen et al conducted a 
series of studies on a cohort of 767 untreated cancer patients. Men with tumours of Gleason 
sum 5 had between 6% to 11% cancer mortality at 20 years. Patients with tumours with a 
higher Gleason sum had up to 70% (Gleason score 7 or 8) and 87% (Gleason score 10) rates 
of death from prostate cancer, with very few of the entire cohort surviving more than 15 years 
after diagnosis (33-34). 
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Table 1.3 Gleason Patterns 
Pattern 1 
 
The cancerous prostate cells closely resemble normal prostate 
cells. The glands are small, well-formed, and closely packed. 
Pattern 2 The glands are larger and have more tissue between them 
Pattern 3 
 
 
The tissue still has recognizable glands, but the cells are darker. 
Some cells have left the glands and have started to invade the 
surrounding tissue. 
Pattern 4 
 
The tissue has few recognizable glands. Many cells are invading 
the surrounding tissue 
Pattern 5 
 
The tissue does not have recognizable glands. There are often just 
sheets of cells throughout the surrounding tissue. 
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1.2.6 Treatment 
Three standard treatments for localised prostate cancer exist; surgery, radiotherapy and active 
surveillance. 
 
Radical prostatectomy surgery is the removal of the prostate gland and any surrounding 
cancerous tissue (35). This is usually a good treatment option for patients whose cancer has 
not yet spread outside the prostate (stages I and II) (36). It can be achieved by either open 
surgery or laparoscopic surgery. In open surgery, the surgeon will make a small incision either 
in the groin (perineal approach) or in the lower abdomen (retropubic approach) (37). The 
retropubic approach is the most common method for treating prostate cancer; however the 
recovery time is longer compared with the perineal approach (38). 
 
In laparoscopic surgery, several small incisions are made in the abdomen and a laparoscope is 
inserted to allow the tumour to be viewed. The surgeon will then remove the prostate by one 
of the other incisions. Men undergoing laparoscopic surgery will lose less blood compared to 
open surgery and also have a shorter recovery time (38). 
 
Radical prostatectomy is very effective in the treatment of early stage cancer (39). With the 
prostate removed and if the cancer has not spread, PSA levels can drop to zero. A recent 
randomized controlled trial by Bill-Axelson et al reported radical prostatectomy was 
associated with a reduction in the rate of death from prostate cancer, as well as a reduced risk 
of metastases compared to the watchful waiting or active surveillance group (40). However in 
some cases the tumour cannot be completely removed and disease can recur. Adverse effects 
31 
 
of radical prostatectomy usually occur within 30 days of surgery and include erectile 
dysfunction and urinary incontinence. These effects can either be short (resolved within 90 
days) or long term (continuing for up to 12 months after surgery). As it is major surgery, 
additional general surgery risks exist such as blood clots, reactions to anaesthesia, blood loss 
and infection of the wound (41). 
 
The second treatment option is radiotherapy. In conformal radiotherapy (CRT), the high 
energy x-rays are carefully shaped to match the shape of the prostate gland, focussing only on 
the affected area and protecting surrounding tissue (38). Intensity modulated radiotherapy 
(IMRT) allows radiation to be adjusted around the target to protect adjacent organs (42).  
 
Short term adverse effects of radiotherapy include bowel disturbances and urinary symptoms 
such as irritative voiding, incontinence and urinary retention (43). Long term erectile 
dysfunction can often occur for up to two years following surgery (42). 
 
For men affected by small low grade tumours, active surveillance is often a preferable initial 
treatment option. It involves the close monitoring of patients with the intention of avoiding 
unnecessary treatment until disease progression occurs or until the patient requests treatment 
(35). Not all patients are able to live comfortably with an untreated tumour. A major 
disadvantage of the active surveillance strategy is the presence of an undetected larger or 
higher grade tumour that might have been missed at the time of biopsy. In terms of adverse 
effects, patients undergoing active surveillance often develop erectile dysfunction and urinary 
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obstruction at the same rate as age matched men without prostate cancer in the general 
population. 
 
Androgen deprivation therapy has been used to treat metastatic prostate cancer for many years 
(44). Combined hormone treatment and external beam radiotherapy is reported to cause 
improvements in advanced prostate cancer. In this process, the locally advanced tumour is 
reduced and metastatic disease in surrounding areas is eradicated (45).  
 
1.2.7 PSA as a diagnostic test 
There are certain conditions for a diagnostic test to be successful, there must be a significant 
burden of the disease, the natural history of the disease must be known, and the test must be 
accurate and have a positive effect on treatment. As previously mentioned, the incidence for 
prostate cancer is increasing and therefore it poses a significant burden on public health. In 
1994, Whitmore estimated that a 50 year old man with a 25 year life expectancy has a 42% 
risk of having prostate cancer, a 9.5% risk of having a clinically evident cancer and a 2.9% 
risk of dying with prostate cancer (46). We can therefore conclude that many more men die 
with the disease rather than of the disease. This poses the question of whether a testing 
programme would be useful as more men would be diagnosed, however, not all would benefit 
from treatment. Asymptomatic tumours are common in men over the age of 60 years, these 
are slow growing and often do not require treatment. However, fast growing tumours can 
spread to surrounding tissue very quickly. A testing programme would be most effective for 
cancers confined to the prostate to begin with, which later metastasise (47). A simple serum 
PSA test costs around £5, more accurate tests, such as the ratio of free to complexed PSA, can 
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cost up to £10. A study by Valeri et al in 2002 measured serum PSA in relatives of over 400 
men with prostate cancer over a period of two years. A PSA of over 0.004 mg/L was detected 
in 12.4% of men over the age of 50 years. Ten prostate cancer cases were detected and nine of 
these were localised tumours, (Gleason scores 5 – 7) (48). A further prostate cancer study in 
Finland identified 103 prostate cancer families. In this sample of 209 first degree unaffected 
and asymptomatic male relatives over the age of 45 years, an abnormally high PSA result was 
detected in 10% (21 men). After biopsies, 3.3% of these (7 cases) were found to have prostate 
cancer (49). A cohort study following 651 men reported that a DRE and PSA test detected 
clinically suspicious areas in 5%, whereas 10% had a raised PSA but normal prostate cells 
(50). The three main treatment options for localised prostate cancer are radical prostatectomy, 
radiation therapy and watchful waiting, where active treatments are used if symptoms 
develop. Although the active treatments have the potential to cure, there are a number of 
adverse effects, such as pain, incontinence, impotence and sometimes death (38). However, 
the adverse effect of watchful waiting is the risk of the cancer progressing and causing death 
in a short space of time. Further studies are required to determine the optimal testing measure 
in men with family history of prostate cancer. 
 
1.3 Epidemiology of Prostate Cancer  
The epidemiology of prostate cancer has been extensively studied. There is an increasing 
burden to public health and the benefit of screening has been debated for some time. Neal et al 
concluded PSA is not a suitable test for prostate cancer as most of the criteria are not met (47). 
However it could be efficiently used to identify the disease in high risk groups, such as men 
with first degree relatives with prostate cancer. 
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1.3.1 Incidence 
In Europe, 382, 000 new cases of prostate cancer were estimated to occur in 2008, making it 
the most common male neoplasm after skin cancer. With almost 90, 000 deaths estimated for 
the year 2008, it was the third most common cause of cancer death in men, after lung and 
colorectal cancers (51). The same study reported increasing trends in 24 European countries, 
with the highest incidence rates in Finland, Sweden and The Netherlands; however rates either 
stabilized or decreased after 2005. In the USA, prostate cancer accounts for 25% of all new 
cases of cancer diagnosed. It was estimated that 91% of all new cases would be diagnosed at a 
local stage, with a 5 year relative survival. Mortality rates for the disease have seen an overall 
decrease since 1990, by about 25% in the USA (52) and some western countries such as UK, 
France and The Netherlands (51). 
 
1.3.2 Burden  
If the incidence rates remain constant, the impact of prostate cancer in the ageing population 
of the West will increase. There is a clear impact on the financial burden of treatment of 
patients, which will only escalate with more patients being diagnosed. There will also be a 
need for more treatment facilities and more trained specialists. Prevention of this type of 
cancer would relieve a heavy burden on public health, both in terms of cost and resources. 
 
A number of economic evaluations of a testing programme have been conducted, with the 
estimated cost of a national testing programme for men aged 50-74 years in the USA is 
between $5.2 billion and $14.1 billion (53), and the UK costs are estimated to be between 
£500 million and £1.5 billion (38). A study by Chadwick et al estimated the cost of testing for 
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prostate cancer, with the cost of detecting 1 case of prostate cancer, using PSA testing and 
TRUS, to be £1654.10 (54). 
 
1.3.3 Trends 
Incidence of prostate cancer has steadily increased since the 1960s worldwide, probably due 
to better diagnosis methods and a larger ageing population. There were large increases in the 
1970s and 1980s in all age groups in England and Wales with a sharp peak in 1994, due to the 
advent of PSA testing (55). In 2002, a review by Quinn and Babb considered trends within 
countries and a wide of range of rates were found in Great Britain. The South and South West 
of England had statistically significantly higher rates of incidence compared to the average 
incidence for Great Britain. Lower rates were found in the North and North West of England 
(see Figure 1.2). Prostate cancer was more commonly seen in affluent areas than deprived 
areas (56). A population based retrospective cohort was recruited in the West Midlands 
between 1977 and 2004 by the West Midlands Cancer Intelligence Unit (WMCIU). In this 
cohort, nearly 45, 000 men were diagnosed with prostate cancer. The European age 
standardized incidence rates (EASR) follow the same pattern as national trends (see Figure 
1.3), with a gradually increasing incidence until the early 1990s, after which a slightly sharper 
rise is observed due to PSA testing (57). 
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Figure 1.2 Incidence of prostate cancer by local authority within counties of Great 
Britain and regions of England, 1991–93 
 
 
Taken from Quinn, M. and P. Babb, Patterns and trends in prostate cancer incidence, survival, 
prevalence and mortality. Part II: individual countries. BJU Int, 2002. 90(2): p. 174-84. 
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Figure 1.3 Incidence of prostate cancer in the West Midlands 1977–2004 directly 
standardized to the European Standard Population  
 
 
 
Taken from Cooper, S.C., et al., Patients with prostate cancer are less likely to develop 
oesophageal adenocarcinoma: could androgens have a role in the aetiology of 
oesophageal adenocarcinoma? Cancer Causes Control, 2009. 20(8): p. 1363-8. 
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1.4 Risk Factors 
In comparison to other common cancers, we know very little on the causes of prostate cancer; 
only age, race and family history are established risk factors. Previous studies have pointed 
towards a combination of both genetic and environmental risk factors at play. 
 
1.4.1 Environmental Risk Factors 
Age is one of the strongest risk factors for the disease. It is more common in men over the age 
of 65, representing approximately 85% of all cases diagnosed. It has a much lower incidence 
in men younger than 50 (less than 0.1% of cases) (58). The introduction of PSA testing in the 
early nineties caused the incidence of prostate cancer in men aged 50-59 years to rise to 50%, 
which was a dramatic increase (59). The current knowledge of risk factors possibly associated 
with the disease is summarized in Table 1.4. 
 
A huge difference in incidence rates of prostate cancer exists in different ethnic groups. The 
lowest incidence rates are observed in Asian men, namely in India, China and Japan. African 
American men have the highest rates. In the USA the annual incidence is 272 new cases per 
100, 000. It has been previously hypothesized that the higher rates in African Americans are 
due to social factors, such as poor access to healthcare systems or poor registry of cancers 
(60). However subsequent studies which have adjusted for such factors have reported 
consistent results, indicating this is not the case. Migration studies have further reported that 
Japanese migrants to the USA have a higher risk of the disease compared to their native 
counterparts, suggesting that there are other unknown environmental risk factors involved.  
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A number of studies have reported an inverse correlation of prostate cancer mortality and 
exposure to sunlight (61-62). Ultraviolet radiation (UVR) is a well known causative factor for 
skin carcinogenesis yet it is also known to decrease the risk of other cancers, such as breast, 
ovarian and colon cancer (63-65). Although the mechanism is unclear, vitamin D status is 
likely to play a role, as it is known to inhibit proliferation and promote differentiation of 
different cell types (66). Vitamin D levels are largely dependent on exposure to sunlight and 
on diet and supplements to a lesser extent. Pigment characteristics that inhibit vitamin D 
synthesis are also implicated; dark skin and ability to tan easily have been found to be 
positively associated with prostate cancer. Some of the known risk factors previously 
mentioned, such as age and ethnicity, are linked to decreased synthesis of vitamin D (67). 
There is a vast difference in incidence rates among different ethnic groups. Asia has the 
lowest rates, especially China, Japan and India and African American men have the highest 
rates (60). Migrant studies have observed men migrating to Western countries have increased 
risks compared to their native counterparts, implicating environmental factors, such as UVR 
exposure, in disease progression. 
 
In 2001, Luscombe et al reported a link between increased UVR exposure and reduced risk of 
advanced stage prostate tumour. This was subsequently replicated by Rukin et al in 2007 (68-
69). A common weakness of studying an exposure such as UVR is small sample sizes of each 
exposure category and therefore lack sufficient power to confirm associations. It can be 
difficult to accurately measure UVR as an exposure; the data are often subject to recall bias 
when subjects are recruited after diagnosis. There are also few data available on the effect of 
UVR on stage of disease. 
40 
 
In this thesis, the effect of UVR exposure on prostate cancer risk is assessed. The hypothesis 
that increased UVR exposure levels are associated with decreased risk of prostate cancer is 
tested and whether this association is stronger among cases with advanced disease. Instead of 
the traditional use of prostate cancer cases and population controls, two case groups and two 
control groups are used. The analysis of between and within group differences allow better 
understanding of how PSA can be used as a marker for prostate cancer, and whether there is a 
difference between the use of hospital based controls or the traditional population based 
controls.  
 
In 2007, the Second Expert Report by the World Cancer Research Fund/American Institute for 
Cancer Research made no formal judgement for an association between physical activity and 
prostate cancer overall. It did however, “note” the evidence from two cohort studies (70-71) 
and suggested that physical activity was associated with a decreased risk of 
advanced/aggressive prostate cancer (72). This report concluded that physical activity which 
“promotes a healthy weight would most likely protect against cancers whose risk is increased 
by weight gain or obesity” (72). A national health and nutrition survey in 2008 was unable to 
detect a significant difference in prostate specific antigen (PSA) level between men of 
different levels of physical activity (73). This was consistent with previous studies (74). 
However a study by Parekh et al only reported physical activity levels in participants for the 
past 30 days. Long term physical activity exposure was not taken into account, which could 
have a different effect. 
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Previous research has been able to identify the benefits of physical activity on colon and 
breast cancer, however, the effect on prostate cancer remains unclear. Earlier studies have 
produced inconsistent results, with a third of all epidemiological studies observing a protective 
effect (75-76), others finding no relation (77-81) and one study reporting a positive effect 
(82). Friedenreich et al (83) estimated that the population attributable risk of prostate cancer 
due to insufficient physical activity by men in Great Britain is 14%.  
 
Apart from regulating the body‟s energy balance, other potential explanatory mechanisms for 
a possible association between physical activity and prostate cancer risk include a modifying 
effect on circulating hormones e.g. testosterone and insulin, reduced inflammation (IL-6) and 
increased production of superoxide dismutase which protects against oxidative stress (72). 
Previous epidemiological studies have not been able to control for testosterone levels in their 
physical activity analysis. With the addition of testosterone data for patients, it might be 
possible to define a biological mechanism for the associations observed. Also, the method of 
assessment for physical activity is difficult and previous studies have employed different 
methods, which could explain the inconsistencies. Epidemiological studies vary in the period 
of assessment (childhood, adulthood, and lifetime) or frequency, duration and intensity of 
exposure.  
 
In this thesis, the association of physical activity and prostate cancer is further examined. 
Using the four distinct comparison groups allows the effect of different types of physical 
activity at different stages of disease to be considered. The control groups have no prostate 
symptoms and normal PSA levels, the high PSA groups which could be considered as an 
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intermediate group for disease and finally the prostate cancer group with confirmed disease. 
Data on different forms of exercise were used and the duration of exposure was considered 
and adjusted for testosterone levels. Associations with prostate cancer and its subtypes 
including advanced and localised disease were examined. 
 
Obesity is a growing epidemic, particularly in the Western world. The USA report some of the 
highest rates in the world, with over two thirds of adults falling in the category of obese or 
overweight (84-86). A study by Wang and Beydoun in 2007 predicted that by the year 2015, 
75% of adults in the USA will be overweight and over 40% will be obese (87). Another global 
trend is ageing; people are living longer than ever before. The Office of National Statistics 
reports that the percentage of people aged 65 and over in the UK has increased from 15% in 
1985 to 17% in 2010, with an increase of 1.7 million people (88). If this trend continues, by 
2035, the percentage is estimated to be 23% of the population. If the obesity epidemic and 
ageing trend continue, the Western world is likely to see a huge increase in the incidence of 
prostate cancer which will further intensify the current burden on public health. Obesity is a 
strong risk factor for a number of cancers, including cancer of the endometrium, kidney, 
breast and colon (89-91). The link between obesity and prostate cancer has been extensively 
researched in recent years; however the reported associations are inconsistent. Gong et al 
compared different body mass indexes (BMIs) and found men with a BMI above 30kg/m
2
 had 
an 18% lower risk of low grade prostate cancer but at the same time had a 29% higher risk of 
high grade prostate cancer (92). In 2006, a meta analysis of 22 epidemiological studies 
reported a weak but statistically significant increased risk. After stratifying for severity of 
tumour, only advanced prostate disease had an association with obesity and not with localised 
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disease (93). Further studies have replicated the link of obesity with high grade tumours (92, 
94-95). Following these studies, it is generally believed that obesity can reduce the risk of 
being diagnosed with non aggressive tumours while also increasing the risk of developing 
aggressive tumours (96). A plausible explanation for this is the difference in testosterone 
levels. Obesity has been linked to lower serum androgen activity, which is due to lower 
concentrations of circulating total testosterone and higher concentrations of oestrogen. All 
these factors are known to decrease the risk of prostate cancer (97-99). However, obesity is 
also linked to higher insulin and free insulin-like growth factor-I and lower sex hormone 
binding globulin concentrations, which may increase risk (99-100). 
 
A particularly important study by Calle et al found the risk of mortality from prostate cancer 
significantly increased with increasing BMI (98). However other studies have produced 
inconsistent results, with some reporting increased risks associated with the disease (80, 101-
104) and few observe a protective effect (95). BMI is often used as a measure of obesity, as it 
is an easy measure to collect; only height and weight parameters are required, however it does 
have limitations (105). Large muscular individuals with little body fat cannot be classified 
accurately (96). Also, different fat distributions, such as visceral and superficial fat, cannot be 
distinguished. The distributions of fat can be important in biological mechanisms, such as 
lipolysis especially in older age (106). Weight very rarely stays stable over time and since 
prostate cancer has very strong associations with older age, weight over lifetime and change at 
different life periods could be a very important factor. To date, very little research has been 
carried out in the area of weight change over time and the disease. Also, most previous studies 
investigating the association have focused on obesity at the time of diagnosis, and not taken 
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into account a history of obesity. Of the few that have, most report contrasting risks (107-
109). 
 
Some studies have also investigated the effect of obesity on PSA, reporting lower PSA levels 
in obese men; however such studies are scarce (98-99, 110). A recent study by Werny et al in 
2011 investigated the association of adiposity with PSA, using BMI and waist circumference 
as measures of adiposity (111). The results were consistent with previous studies, with 
negative trends between PSA and the adiposity measures (105, 110). Lower PSA values in 
obese men could have an impact of the sensitivity of the test when used for diagnosis, as 
tumours in such men may go undetected leading to poorer prognosis (96). More research on 
the link between PSA and obesity is required to fully understand the interaction. 
 
In this thesis, the association of obesity and prostate cancer is further examined to disentangle 
the effect of this factor on the disease. Waist circumference, BMI and weight change over 
time were used as measures of obesity. Associations with total prostate cancer and its subtypes 
including advanced and localised disease were examined. 
 
Occupational factors are also believed to play a role in prostate carcinogenesis. A number of 
studies have investigated occupational exposures to chemical agents, many of which have 
suggested cadmium, poly aromatic hydrocarbons and pesticides to be responsible for 
increased risk (112-114). Previous epidemiological studies have reported increased risks for 
metal workers (115-116) and mechanics (117-118). Other occupations suggested to have 
increased risks include chemical (119) (118) and rubber industry workers (120). These 
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industries encompass a wide range of job titles and activities, therefore small sample sizes of 
each individual job title result in inconsistent findings. 
 
Farming is an important occupational group however extensive association studies 
investigating the potential risks have reported inconsistent results. A number of meta analyses 
have found statistically significant elevated risks among farmers (121-123), whereas others 
have reported no risks or sometimes reduced risks (124-125). Chemical agents used in 
farming differ greatly depending on the type of farming that is carried out, however no study 
has yet investigated differences in risk between livestock and crop farming. The main agents 
thought to affect risk are pesticides and herbicides, which contain organochlorines. Some 
studies have suggested these compounds can increase or mimic the action of androgenic 
hormones, however this remains unproven (126). 
 
Parent and Siemiatycki‟s review on occupation and prostate cancer focused on a few 
occupations and related exposures and concluded that although some strong evidence exists 
for the farming, mining, metal and rubber industries, no definitive conclusions could be drawn 
(127). In 1982, Dost et al initiated a large scale cohort of over 8, 000 rubber factory workers 
to investigate new health problems relating to exposures in this industry. The study was able 
to show that overall mortality for all cancers was better than the national average, suggesting 
working conditions in this industry have improved and had a direct effect on health of the 
workers within it (128). In this thesis, occupations relating to known exposures are 
investigated. All reported occupations are considered rather than just those related to farming 
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or rubber or chemical workers. Also, some newer articles, published after Parent and 
Siemiatycki‟s review were included for an up to date analysis. 
 
Many previous studies have had inconclusive findings, probably due to small sample sizes for 
each occupational group. No comprehensive meta-analysis has been conducted to quantify the 
risks of prostate cancer associated with individual occupations. With a meta-analysis, the 
unreliability caused by small numbers of cases and controls within each occupational group 
can be reduced.  
 
A number of epidemiological studies have implicated diet as a potential risk factor, 
specifically high intake of fat, meat and dairy products. This is consistent with the high 
incidence rates in Western countries where such diets are common. Although fruit and 
vegetable intake have not been strongly associated with the disease, a protective effect has 
been detected for cooked tomatoes. Tomatoes contain high levels of lycopene, a lipophilic 
carotenoid. It is unclear whether the protective effect is due to lycopene or its metabolic 
products. It can reverse the effects of the dihydrotestosterone hormone and can induce 
apoptosis of human prostate cancer cells (129). Studies have investigated high consumption of 
red meat and found a high risk of disease. It has been suggested that cooking the meat at high 
temperatures increases the level of carcinogenic substances. It is also thought that such diets 
are often poor in fruit and vegetable consumption, some of which may protect against cancer. 
Selenium is a trace mineral found in grains, meat, poultry, fish, eggs and dairy products (130). 
In the selenomethionine form, it inhibits proliferation and induces cell cycle arrest in prostate 
cancer cells (131). A number of studies have investigated the association of selenium and 
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prostate cancer. Some have reported a decreased risk of the disease in men with high levels of 
selenium (132-133), however, a recent clinical trial has been unable to confirm these (134). It 
has since been hypothesized that different forms of selenium vary in their biologic effects and 
may only be beneficial for patients with particular genotypes for the SOD2 (superoxide 
dismutase) gene (135). There are inconsistent results for the association of alcohol and 
prostate cancer. Some studies have found an increased risk in men consuming three or more 
alcoholic drinks per day yet some have found no increase in risk. Conversely Schoonen et al 
found a protective effect with consumption of 1-3 glasses of wine per week (136). 
 
No clear association exists between smoking and prostate cancer. Some studies have reported 
smoking to be moderately associated with mortality from the disease. A possible mechanism 
is the exposure to cadmium. Cadmium is known to increase oxidative stress and cause an 
increase in androgen levels, which are thought to be mechanisms that promote prostate 
carcinogenesis. Androgens are responsible for the development and maintenance of the 
prostate. The two principal androgens in adult men are testosterone and dihydrotestosterone. 
Androgen deprivation is known to decrease PSA levels and cause apoptosis of prostate cancer 
cells. Although a number of studies have investigated serum androgens in prostate cancer, the 
results have been inconsistent. Despite this however, it is generally believed that high levels of 
testosterone are associated with an increased risk of prostate cancer. 
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Table 1.4 Possible Risk Factors for Prostate Cancer 
Positive Association Negative Association 
Red meat consumption Tomatoes/lycopenes 
Smoking High intake of fruit and vegetables 
Farming Selenium 
Exposure to cadmium, polyaromatic hydrocarbons 
and pesticides 
UV exposure 
  Physical activity 
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1.4.2 Genetic Factors 
The familial clustering of the disease suggests either an X-linked or recessive mode of 
inheritance. Twin studies further support this idea, where heritability of the disease is 
estimated to be between 50 – 60% (137-138). One of the most investigated genes is the 
androgen receptor gene, known to be implicated in human prostate cancer, as prostate tumours 
do not occur in dogs or humans castrated before puberty (139). Early studies found that the 
length of the CAG repeat region is inversely related to its function (140-141). However in 
2004, Zeegers et al showed that although shorter repeats appeared in prostate cancer cases and 
were moderately associated with the disease, the absolute difference in number of repeats in 
cases and controls was less than one (142).  
 
The advent of genome wide association studies have brought to light a number of loci which 
may harbour prostate cancer susceptibility genes. However the relative importance of variants 
located within them is questionable. A genomewide scan of 91 prostate cancer families 
detected a susceptibility locus at chromosome 1q24, now known as Hereditary Prostate 
Cancer 1 or HPC1 (143). Further studies have revealed this locus to be linked to younger age 
and more advanced stage at diagnosis and a higher grade of tumour. It has also been suggested 
that the RNASEL gene on 1q25 might be responsible for the apparent effects. A meta-analysis 
by Li and Tai in 2006 investigated ten case control studies on RNASEL variants E265X, 
R462Q and D541E and only detected the D541E allele to be associated with the disease; 
however the effect size was small (144). 
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Epidemiological studies on family history report a higher risk of prostate cancer in men with 
an affected brother compared to men with an affected father. These findings point to a 
potential prostate cancer susceptibility locus on the X chromosome. A study by Xu et al 
resulted in a prostate cancer susceptibility locus being mapped on the X chromosome, known 
as Hereditary Prostate Cancer X or HPX, which accounted for 16% of the disease among the 
families studied (145). 
 
The recent surge of genome wide association studies (GWAS) has identified a number of loci 
which may harbour prostate cancer susceptibility genes, however the relative importance of 
variants located within the regions is uncertain. A number of previous studies have implicated 
a region on chromosome 8q24 in prostate cancer. In particular, the variant allele -8 of the 
microsatellite DG8S737 has been shown to have a strong positive signal (OR, 1.79; P = 3.0 x 
10
-6
) (146). This was replicated in Icelandic men (OR, 1.72; P = 1.8 x 10
-3
) and among 
Swedish and European American men. Within the same haplotype block, the SNP rs1447295 
has also been distinguished; allele A was significantly associated with prostate cancer (OR, 
1.72; P = 1.7 x 10
-9
) (146). This study was replicated in 2007 by Suuriniemi et al in European 
men aged 40-64 years. Although they confirmed the association for the rs1447295-A allele, 
the results for DG8S737-8 could not be replicated (147). An interesting result from this study 
was the significant association of the DG8S737-10 allele with high grade tumours. Two 
further genome wide association studies have also confirmed the association of rs1447295-A 
allele and prostate cancer risk (148-149). Since few of the studies have stratified by tumour 
stage, the variability in results could be due to tumour stage heterogeneity, or perhaps genetic 
heterogeneity within and between populations.    
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Genome wide association studies are prone to type 1 errors and therefore confirmation of all 
significant results is required. In this thesis, the association of the rs1447295-A allele, the 
DG8S737-8 and DG8S737-10 alleles are further examined in a population based sample of 
Dutch men. The Dutch cohort is potentially a very interesting one as mutations specific for 
this population have previously been identified, including some predisposing for hereditary 
breast-ovarian cancer and malignant melanoma (150). In the same study, Zeegers et al also 
detected short chromosomal regions that have remained identical by descent, resulting in 
relatively limited genetic heterogeneity, which could therefore increase power to discover 
associations among the Dutch. 
 
It has been hypothesized that other genes involved in testosterone response might play a role, 
such as genes in the polyamine pathway. Polyamines are present in all mammalian cells and 
are essential for normal cell growth and differentiation and also play a role in cell death (151). 
There are three different forms; putrescine, spermidine and spermine, and the prostate has the 
highest polyamine concentration of any tissue. The polyamines in the prostate are controlled 
by androgens and evidence is accumulating that the polyamine system is responsible for all 
final decisions on cell growth, survival and differentiation of cells and eventually death (152). 
The enzymes involved in polyamine biosynthesis, ornithine decarboxylase (ODC), S-
adenosylmethionine decarboxylase (SAMDC) and spermidine synthase (SDS) are also induced 
by androgens (153-154). Studies of ODC activity show that when it is inhibited with 
difluoromethylornithine, the prostate acini decrease in size (155). 
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If the rate of polyamine biosynthesis is increased, causing higher levels of putrescine and 
spermidine in particular, prostate cells will proliferate (156). Prostatic spermine does not 
promote growth, however it can induce a differentiated prostatic epithelium (157). Other 
studies have reported inhibited growth of prostate tumours when spermine levels are high 
(158). In 2002, Rhodes et al conducted a meta analysis to identify candidate genes for prostate 
cancer. Genes involved in the pathway were consistently dysregulated in prostate cancer. The 
enzymes directing synthesis, such as ODC, SDS, aspartate transaminase (GOT2) and 
aminoacyclase (ACY1) were over expressed and ornithine aminotransferase (OAT) was under 
expressed. The overall effect is that polyamines are synthesized at a higher rate, which in turn 
causes cancer cell proliferation (159).  
 
1.5 Research Questions 
Despite the extensive research on risk factors of prostate cancer, only a few have been 
confirmed. The controversy behind PSA continues as the opinions of it as a suitable tumour 
marker remain mixed. For this PhD, the Birmingham Prostatic Neoplasms Association Study 
(BiPAS) was initiated to establish the effect of a wide range of environmental and genetic 
factors on PSA levels and prostate cancer risk. 
 
The classic case control design for prostate cancer has studied prostate cancer cases and 
healthy controls from the population. Here four groups were recruited; two types of cases 
(prostate cancer cases and high PSA cases) and two types of controls (clinical controls and 
hospital controls). All groups were compared to investigate the effect of risk factors on disease 
progression and whether PSA is a good marker for prostate cancer. 
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The only established risk factors are age, ethnicity and family history. The other possible 
modifiable environmental factors are summarized in Table 1.4. Although information was 
collected for all of these factors, only some could be investigated for the purpose of this work. 
The research questions for this thesis therefore are: 
 
1. Is ultraviolet radiation associated with prostate cancer? 
2. Is physical activity associated with prostate cancer? 
3. Is body mass associated with prostate cancer? 
4. Is occupation associated with prostate cancer?  
5. Are polymorphisms on chromosome 8q24 associated with prostate cancer? 
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CHAPTER 2 : THE BIRMINGHAM PROSTATIC 
NEOPLASMS ASSOCIATION STUDY (BiPAS) 
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2.1 Rationale 
Although a large part of the causal pathway to prostate cancer is unknown, a number of 
epidemiological studies have indicated that both genetic and environmental components exist 
(138). Previous epidemiological studies have either been subject to bias or obtained 
inconclusive results due to small sample sizes of exposures. Very few prostate cancer 
susceptibility genes have been identified to date. The HPC1 gene is a potential candidate, as is 
Hereditary Prostate Cancer X or HPX and more recently the chromosomal 8q24 region (143, 
145, 160). Other possibilities include the vitamin D receptor, polyamine pathway and 
androgen receptor (142, 152). It has been suggested that risk of disease may be due a number 
of genes, each conferring a small individual risk.  
 
The Birmingham Prostatic Neoplasms Association Study (BiPAS) was established in order to 
accumulate a large database for use in prostate cancer research, allowing confirmation of the 
roles of a number of environmental risk factors. Information on these factors was obtained by 
means of a questionnaire, which is further discussed in Section 2.5. A second aim was to 
establish a DNA bank with linked clinical and epidemiological data that can be of use to other 
collaborators 
 
In this thesis, a case control design was used to investigate risk factors. In this type of study, 
disease subjects, known as “cases” are compared to non disease subjects, or “controls”. 
Information on exposure variables that may be implicated in the disease of interest is collected 
and significant differences are identified. Case control studies are used for uncommon 
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diseases which require a smaller sample size compared to cohort studies, which follow 
subjects over a long period of time. 
 
In contrast to previous studies, participants were selected from a number of different groups; 
prostate cancer patients, patients with high prostate specific antigen (PSA) levels but no 
clinical symptoms of prostate cancer, hospital based controls and population based controls 
where patients have no symptoms of prostate disease. By comparing the four groups among 
each other, the aetiology of prostate cancer can be disentangled and the effect of these factors 
on PSA levels can be studied.  
 
2.2 Inclusion and Exclusion Criteria 
Eligibility criteria were men who were 50 years of age and over and able to provide informed 
consent. Prostate cancer was defined as ICD-10 code C61, malignant neoplasm of the prostate 
(31). The study excluded vulnerable groups, such as adults with learning disabilities, those 
who were unconscious or severely ill, adults with dementia or with other psychological 
disorders. Men with poor English skills were not automatically excluded; they were recruited 
with help of interpreter services where possible.  
 
2.3 Recruitment  
The study recruited eligible men living in Birmingham (UK) attending clinics. Patients with 
suspected prostate abnormalities and/or high serum PSA levels are routinely referred to the 
Urology Department at The Queen Elizabeth Hospital, Birmingham. After a repeat PSA test, 
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prostate biopsies are carried out where appropriate. All patients were recruited between March 
2007 and October 2010. 
 
The main recruitment strategy can be found in Figure 2.1. Recruitment strategies were adapted 
depending on the recruitment centre. For the Quick Early Diagnosis (QED) clinic at the Queen 
Elizabeth Hospital, the recruitment responsibility was divided between the clinic nurse and a 
member of the BiPAS team. Study information sheets were posted to all subjects attending 
biopsy and urodynamics clinics, along with their appointment letters and biopsy information 
booklets, two weeks before their attendance in accordance to Centre of Research Ethical 
Campaign (COREC) guidelines. The document explained the purpose of the study and the 
requirements, risks of participating and a complaints procedure. After the patient‟s arrival at 
the clinic, a pre-assessment with the nurse was carried out. Unsuitable or ineligible patients 
would continue with a routine appointment. If the nurse or BiPAS researcher concluded that 
the eligibility criteria had been met, informed consent was obtained and the questionnaire was 
completed independently by the participant. The patient would then see the consultant for 
biopsy and an extra blood sample was obtained for the study. Patients with histologically 
confirmed adenocarcinoma of the prostate formed the prostate cancer case group.  High PSA 
cases were defined as patients with a high repeat PSA and negative or no biopsy and were 
identified in both the prostate and lower urinary tract symptoms (LUTS) clinics.  
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Figure 2.1 Recruitment strategies for BiPAS 
 
 
Pt: patient   PSA: prostate specific antigen  
 
BiPAS: Birmingham Prostatic Neoplasms Association Study 
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Hospital control patients were recruited through urodynamics clinics at the Queen Elizabeth 
Hospital, Selly Oak Hospital and City Hospital, Birmingham. These recruitment centres see a 
vast number of patients, most of whom would be ineligible therefore a blanket mailing of the 
information sheet would be unsuitable. For these subjects, the consultant or nurse would 
assess the suitability of patients prior to the clinic and send out information letters to eligible 
subjects only. 
 
Population controls were invited to take part by their general practitioner (GP) surgeries. A 
computer search was carried out at four GP practices for men aged 50 years or over with no 
known prostate cancer symptoms. After suitability was assessed by the GP, invitation letters 
were sent out to a random sample of patients and home visits or clinic appointments were 
arranged for positive replies. No genetic sample was obtained for this group. The recruitment 
target for this group was 160 patients (40 patients per practice), however, a high response rate 
meant the target was exceeded (45 patients were recruited at Quinton Medical Practice, 44 
patients at The Old Priory, 44 patients at Quinborne and 42 patients at Grange Hill).  
 
All recruitment documents given to the patients received favourable ethical opinion by the 
South Staffordshire Ethics Committee. The study was conducted in accordance with the 
principles of the International Conference of Humanisation guidelines on Good Clinical 
Practice (ICH-GCP). The study protocol containing the questionnaire, study information sheet 
and consent form can be found in Appendices 1 – 3.  
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2.4 Data collection and handling 
The environmental data were collected in the form of a questionnaire and DNA formed the 
genetic sample. The blood sample for each patient was obtained by either a doctor or a 
phlebotomist using standard venipuncture methods. The blood was contained in a 5ml tube 
containing EDTA and stored at 2ᵒC for the duration of the clinic. The samples were then 
transported in a cool bag with cool packs to the BiPAS freezer and stored at -20ᵒC until DNA 
extraction took place. DNA was extracted using QIAGEN maxi blood kit. For population 
controls, a blood sample was obtained for PSA testing and transported to Selly Oak Hospital. 
For all participants, the Roche E170 assay was used to determine PSA level. For population 
controls with a raised PSA, a standard operating procedure (SOP) was developed to inform the 
general practitioner for further management. 
 
The genetic data from BiPAS have contributed towards the Prostate Cancer Association 
Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) 
consortium. DNA samples for prostate cancer cases and hospital based controls were sent to 
the consortium for a follow up of a previous genome wide association study, which led to a 
publication in Nature Genetics (161). Selected SNPs were investigated in 3, 650 cases and 3, 
940 controls. All the previously identified loci were confirmed and an additional seven new 
prostate cancer susceptibility loci on chromosomes 8, 4, 8, 11 and 22 were identified (161-
162).  
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2.5 Measurement of environmental exposures 
The questionnaire was divided into various sections investigating different environmental 
factors. The first section related to background information, such as address, marital status, 
ethnicity, educational qualifications received and past history of cancer. Section two asked of 
occupational history, starting with most recent and all other past jobs. Subjects were asked to 
record their occupational activities, duration of employment, whether it was shift work and if 
the job involved indoor or outdoor work (Figure 2.2). Section three was dietary information, 
with 39 different food items classified into a number of categories; staple foods (bread, 
potatoes, pasta etc...), meat products, fish, vegetables, fruit, dairy products, foods of interest 
(fast food, restaurant etc...) and other foods (pulses, nuts and seeds etc...). A similar approach 
was used for fluid intake, with categories including alcoholic drinks, hot and cold drinks. For 
each product, patients were asked to indicate how frequently it was consumed over the last 12 
months. The options were “never or less than once a month”, “1-3 times per month”, “once a 
week”, “2-4 times per week”, “5-6 times per week” and “at least once a day”. A small section 
of the table used to record dietary intake can be found in Figure 2.3. Section four was 
ultraviolet (UV) light exposure; patients were asked to describe their skin type, hair and eye 
colour. They also recorded average times spent in the sun and different life periods (age 60 
onwards, age 40-59 and 20-39 years) during the weekdays and weekends (Figure 2.4). Section 
five was based on physical activity; patients were asked how often they do walking, cycling, 
gardening, housework, competitive and non competitive sport at different periods in life. 
Tobacco use was investigated in section six, patients were asked the maximum number they 
currently or used to smoke and duration of smoking. Section seven investigated body 
dimensions at current age and at younger ages (Figure 2.5). Section eight was based on family 
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history of cancer, including details of parents, siblings and children (Figure 2.6). The final 
section was on testosterone levels, based on the androgen deficiency in ageing males (ADAM) 
scale (163). There were ten questions within this section relating to different androgen related 
parameters (Figure 2.7). 
 
The data were entered into a password protected Microsoft Access database and later 
converted to a STATA data file. The paper questionnaires were electronically scanned and 
archived according to the original ethics application. 
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Figure 2.2 Table to record occupational history for BiPAS participants 
Job Title 
Time period that you 
worked there Description of 
Activities 
Name of 
Organisation 
Location 
(Town/City) 
Type of Business 
Mainly 
indoor 
activity 
Mainly 
outdoor 
activity 
Shift 
work 
From (y) To (y) Please tick one 
EXAMPLE: 
DRIVER 
1972 1996 HGV DRIVER 
JO BLOGGS 
BUILDERS 
BIRMINGHAM 
BUILDING  
CONTRACTORS 
  YES 
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Figure 2.3 Table to record dietary intake for BiPAS participants 
 
 
 
Average Use Last Year 
Never or 
less than 
once per 
month 
1-3 per 
month 
Once a 
week 
2-4 
per 
week 
5-6 
per 
week 
At least 
once per 
day 
STAPLE FOODS       
Bread ………………………………… □ □ □ □ □ □ 
Potatoes………………………………. □ □ □ □ □ □ 
Pasta…………………………………………… 
(eg. Macaroni, Spaghetti) 
□ □ □ □ □ □ 
Rice ……………………………………………… □ □ □ □ □ □ 
Noodles………………………………………… □ □ □ □ □ □ 
Wheat ……………………………………………. 
(eg. Whole grain bread) 
□ □ □ □ □ □ 
Cereal…………………………………………….. 
(eg. Oats, bran, corn) 
□ □ □ □ □ □ 
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Figure 2.4 Table to record UVR exposure for BiPAS participants 
 
 
On average how many hours per day did you spend outdoors during early adult life (20-
39)? 
 
 Weekdays   never          Weekends        never   
                               0 – 4 hours                                            0 – 4 hours   
                               5 – 9 hours                                            5 – 9 hours   
                               10 – 14 hours                                        10 – 14 hours  
                                More than 15 hours                      More than 15 hours  
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Figure 2.5 Table to record body dimensions for BiPAS participants 
Please answer the following questions using either metric (cm, kg) or imperial (feet, 
inches, stones, pounds) measurements 
 
What is your current height (in bare 
feet)? 
feet inches Or 
cm 
 
What is your current weight (in light 
clothing)? 
stone pounds Or 
kg 
How much did you weigh at age 20? stone pounds Or 
kg 
How much did you weigh at age 30? stone pounds Or 
kg 
How much did you weigh at age 40? stone pounds Or 
kg 
 
What is your current waist size? 
inches Or 
cm 
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Figure 2.6 Table to record family history of cancer for BiPAS participants 
 
SIBLING’S MEDICAL HISTORY 
 
We would now like you to provide some more information about your brothers and 
sisters including any medical history of cancer.  You DO NOT need to tell us about 
any adopted or step-relations. 
 
 
Gender 
(Please tick) Year of Birth 
Have they ever 
had cancer? 
(Please tick) 
If Yes, which 
type of cancer? 
Age at which 
cancer was 
diagnosed 
(if known)  Male Female Yes No 
1        
2 
       
3 
   
  
  
4 
   
  
  
5 
       
6 
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2.6 Assessment of Exposures 
A validated UVR exposure section recorded the amount of hours patients spent in the sun 
during different time periods (61). Life course was split into three different periods; early 
adult life (20-39 years) and middle age (40-60 years) and late adult life (60+ years). This 
allowed for the wide range of age at diagnosis for both cancer and control groups. Time 
spent outside was calculated by summing the weighted numbers of hours spent outdoors 
during weekdays and weekends (weights: never = 0, 0 – 4 hours/day = 1, 5 – 9 hours/day 
= 2, 10 – 14 hours/day = 3). Missing answers were removed from the dataset. The 
distribution of this score was then further classified into tertiles based upon the 
distribution of the total control population: “low”, “medium” and “high” UVR exposure. 
A separate score for lifetime sun exposure was derived by summing all three life periods 
using the same method. Further detail on the number of times men were sun burnt as 
children, how often they use sun beds per year and if they have ever lived abroad in a 
sunny country were also analyzed. Subjects were also asked for pigmentation information 
(skin reaction to the sun and hair colour) and behaviours which affect UVR exposure 
such as details of sun protection used.  
 
The Physical Activity questions were based on the standardized questions from the short 
version of the International Physical Activity Questionnaire (IPAQ) (164). The IPAQ is a 
recall assessment method designed by physical activity experts in 2000 (165). The 
reliability of the test was reported to be ƿ = 0.76 (166). Participants were asked questions 
on different types of physical activities e.g. mode of transport (walking, cycling) 
household activity (housework, gardening) and recreational activity (non-
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competitive/social and competitive sport). Levels of physical activities were reported for 
three distinct periods in life, (12-19 years, 20-39 years and from the age of 40 to 
diagnosis/entry in the study). Participants were asked to indicate the level of physical 
activity in terms of hours per week they undertook each of the various activities at each 
age-group according to five predefined categories: never, 0-4 hours, 5-9 hours, 10-14 
hours and more than 15 hours per week. The main focus of the analyses was the level of 
physical activity since the age of 40. As the average age for men in all groups were mid 
60s, this covered approximately 25 years of physical activity behaviour. Testosterone 
summary scores were obtained using the androgen deficiency in ageing males (ADAM) 
scale (163). There were ten questions within this section (see Figure 2.7) on different 
androgen related parameters. A positive result was defined as an affirmative answer for 
question 1 or 7, or for any other 3 questions. 
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Figure 2.7 Androgen deficiencies in ageing males (ADAM) scale 
 
1. Do you have a decrease in libido (sex drive)? 
Yes No  
2. Do you have a lack of energy? 
Yes No  
3. Do you have a decrease in strength and/or endurance? 
Yes No  
4. Have you lost height? 
Yes No  
5. Have you noticed a decreased "enjoyment of life" 
Yes No  
6. Are you sad and/or grumpy? 
Yes No  
7. Are your erections less strong? 
Yes No  
8. Have you noticed a recent deterioration in your ability to play sports? 
Yes No  
9. Are you falling asleep after dinner? 
Yes No  
10. Has there been a recent deterioration in your work performance? 
Yes No  
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Obesity was measured as BMI using self reported measures of height and weight at 
diagnosis. The anthropometry section included questions on body size at time of 
diagnosis and at different periods in life, including questions regarding current height in 
feet/inches or cm, current weight in stones/pounds or kilograms and current waist 
circumference in inches or cm. Weight in stones/pounds or kilograms at age 20, 30 and 
40 years was also obtained. Finally, patients were given a pictogram (Figure 2.8) with 9 
different options and asked to mark the one they thought corresponded to their body size 
at ages 20, 30, 40 and their current age. These figures were obtained from the 
standardized visual stimuli set designed by Bulik and colleagues (167). Since BMI is 
questionable as a measure of obesity, it could be that self perceived body size could be a 
better measure for fat distribution. The figures take into account different central fat 
distributions, which is common in men (167). All reported weights were converted from 
stones and pounds into kg and height was converted from feet and inches into metres. 
BMI was derived from weight and height measurements at time of diagnosis as kg/m
2
. 
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Figure 2.8 Pictogram for self perceived body size 
 
 
 
 
 
 
 
 
 
 
 
 
At around age 20               
 
At around age 30               
 
At around age 40               
 
 
                     Now                 
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2.7 Statistical Analysis 
Statistical Analysis for Chapter 3 – 5: BiPAS 
The Birmingham Prostatic Neoplasms Association Study recruited 314 prostate cancer 
cases, 381 cases with high PSA but no prostate cancer, 201 hospital based controls and 
175 population based controls between 2007 and 2010. For the analysis, men were 
categorized into two different case groups and two control groups. The case groups 
consisted of biopsy confirmed prostate cancer cases and other patients with high PSA, in 
which cancer could not be confirmed (high PSA cases). The control group also had two 
further groups; hospital based controls and population based controls (see figure 2.9). The 
different cases and control groups allowed comparison of PSA level, suggesting differing 
disease stage rather than the traditional disease vs. non disease approach.  
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Figure 2.9 Case Control Strategies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LUTS: Lower urinary tract symptoms PSA: Prostate specific antigen 
 
 
POPULATION 
BASED 
CONTROLS 
HOSPITAL 
BASED 
CONTROLS 
HIGH PSA 
CASES 
PROSTATE 
CANCER 
CASES 
NEGATIVE 
BIOPSY 
POSITIVE 
BIOPSY 
NORMAL PSA HIGH PSA NORMAL PSA HIGH PSA 
NO LUTS IN GP 
PRACTICES 
LUTS AND HIGH PSA 
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For each analysis chapter, the following comparisons were analyzed, however not all 
tables are presented: 
1. Combined cases vs. hospital based controls 
2. Combined cases vs. population based controls 
3. Combined controls vs. prostate cancer cases 
4. Combined controls vs. high PSA cases 
5. Combined cases vs. combined controls 
 
All additional analyses can be found in appendices 4 – 7. Odds ratios were used to 
measure the association between exposure variables and prostate disease. This is the ratio 
of the odds of exposure in cases and odds of the exposure in controls. If an odds ratio is 
above 1, it is said that the variable is more likely to be exposed to cases compared to 
controls. Since the case control design only includes a sample of the population, the odds 
ratios are only estimates of association; 95% confidence intervals are therefore calculated 
for accuracy. These indicate the limits in which the true value of association will lie. A 
confidence interval that does not include the value 1.00 is considered statistically 
significant. Logistic regression was used to calculate odds ratios and corresponding 95% 
confidence intervals for all associations. All hypothesis tests were two-sided and p-values 
less than 0.05 were considered to be statistically significant. All analyses were performed 
in STATA 11.0 (StataCorp, 2009). 
 
Both crude and multivariable (age, ethnicity and family history of prostate cancer) 
adjusted analyses were performed. Confounding factors were adjusted for according to 
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the variable of interest. In chapter three, pigmentation can affect behaviours when 
exposed to sunlight. For example, usual reaction to sunlight and hair colour can affect 
vitamin D absorption; therefore adjustment was made for these variables where 
applicable. In chapter four, additional adjustment included regular smoking (never vs. 
ever), education level and BMI (kg/m
2
) and testosterone summary scores. In chapter five, 
testosterone summary score adjusted analyses were performed. Associations with the 
localised tumour stage (Gleason score between 2 and 6) or advanced tumours (Gleason 
score between 7 and 10) were also evaluated. For this analysis, the standard clinical 
classification for risk (D‟Amico scale) was adapted for larger sample sizes.  
 
Due to the small number of participants in some of the five categories for the different 
physical activities, some groups were combined to create new categories. These 
categories were either low, medium and high (e.g. walking, gardening and housework; 
highest vs. lowest level) or they were dichotomized into ever vs. never (e.g. cycling, non-
competitive/social sport and competitive sport). Social sport (or non competitive) was 
defined as aerobics, golf, sailing and skiing. Competitive sport was defined as cricket, 
football, badminton, squash, athletics and dance. 
 
Duration of physical activity across lifetime was also assessed by comparing the levels of 
non-occupational physical activity between participants for each of the three age groups: 
12-19 years, 20-39 years and from 40 years to diagnosis/entry in the study and 
calculating ORs and 95% CIs for the physical activities at each of these age categories.  
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The intensity of physical activity was assessed by multiplying the weekly hours 
performing each activity (mid value) by its metabolic equivalent (MET) value. METs can 
be defined as the “ratio of associated metabolic rate for a specific activity compared to 
the resting metabolic rate” (12). To assign METs to each of the particular physical 
activities, values from the Compendium of Physical Activities were used, specifically 3.0 
for walking, 8.0 for cycling, 3.5 for housework, 4.0 for gardening, 4.8 for non-
competitive sport (based on value for golf) and 8.0 for competitive sport (168). METs for 
total physical activities were calculated as continuous variables and were subsequently 
categorized as low, medium and high intensity levels of physical activity based on cut-off 
points determined from the distribution among the controls.  
 
BMI was categorised into quartiles according to the WHO guidelines for evaluation of 
obesity; <18.5 (underweight), 18.5 – 24.99 (normal), 25.0 – 29.9 (overweight) and ≥ 30.0 
(obese). Where numbers were small, overweight and obese categories were combined 
into one overweight category. Waist circumference was categorised into tertiles based on 
the distribution amongst controls; <34.0, 34.1 – 37.0, ≥ 37.1 inches. Weight data for each 
decade were converted into a BMI category. Weight change over lifetime was obtained 
by calculating the difference between body weight in kg for current age and body weight 
at age 20. The weight changes were then converted into categorical variables, with a 
stable weight classed as gain or loss of ≤5 kg over lifetime as the reference group. 
Relative weight change was also examined, defined as weight change over lifetime 
divided by weight at age 20.  
 
79 
 
Statistical Analysis for Chapter 6: Meta analysis 
Search Strategy  
The Medline/PubMed and EMBASE databases were searched to identify all relevant 
literature up until December 2010. The search terms used were combinations of the 
following keywords: prostate cancer, prostatic neoplasms, urologic, occupation, work, 
industry, meta-analysis, review, epidemiology, cohort study, case control and nested case 
control studies. Titles and abstracts were systematically reviewed against the original 
inclusion.  
 
Inclusion criteria 
Bibliographies of all studies included were checked for earlier publications until no new 
studies were found. All case-control and cohort studies measuring prostate cancer as the 
outcome of interest and occupation as an exposure variable were included. A measure of 
strength of association must have been reported as odds ratio (OR) or risk ratio (RR), or 
sufficient data available to calculate this and 95% confidence intervals (95% CI) from 
raw data. Mortality studies were not included in this meta analysis as cancer incidence 
was the outcome of interest. If standard errors for odds ratios were not reported, they 
were calculated. A standardized reporting form was used to extract the following data: 
author, country, year of publication, sample size, mean age or age range of cases and 
controls, study design, assessment method, covariates for multivariable models, risk 
estimates and 95% confidence intervals. Occupations were coded using the Standard 
Occupation Classification (SOC2000) devised by the Office for National Statistics, UK 
(169). To examine associations, each category of classification was compared according 
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to the SOC2000 guide; major groups (9 occupational groups), sub-major groups (19 
occupational groups) and minor groups (24 occupational groups) (169).  
 
All risk estimates from each individual study were grouped together by their 
classification codes and pooled to produce a single estimate using a fixed effects model. 
For example, where a risk estimate for nurses and another for midwives existed in the 
same study, the two were pooled into a single estimate for health associate professionals. 
These occupational estimators or odds ratios (OR) were then pooled by each occupational 
classification using a random effects model to produce a summary odds ratio (SOR) and 
corresponding 95% confidence intervals were calculated. Meta-regression models were 
used to examine whether the country where the study was conducted and study design 
had an effect on the SORs for study comparability. Publication bias was investigated by 
the use of funnel plots and also statistically by the Begg and Mazumdar test (170).  
 
Statistical Analysis for Chapter 7: NLCS 
Study Population 
The study population for this chapter was obtained from the Netherlands Cohort Study 
(NLCS) (171). In brief, the study recruited over 58, 000 men between the ages of 55 and 
69 years at baseline. This chapter reports from the dataset after 8.3 years of follow up, 
using a case cohort approach. After the follow up period, prostate cancer cases were 
identified using computerized record linkage with all nine cancer registries in the 
Netherlands. Controls were selected from a random sub cohort sample of 2,411 men and 
followed up for information on vital status. The epidemiological dataset for analysis was 
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provided by Dutch collaborators at Maastricht University (MP Zeegers, LJ Schouten, 
BAC van Dijk, RA Goldbohm, J Schalken and PA van den Brandt). 
 
Biological Samples 
Paraffin blocks of tumour and normal tissue samples were obtained from cases. After 
exclusions of insufficient non tumour tissue, 300 cases were available for analysis. 
Buccal swab samples were obtained from 300 controls from the NLCS sub cohort. 
Genotyping was performed by collaborators at New York University (A Pearlman, S 
Shajahan, C Oddoux and H Ostrer) using Genemapper software version 4.0 and the 
Taqman SNP Genotyping Assay (Applied Biosystems, CA) for the rs1447295 SNP 
marker.  
 
Statistical Analysis 
Linkage disequilibrium between marker alleles and deviation from Hardy Weinberg 
equilibrium were tested by χ2 tests. Associations for the SNP and microsatellite were 
tested by both allelic and genotypic analysis. Odds ratios and corresponding 95% 
confidence intervals were calculated using logistic regression. For allelic analyses, robust 
standard errors were calculated to model potential clustering of alleles within individuals.  
 
In microsatellite analyses, alleles -8 and -10 were compared to all other alleles, using the 
most common allele (-14) as the reference group. The microsatellite was further tested at 
different breakpoints to test association between groups of alleles. Both crude and 
multivariable (age, alcohol intake from wine, body mass index (BMI), energy intake, 
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family history of prostate cancer and level of education) adjusted analyses were 
performed. Differences in associations with the localised tumour stage (T0-2, M0) and 
advanced (T3-4, M0 and T0-4, M1) were also investigated. Stage was reported by the 
cancer registries and coded according to the UICC TNM (172). All statistical analysis 
was carried out by H Khan.   
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By October 2010, a total of 1,071 men had been recruited to the BiPAS project. The 
questionnaire was completed by 314 prostate cancer cases, 381 high PSA cases, 201 
hospital based controls and 175 population based controls. The study sample 
characteristics can be found in Table 3.1. The mean age within each group was 68 years, 
65.2 years, 66.6 years and 64.8 years respectively. The percentage of family history 
within each group also differed slightly, 12.8%, 8.6%, 11.4% and 4.7% respectively. In 
the prostate cancer case group, 133 subjects had localised disease and 178 were described 
as advanced tumour stage. In all groups, more than 85% of patients were Caucasian. 
 
There was very little difference in results when the combined high PSA group were 
compared to either the hospital controls or the population controls (see appendix 4). Both 
analyses reported an increase in risk of high PSA level with low exposure to sunlight.  
 
When the two control groups were compared to a high PSA control group, again there 
was little difference when compared to prostate cancer cases and other high PSA cases 
separately (see Table 3.2). Both analyses detected trends indicating decreasing risks for 
more time spent outside in the sun. Significant results were observed for early adulthood 
in particular, with an increased risk of prostate cancer associated with lower sun 
exposure, an OR of 4.92 was observed (95% CI 1.63 – 14.89; p trend 0.02). This was 
consistent for the high PSA cases, however it was not quite statistically significant; an 
OR of 3.71 was observed (95% CI 1.20 – 11.46; p trend 0.07). A statistically significant 
protective effect was observed in men who rarely or never burn in the sun, (OR 0.65; 
95% CI 0.47 – 0.90; p trend 0.01). 
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All other analyses also pointed to the same direction. For example, in prostate cancer 
cases, a moderately high exposure to sun during the life course in prostate cancer cases 
resulted in an OR of 1.07 (95% CI 0.56 – 2.05) compared to low exposure, where the risk 
increases with an OR of 1.59 (95% CI 0.70 – 3.60). A similar pattern was observed in 
high PSA cases, where the OR for moderate exposure was 0.65 (95% CI 0.31 – 1.36) and 
increased to 1.55 (95% CI 0.68 – 3.53). 
 
Table 3.3 shows the results for the combined case group compared to the combined 
control group. Again, a statistically significant protective effect for higher UVR exposure 
was observed in early adulthood, OR 4.28; 95% CI 1.49 – 12.3; p trend 0.03. This was 
consistent for the life course analysis however it was not statistically significant.  
 
The results of the advanced (Gleason score above 7) and localised (Gleason score ≥ 10) 
analysis can be found in the appendix. Although no statistically significant results were 
seen, some effect estimates were in the same direction as previous literature, such higher 
risk of advanced disease for men who rarely or never burn in the sun (OR 1.36; 95% CI 
0.82 – 2.28). Interestingly, there was very little difference in risk for different sun 
exposures in early adulthood, for moderate exposure an OR of 1.34 (95% CI 0.65 – 2.73) 
compared to low exposure, with an OR of 1.35 (95% CI 0.43 – 1.20). 
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Table 3.1: Study Characteristics for UV – Results from the Birmingham Prostatic Neoplasms Association Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Gleason score between 2 and 6  **Gleason score between 7 and 10 
 
Prostate cancer cases  
n (%) 
High PSA cases   
n (%) 
Hospital controls   
n (%) 
Population controls   
n (%) 
Age group (years)         
40 - 50 0 7 (1.8) 3 (1.5) 3 (1.7) 
51 - 60 57 (18.2) 111 (29.1) 57 (28.4) 61 (34.9) 
61 - 70 134 (42.7) 171 (44.9) 69 (34.2) 65 (37.1) 
71 - 80 104 (33.1) 78 (20.5) 55 (27.4) 37 (21.2) 
≥ 81 19 (7.0) 14 (3.7) 17 (8.5) 9 (5.1) 
Ethnicity       
Caucasian 274 (94.2) 298 (89.0) 155 (86.6) 163 (94.2) 
Non Caucasian 17 (5.8) 37 (11.0) 24 (13.4) 10 (5.8) 
Family history of prostate cancer       
Yes 37 (12.8) 28 (8.6) 20 (11.4) 8 (4.7) 
No 253 (87.2) 297 (91.4) 156 (88.6) 162 (95.3) 
Smoking status       
Never smoked 126 (44.7) 148 (46.3) 76 (45.0) 51 (29.8) 
Used to/still smokes 156 (55.3) 172 (53.7) 93 (55.0) 120 (70.2) 
Education history       
Low 50 (27.8) 66 (27.2) 28 (21.5) 38 (31.9) 
Medium 64 (35.6) 77 (31.7) 49 (37.7) 50 (42.0) 
High 66 (36.6) 100 (41.1) 53 (40.8) 31 (26.1) 
Tumour Grade       
Localised* 133 (42.8)      
Advanced**  178 (57.2)       
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Table 3.2: Odds Ratios and 95% Confidence intervals for UVR comparing combined controls with prostate cancer cases and high PSA cases - Results 
from The Birmingham Prostatic Neoplasms Association Study 
 Combined Controls Prostate cancer  Adjusted p value/  High PSA  Adjusted p value/  
  n (%) cases n (%) OR (95% CI) p trend cases n (%) OR (95% CI) p trend 
Usual reaction to sunlight              
Always/easily burns 109 (31.4) 97 (33.0)     135 (41.2)     
Rarely/never burns 238 (68.6) 197 (67.0) 0.94 (0.67 - 1.33)* 0.74 193 (58.8) 0.65* (0.47 - 0.90) 0.01 
Number of times severely sunburnt as a                
child                                                            1 29 (8.8) 21 (7.5)     26 (8.2)     
≥ 2 299 (91.2) 258 (92.5) 1.14 (0.61 - 2.10)* 0.69 290 (91.8) 1.18 (0.67 - 2.07)* 0.57 
Ever lived abroad in a sunny country  No   276 (82.9) 220 (81.8)     235 (75.1)     
Yes 57 (17.1) 49 (18.2) 0.95 (0.62 - 1.47)* 0.83 78 (24.9) 1.61 (1.10 - 2.36)* 0.02 
Time spent outside               
Early adulthood (20-39 years)            High  4 (1.4) 14 (6.4)     12 (4.7)     
Medium 54 (18.4) 46 (21) 1.22 (0.78 - 1.93)**   44 (17.1) 0.94 (0.60 - 1.47)§   
Low 236 (80.2) 159 (72.6) 4.92 (1.63 - 14.89)** 0.02§ 201 (78.2) 3.71 (1.20 - 11.46)§ 0.07§ 
Middle age (40-60 years)                     High 20 (7.0) 21 (9.8)     17(6.6)     
Medium 79 (27.8) 63 (29.4) 1.13 (0.75 - 1.70)**   61 (23.6) 0.79 (0.53 - 1.18)§   
Low 185 (65.2) 130 (60.8) 1.36 (0.70 - 2.65)** 0.62§ 180 (69.8) 0.88 (0.44 - 1.77)§ 0.5§ 
Late adulthood (60+ years)                High 6 (30.0) 9 (34.6)     4 (22.2)     
Medium 5 (25.0) 12 (46.2) 6.70 (1.20 - 37.39)**   5 (27.8) 1.68 (0.31 - 9.20)§   
Low 9 (45.0) 5 (19.2) 4.19 (0.67 - 26.18)** 0.09§ 9 (50.0) 0.89 (0.16 - 4.92)§ 0.76 
Life course                                            High 12 (7.7) 15 (10.7)     15 (10.1)     
Medium 23 (14.8) 22 (15.7) 1.07 (0.56 - 2.05)**   16 (10.8) 0.65 (0.31 - 1.36)§   
Low 120 (77.5) 103 (73.6) 1.59 (0.70 - 3.60)** 0.84§ 117 (79.1) 1.55 (0.68 - 3.53)§ 0.26§ 
Sunbathing in life course                    High 57 (24.4) 49 (24.1)     69 (27.8)     
Medium 89 (38.0) 83 (40.9) 1.21 (0.78 - 1.87)**   77 (31.0) 0.82 (0.53 - 1.27)§   
Low 88 (37.6) 71 (35.0) 1.14 (0.68 - 1.91)** 0.7§ 102 (41.2) 1.21 (0.74 - 1.99)§ 0.29§ 
* Adjusted for age at diagnosis, ethnicity and family history of prostate cancer  ** Adjusted for age at diagnosis, family history of prostate cancer, skin type and hair colour 
§ P trend         Combined controls: hospital + population controls 
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Table 3.3 Odds Ratios and 95% Confidence intervals for UVR comparing combined controls and combined case groups - Results from 
The Birmingham Prostatic Neoplasms Association Study 
 
Combined Controls n 
(%) 
Combined Cases n 
(%) 
Crude  
OR 
Adjusted OR*  
(95% CI) 
P value or 
 p trend § 
Usual reaction to sunlight          
Always/easily burns 109 (31.4) 232 (37.3)       
Rarely/never burns 238 (68.6) 390 (62.7) 0.77 0.78 (0.59 - 1.03)* 0.08 
Number of times severely sunburnt as a child           
1 29 (8.8) 47 (7.9)       
≥ 2 299 (91.2) 548 (92.1) 1.13 1.18 (0.71 - 1.92)* 0.52 
Ever lived abroad in a sunny country          No 276 (82.9) 455 (78.2)       
Yes 57 (17.1) 127 (21.8) 1.35 1.30 (0.92 - 1.85)* 0.14 
Time spent outside           
Early adulthood (20-39 years)                    High 4 (1.4) 26 (5.5)       
Medium 54 (18.4) 90 (18.9) 1.08 1.07 (0.73 - 1.57)**   
Low 236 (80.2) 360 (75.6) 4.22 4.28 (1.49 - 12.3)** 0.03§ 
Middle age (40-60 years)                             High 20 (7.0) 38 (8.1)       
Medium 79 (27.8) 124 (26.3) 0.93 0.94 (0.67 - 1.33)**   
Low 185 (65.2) 310 (65.6) 1.12 1.08 (0.61 - 1.03)** 0.89§ 
Late adulthood (60+ years)                         High 6 (30.0) 13 (29.5)       
Medium 5 (25.0) 17 (38.6) 2.19 3.01 (0.77 - 11.73)**   
Low 9 (45.0) 14 (31.9) 1.39 1.94 (0.46 - 8.16)** 0.28§ 
Life course                                                    High 12 (7.7) 30 (10.4)       
Medium 23 (14.8) 38 (13.2) 0.91 0.85 (0.48 - 1.53)**   
Low 120 (77.5) 220 (76.4) 1.37 1.56 (0.76 - 3.23)** 0.38§ 
Sunbathing in life course                            High 57 (24.4) 118 (26.2)       
Medium 89 (38.0) 160 (35.5) 0.92 0.99 (0.68 - 1.45)**   
Low 88 (37.6) 173 (38.3) 1.07 1.16 (0.75 - 1.80)** 0.74§ 
* Adjusted for age at diagnosis, ethnicity  and family history of prostate cancer  ** Adjusted for age at diagnosis, family history of prostate cancer, skin type and hair colour 
§ P trend    Combined controls: hospital + population controls  Combined cases: prostate cancer cases + high PSA cases 
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Conclusion 
The results show a marked decreased risk associated with high levels of sun exposure 
in early adulthood in particular, consistent with previous studies. A study of 210 
prostate cancer cases and 155 benign prostatic hyperplasia (BPH) controls in North 
Staffordshire, England compared acute and chronic sun exposures (173). High 
sunbathing scores, regular foreign holidays and sunburn in childhood had a protective 
effect. In the case group, men with lowest exposures developed prostate cancer 
earlier; the median age of diagnosis was 67.7 years compared to 72.1 years of age for 
all other patients. Although these results were in the same direction as other UVR 
studies, further confirmation was required. A further 212 prostate cancer cases and 
135 BPH controls were subsequently recruited between 2001 and 2002 (61). This 
study confirmed all the previous results; men with the lowest quartile of UVR 
exposure had almost a threefold increased risk of prostate cancer compared to men in 
the highest quartile. These replicated findings show the original associations were not 
spurious and that UVR exposure may have a protective role in prostate cancer.  
 
The significant results for early adulthood suggest that acute exposures may be more 
important in prostate carcinogenesis than chronic exposures over time. Also, in early 
adulthood, more time is generally spent outdoors, for example in recreational 
activities, holidays abroad or working hours. Younger adults may also be more health 
conscious and take vitamin supplements, which will include vitamin D or eat more 
vitamin D rich foods.  
 
Although the exact mechanism for this protective effect is unclear, vitamin D 
synthesis has been implicated. Figure 3.2 shows the current understanding of the role 
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of vitamin D on prostate cancer. After exposure to UVR, 7-dehydrocholesterol in the 
skin is converted to vitamin D3. Vitamin D3 can also be obtained by diet; this is 
especially true for USA, where small quantities are added to milk, cereals and orange 
juice. In order to become biologically active, the D3 form then undergoes two 
hydroxylation processes, firstly in the liver and then again in the kidney, colon and 
prostate cells. The active form, known as calcitriol is involved in cell differentiation 
and proliferation.   
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Figure 3.2 Role of Vitamin D on cancer 
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It is known that vitamin D deficiency leads to diseases such as rickets or 
osteomalacia; however levels sufficient for a healthy skeleton may be inadequate for a 
healthy prostate. Well established risk factors can also be related to the vitamin D 
hypothesis; prostate cancer risk is known to increase with age, as does vitamin D 
deficiency. Older people have less exposure to UVR, especially if they are 
housebound or have limited mobility. They also have a thinner epidermis which 
contains less 7-dehydrocholesterol than younger people, resulting in lower levels of 
active form of the vitamin.  
 
Another well studied risk factor is ethnicity; African American men have between 1.3 
– 2 times higher incidence than Caucasian men (174). Dark skinned individuals 
absorb UV rays, which will inhibit vitamin D synthesis. In contrast, a traditional 
Asian diet in Japan contains oily fish, which is a rich source of vitamin D. This could 
cause the low risk of prostate cancer in Japanese men living in Japan. There is also 
evidence for an inverse relationship between UVR exposure and vitamin D levels and 
other diseases, such as type 1 diabetes, multiple sclerosis and arthritis (175-177).  
 
This study is a novel approach in the current methods of case control analyses, due to 
the comparison of four distinct groups. The results showed little difference when the 
case group was prostate cancer or the high PSA cases. Following these results, PSA 
could potentially be used as an intermediate marker for prostate cancer, and where 
cancer cases are difficult to recruit, high PSA cases could be used as an alternative.  
 
The data are mostly consistent with previous findings, and are therefore compatible 
with the hypothesis that low levels of active vitamin D increase prostate cancer risk. 
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However the public health implications of UVR exposure are important therefore 
these data should be interpreted with caution. Although high levels of sun exposure 
have a consistently protective effect, the risk of skin cancer will also increase (178). A 
controlled level or pattern of UVR exposure or perhaps increased dietary intake that 
results in sufficient synthesis of vitamin D is required that does not increase risks for 
skin cancer.  
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CHAPTER 4  
IS PHYSICAL ACTIVITY ASSOCIATED 
WITH PROSTATE CANCER? 
 
 
 
 
 
 
 
 
 
 
 
 
  
96 
 
Table 4.1 presents key study characteristics and physical activity behaviour (for the 
oldest age category; from 40 years to diagnosis/entry into the study) for the prostate 
cancer cases, high PSA cases, hospital controls and healthy population controls.  
Overall, prostate cancer cases were older than the two control groups (p<0.001).  
They also had a statistically significant higher percentage of family history of prostate 
compared to population controls but not for the hospital controls. In terms of the 
number of hours engaged in the different types of physical activity only participation 
in social sport was significantly different overall (highest non-participation in social 
sport) (p=0.02).  This trend was consistent across all the three age groups (data not 
shown). 
 
The ORs and 95% CIs for the number of hours per week engaged in the different 
physical activities from the age of 40 onwards for prostate cancer cases compared 
with combined control groups are shown in Table 4.2. Although an inverse 
association was observed for participants who had ever cycled, ever taken part in 
social sport and higher levels of housework, they were not statistically significant. 
Increased risks were observed for high levels (>10 hours per week) of walking (OR 
1.42; 95% CI 0.69 – 1.65; p trend = 0.63), medium levels (5 – 9 hours per week) of 
gardening (OR 1.29; 95% CI 0.68 – 2.43; p trend = 0.72) and participation of 
competitive sport (OR 1.41; 95% CI 0.95 – 2.09; p trend = 0.09). 
 
Table 4.3 shows the results of the combined cases and controls when a low versus 
high PSA comparison is made. Although no statistically significant associations were 
observed, similar results were observed for cycling (OR 0.90; 95% CI 0.64 – 1.27; p 
value = 0.55), medium levels of housework (OR 0.84; 95% CI 0.40 – 1.77; p trend = 
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0.83). Increased risks were again associated with walking (OR 1.57; 95% CI 0.87 – 
2.83; p trend = 0. 23), medium levels (5 – 9 hours per week) of gardening (OR 1.29; 
95% CI 0.76 – 2.19 p trend = 0.58) and participation of competitive sport (OR 1.29; 
95% CI 0.93 – 1.78; p trend = 0.13). These effects remained when controlled for 
testosterone levels. 
 
Table 4.4 presents the results after stratification by severity of disease. Although 
statistical significance was not achieved, some of the effect estimates were in the 
same direction. The associations for participants who had ever cycled, level of 
housework and participation in competitive sport produced consistent results with 
table 4.3. In general, more similar associations were observed for advanced tumours, 
indicating physical activity has a similar effect on advanced carcinogenesis as normal 
disease progression. 
 
When the results were repeated for the younger two age groups (combined cases vs. 
combined controls; 12-19 years and 20-39 years) a statistically significant inverse 
association for participating in social sport between the ages of 20-39 years (p=0.02). 
This association also gave a borderline significant result in 12-19 years (p=0.07) (see 
appendix table). 
 
No potential association or trend was observed when the intensity of the combined 
activities was assessed in terms of METs for this age category (low: 6-30; medium 
31-51, high ≥51.5 METs) (data not shown). 
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Table 4.1 Study sample characteristics for physical activity – Results from the Birmingham Prostatic Neoplasms Association Study 
Variable Prostate Cancer Cases High PSA cases Hospital Controls Population Controls 
Age 67.9 (8.0) 64.7 (7.6) 65.7 (8.5) 64.6 (9.3) 
Ethnicity 
White 
Non-White 
 
238 (96%) 
9 (4%) 
 
275 (91%) 
27 (9%) 
 
132 (89%) 
16 (11%) 
 
161 (94%) 
10 (6%) 
Ever-smoker 
No 
Yes 
 
109 (44%) 
136 (56%) 
 
141 (47%) 
162 (53%) 
 
67 (45%) 
82 (55%) 
 
50 (30%) 
119 (70%) 
Family History 
Prostate Cancer 
No 
Yes 
 
 
214 (86%) 
34 (14%) 
 
 
277 (91%) 
26 (9%) 
 
 
132 (87%) 
20 (13%) 
 
 
160 (95%) 
8 (5%) 
Education 
Early leaver 
High School Cert 
Trade/Diploma 
University degree 
 
88 (35%) 
44 (18%) 
57 (23%) 
61 (24%) 
 
74 (24%) 
61 (20%) 
73 (24%) 
98 (32%) 
 
44 (29%) 
18 (12%) 
45 (29%) 
47 (31%) 
 
53 (31%) 
38 (22%) 
49 (29%) 
31 (18%) 
BMI 27.0 (4.1) 26.8 (3.8) 26.8 (4.3) 27.5 (4.6) 
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Table 4.2: Odds Ratios and 95% Confidence intervals for physical activity comparing combined controls and prostate cancer case 
group: Results from the Birmingham Prostatic Neoplasms Association Study 
 Combined Controls Prostate cancer Cases Non Adjusted Adjusted Adjusted p value or  
 n (%) n (%) OR OR* 95%CI p trend§ 
Walking hours per week       
Low (Never – 4) 225 (67.8) 173 (65.3) 1 1     
Medium (5-9) 80 (24.1) 69(26.0) 1.12 1.07 0.69 - 1.65   
High (≥10) 27 (8.1) 23 (8.7) 1.11 1.42 0.69 - 2.90 0.63§ 
Cycling hours per week             
Never 203 (66.8) 168 (72.1) 1 1     
Ever 101 (33.2) 65 (27.9) 0.78 0.85 0.55 - 1.30 0.45 
Gardening hours per week             
Low (Never – 4) 292 (89.3) 227 (88.0) 1 1     
Medium (5-9) 32 (9.8) 28 (10.9) 1.13 1.29 0.68 - 2.43   
High (≥10) 3 (0.9) 3 (1.1) 1.29 0.9 0.18 - 4.59 0.72§ 
Housework hours per week             
Low (Never – 4) 291 (93.3) 232 (95.1) 1 1     
Medium (5-9) 19 (6.1) 11 (4.5) 0.73 0.63 0.23 - 1.73   
High (≥10) 5 (0.6) 1 (0.4) 0.25 0.4 0.06 - 2.50 0.42§ 
Social Sport hours per week             
Never 191 (62.6) 151 (66.8) 1 1     
Ever 114 (37.4) 75 (33.2) 0.83 0.75 0.49 - 1.15 0.18 
Competitive Sport hours per week             
Never 204 (66.2) 133 (57.1) 1 1     
Ever 104 (33.8) 100 (42.9) 1.47 1.41 0.95 - 2.09 0.09 
       
* Adjusted for age at diagnosis, family history of prostate cancer, ethnicity, education, ever smoker and BMI  § P trend  
Combined controls = hospital controls + population controls 
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Table 4.3: Odds Ratios and 95% Confidence intervals for physical activity comparing combined controls and combined case group: 
Results from the Birmingham Prostatic Neoplasms Association Study 
 
 Combined Controls Combined Cases Crude Adjusted p value or  Adjusted p value or  
 n (%) n (%) OR OR* (95% CI) p trend§ OR**95%CI p trend§ 
Walking hours per week        
Low (Never – 4) 225 (67.8) 387 (66.8) 1 1    1   
Medium (5-9) 80 (24.1) 140 (24.2) 1.02 1.09 (0.75 - 1.57)   0.85 (0.54 – 1.32   
High (≥10) 27 (8.1) 52 (9.0) 1.12 1.57 (0.87 - 2.83) 0.32§ 1.73 (0.86 – 3.51) 0.19§ 
Cycling hours per week               
Never 203 (66.8) 356 (69.3) 1 1    1   
Ever 101 (33.2) 158 (30.7) 0.89 0.9 (0.64 - 1.27) 0.55 0.88 (0.59 – 1.31) 0.53 
Gardening hours per week               
Low (Never – 4) 292 (89.3) 501 (88.4) 1 1    1   
Medium (5-9) 32 (9.8) 57 (10.1) 1.04 1.29 (0.76 - 2.19)   1.31 (0.67 – 2.56)   
High (≥10) 3 (0.9) 9 (1.5) 1.75 1.4 (0.35 - 5.57) 0.58§ 1.60 (0.33 – 7.91) 0.63§ 
Housework hours per week               
Low (Never – 4) 291 (93.3) 505 (93.5) 1 1    1   
Medium (5-9) 19 (6.1) 27 (5.0) 0.82 0.84 (0.40 - 1.77)   1.13 (0.45 – 2.83)   
High (≥10) 5 (0.6) 8 (1.5) 0.92 1.26 (0.40 - 3.94) 0.83§ 1.43 (0.41 – 5.02) 0.83§ 
Social Sport hours per week               
Never 191 (62.6) 307 (61.8) 1 1    1   
Ever 114 (37.4) 190 (38.2) 1.04 0.96 (0.69 - 1.34) 0.82 0.84 (0.55 – 1.28) 0.43 
Competitive Sport hours per week               
Never 204 (66.2) 201 (66.3) 1 1    1   
Ever 104 (33.8) 102 (33.7) 1.32 1.29 (0.93 - 1.78) 0.13 1.08 (0.73 – 1.59) 0.70 
* Adjusted for age at diagnosis, family history of prostate cancer, ethnicity, education, ever smoker and BMI    
** Adjusted for age at diagnosis, family history of prostate cancer, ethnicity, education, ever smoker, BMI and testosterone summary score 
Combined cases = prostate cancer cases + high PSA cases     
Combined controls = hospital controls + population controls    § P trend 
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Table 4.4: Odds Ratios and 95% Confidence intervals for physical activity after stratification for severity of disease - Results from the 
Birmingham Prostatic Neoplasms Association Study 
 
 Localised   Advanced   
 Adjusted OR* (95% CI) p value Adjusted OR* (95% CI) p value 
 Localised   Advanced   
Walking hours per week     
Low (Never – 4) 1  1   
Medium (5-9) 0.98 (0.69 - 1.38) 0.9 1.10 (0.77 - 1.94) 0.63 
High (≥10) 1.14 (0.77 - 1.94) 0.64 1.70 (0.92 - 3.13) 0.09 
Cycling hours per week         
Never 1   1   
Ever 0.96 (0.69 - 1.32) 0.79 0.93 (0.65 - 1.33) 0.7 
Gardening hours per week         
Low (Never – 4) 1   1   
Medium (5-9) 0.99 (0.60 - 1.62) 0.79 1.35 (0.79 - 2.33) 0.28 
High (≥10) 2.11 (0.55 - 8.06) 0.27 1.30 (0.28 - 5.96) 0.74 
Housework hours per week         
Low (Never – 4) 1   1   
Medium (5-9) 0.86 (0.45 - 1.63) 0.64 0.86 (0.45 - 1.63) 0.64 
High (≥10) 1.08 (0.34 - 3.42) 0.9 1.08 (0.34 - 3.42) 0.9 
Social Sport hours per week         
Never 1   1   
Ever 1.04 (0.76 - 1.43) 0.79 1.11 (0.78 - 1.57) 0.57 
Competitive Sport hours per week         
Never 1   1   
Ever 1.20 (0.88 - 1.65) 0.26 1.33 (0.95 -1.87) 0.1 
* Adjusted for age at diagnosis, family history of prostate cancer, ethnicity, education, ever smoker and BMI 
Localised Gleason score between 2 and 6  Advanced Gleason between 7 and 10 
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Conclusion 
Although no strong significant associations were detected, there are indications for 
either direction. A consistent reduced risk of prostate cancer was observed for men 
who ever cycled in all analyses. This was also true for associations in the 12-19 and 
the 20-39 years age category.  
 
Conversely, ever having played competitive sports was associated with increased risk 
of prostate cancer among all comparison groups, including for both localised and 
advanced tumours and when adjusted for testosterone levels, therefore the results 
cannot be explained by testosterone. Five or more hours of housework per week 
appeared to be protective. High levels or ever participating in lower intensity type 
activities, such as walking or gardening appeared to be inversely associated with the 
odds of prostate cancer in most comparison groups. Although housework would be 
considered to be a low intensity type of physical activity, men who were classified in 
the highest category for this (i.e. 10 or more hours per week) were potentially at 
increased risk of prostate cancer. 
 
The results remain similar for all case control comparisons (see appendix tables), 
therefore it can be concluded that physical activity has the same effect on prostate 
cancer and men with high PSA. This serves as further proof, along with previous 
chapters, that this group of men with high PSA levels could be used instead of or in 
conjunction with confirmed prostate cancer cases. 
 
The results do not fully support the hypothesis that high levels of all physical activity 
protect against prostate cancer. The type of activity was distinguished into two 
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categories; low intensity (including activities such as walking, gardening and 
housework) and high intensity (such as cycling, social sport and competitive sport). 
When categorized, high levels of low intensity activity were generally found to have 
an increased risk and participants who had ever taken part in high intensity activity 
generally had a decreased risk.  
 
In this context, the results are consistent with previous studies. Vigorous activity is 
known to be associated with reduced risk of advanced disease (70, 179). When 
corrected for testosterone, the results were not altered; therefore other biological 
pathways could be involved. The main mechanism of physical activity is via insulin 
and insulin-like growth factor (IGF). IGF and insulin binding is involved in cell 
proliferation, differentiation, apoptosis and angiogenesis (180). Vigorous exercise 
also increases sensitivity of insulin and lowers inflammatory factors and increases 
anti-inflammatory cytokines (181-183). It is difficult to pinpoint a specific biological 
mechanism as exercise can simultaneously affect multiple biological pathways. The 
potential biomarkers that are currently known include insulin and IGF-1, mentioned 
previously, also leptin, tumour necrosis factor-alpha (TNF-α) and vitamin D. Their 
role in increasing cell proliferation and decreasing apoptosis is known; however they 
may be involved in several other pathways causing an additional indirect effect on 
prostate carcinogenesis.  
 
A limitation to this study is selection bias. Men who are healthier and are more 
physically active may be more likely to attend prostate cancer testing than less active 
men. Also, the slow growing nature of a prostatic tumour means more men will die 
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with undiagnosed prostate cancer, and these patients may be incorrectly categorized 
as control patients. 
 
In conclusion, physical activity is an important risk factor in reducing prostate cancer 
risk. There is increasing evidence emerging for underlying biological mechanisms 
involved. The study reported a protective effect associated with high intensity 
physical activity levels. However a contrasting increased risk associated with low 
intensity exercise, such as walking and gardening is observed. The associations were 
similar in all case control comparisons, further supporting the use of high PSA cases. 
These results warrant further study on the effect of physical activity, especially at 
different intensities. Future studies should also investigate the multi faceted effect on 
biomarkers, for example how low insulin levels and inflammatory markers are related 
to prostate cancer. Genetic subtypes could also be analysed, to investigate individual 
responses to biomarkers at different levels of physical activity. 
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CHAPTER 5 
IS BODY SIZE ASSOCIATED WITH 
PROSTATE CANCER? 
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The study sample characteristics in relation to obesity can be found in Table 5.1 
including waist circumference, BMI and self perceived body size categories. The 
numbers for self perceived obese men at age 20 and 30 were very small; these were 
later combined into one overweight group for analysis. 
 
Table 5.2 shows the results for waist circumference and adult weight change. 
Interestingly, a statistically significant protective effect was observed for a large waist 
circumference; however the risk did not differ as circumference increased. An 
increasing risk was detected as adult weight change increased, however none of the 
estimates was statistically significant. Interestingly an increased risk was also 
associated with adult weight loss (OR 1.44; 95%CI 0.57 – 3.63). This trend continued 
when weight change from different ages (such as weight change from age 20 to age 
30 and from age 20 to age 40) was calculated (data not shown). 
 
Table 5.3 shows results for actual and self reported body size at different ages over 
lifetime. A protective effect was associated with men defined as overweight by the 
WHO guidelines, however an increased risk was observed in obese men. Although 
this result was in contrast with previous studies, it is consistent with the results for self 
perceived body size at different ages. In these analyses, a lower risk is associated with 
a BMI of between 25.0 and 29.99 and an increased risk is observed for a BMI of 30 or 
over. The most interesting result was detected for men at age 20, a highly significant 
increased risk was detected for obese men, using the BMI measures (OR 1.84; 95% 
CI 1.23 – 2.75).  
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Table 5.4 shows the results stratified by stage of disease. Most effect estimates were 
in the same direction as previous analyses, there was a consistent decreased risk 
associated with waist circumference for both overweight and obese men, and this was 
statistically significant. There was an interesting observation for the current BMI. 
Instead of a decreased risk associated in overweight men and an increased risk 
associated with the obese, the risk of localised disease was decreased for both 
overweight and obese groups (OR 0.90/0.98; 95%CI 0.63 – 1.28/0.68 – 1.41). The 
risk of advanced disease had an increased risk for both groups, although this was only 
marginal in overweight men (OR 1.01/1.20; 95% CI 0.71 – 1.45/0.84 – 1.72). 
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Table 5.1 Study Sample Characteristics from The Birmingham Prostatic Neoplasms Association Study 
Variable Prostate Cancer Cases (n 314)  High PSA Cases (n 381)  Hospital Controls (n 201) Population Controls (n 175)  
BMI age 20                                             Underweight 85 108 52 23 
Normal  61 63 30 35 
Overweight 16 22 12 13 
Obese  45 72 37 8 
BMI age 30                                             Underweight 51 57 33 18 
Normal  164 181 86 99 
Overweight  53 64 41 45 
Obese 46 79 41 13 
BMI age 40                                             Underweight 174 189 88 80 
Normal  73 68 45 55 
Overweight  25 52 28 30 
Obese  42 72 40 10 
BMI current age                                      Underweight  3 2 2 0 
Normal  77 86 44 49 
Overweight  97 131 63 78 
Obese  137 162 92 48 
Self perceived body size age 20              Underweight  44 63 25 32 
Normal  152 157 99 84 
Overweight  68 82 42 56 
Obese  6 3 0 1 
Self perceived body size age 30              Underweight  6 14 4 7 
Normal  119 133 74 71 
Overweight  139 150 87 91 
Obese  4 7 2 4 
Self perceived body size age 40              Underweight  1 2 2 3 
Normal  62 90 36 36 
Overweight  194 188 116 126 
Obese  13 26 13 8 
Self perceived body size current age      Underweight  4 7 4 1 
Normal  25 39 18 21 
Overweight  166 197 105 104 
Obese 77 63 41 44 
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Table 5.2 Odds Ratios and 95% Confidence intervals for waist circumference and weight loss over time - Results from The Birmingham 
Prostatic Neoplasms Association Study 
 
Variable Combined controls n Prostate cancer cases n Crude OR Adjusted  OR* Adjusted* 95%CI P value 
Waist Circumference (cm)       
<34.0 147 158 1 1   
34.1 - 37.0 85 57 0.62 0.6 0.40 - 0.92  
≥37.1 128 91 0.66 0.64 0.44 - 0.93 0.02
§
 
       
Adult weight change categorical (kg)       
≥ 5 kg weight loss 13 12 1.46 1.44 0.57 – 3.63 0.44 
≤5 kg Weight loss and ≤5 kg weight gain  41 26 1 1   
≤15 kg weight gain 109 72 1.04 1.04 0.58 – 1.88 0.89 
≤25 kg weight gain 75 49 1.03 1.12 0.61 – 2.09 0.70 
≤45 kg weight gain 37 30 1.28 1.31 0.65 – 2.65 0.45 
 
 
 
* Adjusted for age at diagnosis, ethnicity, family history of prostate cancer and testosterone summary score  
§ 
P trend   Combined controls = hospital controls + population controls  
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Table 5.3: Odds Ratios and 95% Confidence intervals for actual and self reported BMI for different age categories - Results from The 
Birmingham Prostatic Neoplasms Association Study 
 
 
*Adjusted for age at diagnosis, ethnicity, family history of prostate cancer and testosterone summary score  
  
 
 
  
 
 
 
 
 
Variable OR* (95% CI)  P trend OR* (95% CI)  P trend OR* (95% CI)  P trend OR* (95% CI)  P trend 
Age (years) 20   30  40  50   
BMI         
Underweight (<18.4) 0.51 (0.19 – 1.39)  1.09 (0.75 – 1.60)  1.49 (1.09 – 2.05)  1.24 (0.24 – 6.48)  
Normal (18.5 – 24.99) 1.00  1.00  1.00  1.00  
Overweight (25.0 – 
29.99) 
0.91 (0.54 – 1.53)  0.73 (0.52 – 1.02)  0.95 (0.62 – 1.46)  0.94 (0.67 – 1.30)  
Obese (≥30) 1.84 (1.23 – 2.75) 0.001 0.96 (0.58 – 1.59) 0.24 1.11 (0.62 – 1.99) 0.03 1.13 (0.80 – 1.60) 0.68 
         
Self perceived body size         
Underweight (<18.4) 0.89 (0.56 – 1.41)  0.56 (0.19 – 1.59)  0.28 (0.07 – 1.19)  1.29 (0.41 – 4.09)  
Normal (18.5 – 24.99) 1.00  1.00  1.00  1.00  
Overweight (25.0 – 
29.99) 
0.93 (0.64 – 1.36) 0.85 0.96 (0.69 – 1.35) 0.57 0.76 (0.55 – 1.06)  1.09 (0.71 – 1.69)  
Obese (≥30)     0.93 (0.51 – 1.71) 0.17 1.04 (0.64 – 1.68) 0.95 
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Table 5.4: Odds Ratios and 95% Confidence intervals for obesity stratified by severity of disease - Results from The Birmingham 
Prostatic Neoplasms Association Study 
 
Variable Localised  Advanced  
Waist Circumference (cm) Adjusted OR* (95% CI) p value Adjusted OR* (95% CI) p value 
<34.0 1  1  
34.1 - 37.0 0.65 (0.45 - 0.94) 0.02 0.66 (0.46 - 0.96) 0.03 
≥37.1 0.62 (0.44 - 0.86) 0.005 0.63 (0.46 - 0.88) 0.006 
Self perceived body size age 20     
18.5 - 24.99 1  1  
25.0 - 29.99 0.87 (0.63 - 1.20) 0.4 0.89 (0.65 - 1.22) 0.48 
≥30.0 4.66 (0.55 - 39.67) 0.16 4.45 (0.55 - 35.86) 0.16 
Self perceived body size age 30     
18.5 - 24.99 1  1  
25.0 - 29.99 0.85 (0.64 - 1.14) 0.29 0.97 (0.73 - 1.30) 0.86 
≥30.0 1.08 (0.38 - 3.11) 0.88 1.17 (0.41 - 3.38) 0.77 
Self perceived body size age 40     
18.5 - 24.99 1  1  
25.0 - 29.99 0.68 (0.49 - 0.95) 0.02 0.80 (0.57 - 1.12) 0.2 
≥30.0 0.90 (0.48 - 1.69) 0.75 1.03 (0.55 - 1.92) 0.94 
Self perceived body size current age     
18.5 - 24.99 1  1  
25.0 - 29.99 0.94 (0.62 - 1.45) 0.79 1.03 (0.67 - 1.58) 0.91 
≥30.0 0.80 (0.49 - 1.31) 0.38 0.94 (0.58 - 1.53) 0.81 
Current BMI     
18.5 - 24.99 1  1  
25.0 - 29.99 0.90 (0.63 - 1.28) 0.56 1.01 (0.71 - 1.43) 0.95 
≥30.0 0.98 (0.68 - 1.41) 0.92 1.20 (0.84 - 1.72) 0.32 
 
*Adjusted for age at diagnosis, ethnicity, family history of prostate cancer and testosterone summary score  
Localised Gleason scores between 2 and 6
 
Advanced Gleason score between 7 and 10 
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Conclusion 
A statistically significant increased risk was associated with a BMI classified as obese 
at age 20; however this effect seemed to disappear with age. This suggests that obesity 
at an early age has a real impact on the risk of prostate cancer later in life. The effect 
of body size in early life could either be on prostate carcinogenesis, or even PSA 
levels. Risk of prostate cancer increased with increasing adult weight change; 
however this was also true for adult weight loss. This was one of the few studies 
looking at a lifetime history of obesity so it can be concluded that in this study 
sample, obesity at an early age has a significant effect on the risk of prostate cancer 
and high PSA. Different associations for waist circumferences and BMI were 
observed; the risk of disease actually decreases with an increasing circumference. A 
recent review by Browning et al reported waist circumference to be a better predictor 
for cardiovascular disease more often that BMI (184). Larger waist circumference is 
used as a measure of central fat distribution, which is known to be more common in 
men. A further study by Pi-Sunyer reports this type of fat distribution to have a 
biological mechanism relating to increased lipolysis, which could have a direct effect 
on the risk of type 2 diabetes mellitus and cardiovascular disease (106). It could be 
that the proposed mechanism has a protective effect in prostate carcinogenesis in 
some way; however this has not been further investigated. It can therefore be 
concluded that waist circumference cannot be used instead of BMI as a measure for 
obesity in prostate studies. The problems of BMI as a measure are limited to high lean 
body mass and large framed subjects. However these individuals only constitute a 
relatively small proportion of most populations, therefore we can assume BMI is a 
relatively accurate measure (96). Our inclusion of the pictogram (Figure 5.1) allows 
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the differentiation of fat distributions. Where BMI is lacking as a measure of obesity, 
the pictogram compensates by differentiating distribution of body fat.  
 
Generally a decreased risk was associated with overweight men and a positive 
association was observed in obese men. This was true for both BMI and self perceived 
body size and in all other analyses (see appendix 6), therefore it can be concluded that 
obesity has the same effect on prostate cancer and men with high PSA. The self 
perceived body image was used as a tool for estimating BMI at different ages. 
Although the results for current self perceived body image were similar to actual 
BMI, the t test gave a statistically significant p value, meaning the two measures are 
not comparable. This result supports the use of the self perceived visual stimuli in 
addition to actual measures, which takes into account fat distributions. 
 
The actual BMI was calculated from the height and weight measure reported by the 
patient. Although this is still self reported, patients recruited in the hospital had their 
weight and height measured by the clinic nurse just minutes before they completed the 
questionnaire, therefore it can be assumed that the measures are fairly accurate, with 
perhaps just a small degree of error. Adult weight gain did not have a significant 
association with prostate cancer in this sample. A recent study in Japan by Mori et al 
reported a highly significant increased risk associated with adult weight gain and 
prostate cancer in men, specifically for a weight gain of 10 – 14.9 kg (185). Incidence 
patterns vary greatly between the UK and Japan, so this could be an important factor 
to explain the differences. Another study by Hernandez et al actually observed a 
decreased risk associated in Japanese men in Hawaii and California, but an increased 
risk for weight gain in African American men in the same cohort (186). Differences in 
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ethnicity cause differences in accumulation of body fat, particularly in adipose tissue 
around the abdominal region (187-189). This could explain the conflicting results for 
adult weight gain in the various studies, including this one. 
 
After stratification according to severity of disease the results support the general idea 
that obesity could reduce the risk of localised disease, yet at the same time, increase 
the risk of advanced disease. Previous studies have confirmed obesity can play a role 
in aggressiveness of tumours, causing higher stage and grade of tumours and 
sometimes increase the risk of recurrence (190-191). As previously discussed, obesity 
can reduce PSA levels, causing early stages of cancer to go undetected. Also the other 
hormonal factors affected by obesity, such as steroid hormones, adipokines and 
inflammatory mediators could have a biological mechanism on prostate 
carcinogenesis (190).  
 
In summary, waist circumference was negatively associated with prostate cancer in 
this sample and obesity at a younger age increased the risk of disease. When obesity 
over lifetime was investigated, the risk was usually lower for men described as 
overweight and higher for obese men. The associations were similar in all case control 
comparisons, further supporting the use of high PSA cases. Although the results 
confirm the findings of most previous studies, further research into the complex 
association is required to fully elucidate the biological action of obesity on prostate 
carcinogenesis. 
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CHAPTER 6 
IS OCCUPATION ASOCIATED WITH 
PROSTATE CANCER? 
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After exclusion of non original results (such as editorials, comments and reviews) 43 
abstracts remained. A further 10 abstracts were identified from references lists of 
publications. Of the 53 publications retrieved, 17 met the inclusion criteria and were 
extracted for meta-analysis (Table 6.1). Most of the studies were conducted in 
Western countries; ten in the USA (78, 119, 121, 123-124, 192-196), five in Europe 
(117, 197-200), one in Japan (201) and one in New Zealand (202). In total, 7, 762 
cases and 20, 634 controls were analysed. 
 
None of the associations in the meta analysis was statistically significant. When 
analysing the occupations by their major classification (Table 6.2), decreased risks 
(SOR below 1) were found for personal service occupations (SOR 0.85; 95%CI 0.33 – 
2.20), process, plant and machine operatives (SOR 0.94; 95%CI 0.72 – 1.23) and 
elementary occupations (SOR 0.91; 95%CI 0.59 – 1.39). When classifying by sub 
major occupations (Table 6.3), an increased risk was associated (SOR above 1.2) with 
agriculture managers (SOR 1.23; 95%CI 0.88 – 1.79), teaching and research 
professionals (SOR 3.18; 95%CI 0.51 – 19.82), secretarial and related occupations 
(SOR 1.33; 95%CI 0.74 – 2.39), customer service occupations (SOR 1.39; 95%CI 
0.82 – 2.38) and elementary administration and service occupations (SOR 1.35; 
95%CI 0.31 – 5.83). A decreased risk was associated with corporate managers (SOR 
0.74; 95%CI 0.49 – 1.13), health and social welfare professionals (SOR 0.78; 95%CI 
0.24 – 2.58), process, plant and machine operatives (SOR 0.83; 95%CI 0.57 – 1.21) 
and elementary trades, plant and storage related occupations (SOR 0.91; 95%CI 0.56 
– 1.5). The minor occupational group analysis (Table 6.4) showed increased risks 
associated with secretarial and related occupations (SOR 1.33; 95%CI 0.74 – 2.39), 
construction trades (SOR 1.27; 95%CI 0.69 – 2.35), customer service occupations 
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(SOR 1.39; 95%CI 0.82 – 2.38) and elementary personal service occupations (SOR 
1.35; 95%CI 0.31 – 5.83). A decreased risk was associated with functional managers 
(SOR 0.79; 95%CI 0.56 – 1.12), government related administrative occupations (SOR 
0.89; 95%CI 0.58 – 1.36), electrical trades (SOR 0.66; 95%CI 0.29 – 1.51), sales 
assistant and retail cashiers (SOR 0.88; 95%CI 0.42 – 1.80), elementary agricultural 
occupations (SOR 0.67; 95%CI 0.29 – 1.51) and elementary construction occupations 
(SOR 0.76; 95%CI 0.35 – 1.65). 
 
Study design and country were examined as potential causes of heterogeneity 
however no significantly decreased P values for interaction were observed. There was 
no strong evidence for publication bias as funnel plots of the relative risk estimates 
showed no clear asymmetry for studies. 
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Table 6.1: Publications included for meta-analysis on occupation and prostate cancer 
 
AUTHOR REFERENCE LOCATION PUBLICATION 
DATE 
STUDY DESIGN 
ERNSTER (119) USA 1979 CASE CONTROL 
PEARCE (202) NEW ZEALAND 1987 CASE CONTROL 
BROWNSON (192) USA 1988 CASE CONTROL 
YU (193) USA 1988 CASE CONTROL 
OISHI (201) JAPAN 1989 CASE CONTROL 
LE MARCHAND (78) USA 1990 CASE CONTROL 
VAN DER GULDEN (197) NETHERLANDS 1992 CASE CONTROL 
HIATT (194) USA 1994 NESTED CASE CONTROL 
VAN DER GULDEN (117) NETHERLANDS 1995 CASE CONTROL 
ANDERSSON (198) SWEDEN 1996 CASE CONTROL 
ARONSON (195) USA 1996 CASE CONTROL 
EWINGS (199) UK 1996 CASE CONTROL 
KRSTEV (203) USA 1998 CASE CONTROL 
BAND (123) USA 1999 CASE CONTROL 
PARKER (121) USA 1999 COHORT 
SANDERSON (196) USA 2004 CASE CONTROL 
ZEEGERS et al (200) NETHERLANDS 2004 NESTED CASE CONTROL 
 
 
 
 
 
 
 
 
 
 
  
119 
 
Table 6.2: Summary odds ratios for prostate cancer associated with major group classifications 
 
Major Group SOC 2000 Code [20] SOR (95% CI) Number of studies (reference) 
Managers and senior officials 1 1.01 (0.82 – 1.23) 4 (78, 117, 123, 202)  
Professional occupations 2 1.06 (0.84 – 1.03) 4 (117, 123, 194, 200) 
Associate professional and technical occupations 3 1.02 (0.88 – 1.19) 5 (123, 195, 200, 202-203) 
Administrative and secretarial occupations 4 1.11 (0.92 – 1.34) 6 (78, 117, 123, 195, 200, 203) 
Skilled trades occupations 5 1.09 (0.95 – 1.25) 5 (117, 123, 194-195, 200) 
Personal service occupations 6 0.85 (0.33 – 2.20) 2 (194, 202) 
Sales and customer service occupations 7 1.01 (0.79 – 1.29) 5 (78, 123, 200, 202-203) 
Process, plant and machine operatives 8 0.94 (0.72 – 1.23) 4 (78, 117, 123, 200) 
Elementary occupations 9 0.91 (0.59 – 1.39) 5 (78, 117, 194, 200, 202) 
 
 
 
SOR = summary odds ratio for major group occupation ever held 
95%CI = 95% confidence interval 
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Table 6.3: Summary odds ratios for prostate cancer associated with sub major group classifications 
 
Sub major group SOC 2000 Code (169) SOR (95% CI) Number of studies (reference) 
Corporate managers 11 0.74 (0.49 – 1.13) 2 (123, 202) 
Managers and proprietors in agriculture and services 12 1.25 (0.88 – 1.79) 2 (123, 202) 
Science and technology professionals 21 1.03 (0.70 – 1.51) 3 (123, 194, 200) 
Teaching and research professionals 23 3.18 (0.51 – 19.82) 3 (117, 123, 200) 
Business and public service professionals 24 1.08 (0.69 – 1.71) 2 (117, 123) 
Health and social welfare associate professionals 32 0.78 (0.24 – 2.58) 2 (123, 203) 
Protective service occupations 33 1.05 (0.84 – 1.31) 4 (123, 195, 200, 202) 
Business and public service associate professionals 35 0.94 (0.76 – 1.16) 2 (123, 202) 
Administrative occupations 41 1.07 (0.88 – 1.31) 4 (117, 123, 200, 203) 
Secretarial and related occupations 42 1.33 (0.74 – 2.39) 2 (123, 195) 
Skilled agricultural trades 51 1.17 (0.97 – 1.41) 4 (117, 123, 195, 200) 
Skilled metal and electrical trades 52 1.02 (0.77 – 1.34) 4 (117, 123, 195, 200) 
Skilled construction and building trades 53 1.09 (0.85 – 1.378) 4(117, 123, 195, 200) 
Textiles, printing and other skilled trades 54 1.01 (0.73 – 1.78) 4 (117, 123, 195, 200) 
Sales occupation 71 1.04 (0.79 – 1.36) 4 (123, 200, 202-203) 
Customer service occupations 72 1.39§  (0.82 – 2.38) 2 (78, 198) 
Process, plant and machine operatives 81 0.83 (0.57 – 1.21) 2 (123, 200) 
Elementary trades, plant and storage related occupations 91 0.91 (0.56 – 1.47) 4 (117, 194, 200, 202) 
Elementary administration and service occupations 92 1.35 (0.31 – 5.83) 2 (117, 202) 
 
 
SOR = summary odds ratio for sub major occupation ever held  95%CI = 95% confidence interval 
SOR§ = summary odds ratio for longest held occupation (when ever held occupation was not available) 
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Table 6.4: Summary odds ratios for prostate cancer associated with minor group classifications 
Minor Group SOC 2000 Code (169) SOR (95% CI) Number of studies (reference) 
Functional Managers 113 0.79 (0.56 – 1.12) 2 (123, 202) 
Managers in farming, horticulture, forestry and fishing 121 1.01§ (0.50 – 2.06) 2 (78, 198) 
Science professionals 211 0.99 (0.55 – 1.77) 2 (123, 200) 
Engineering professionals 212 0.95§ (0.19 – 4.87) 2 (123, 201) 
Teaching professionals 231 1.02 (0.69 – 1.50) 3 (117, 123, 200) 
Protective service occupations 331 1.05 (0.84 – 1.31) 4 (123, 195, 200, 202) 
Sales and related associate professionals 354 0.94 (0.80 – 1.12) 2 (123, 202) 
Administrative: government and related 411 0.89 (0.58 – 1.36) 2 (117, 200) 
Administrative: general 415 1.05 (0.80 – 1.39) 2 (117, 203) 
Secretarial and related occupations 421 1.33 (0.74 – 2.39) 2 (123, 195) 
Agricultural trades 511 1.17 (0.97 – 1.41) 4 (117, 123, 195, 200) 
Metal forming, welding and related trades 521 0.97 (0.42 – 2.26) 3 (117, 123, 200) 
Vehicle trades 523 1.06 (0.86 – 1.30) 4 (117, 123, 195, 200) 
Electrical trades 524 0.66 (0.29 – 1.51) 4 (117, 123, 195, 200) 
Construction trades 531 1.27 (0.69 – 2.35) 3 (117, 123, 195) 
Building trades 532 1.11 (0.57 – 2.15) 3 (117, 123, 200) 
Textiles and garments trades 541 0.90 (0.45 – 1.81) 3 (123, 195, 200) 
Food preparation trades 543 1.05 (0.77 – 1.53) 4 (117, 123, 195, 200) 
Sales assistants and retail cashiers 711 0.88 (0.42 – 1.82) 3 (123, 200, 202) 
Sales related occupations 712 0.96 (0.64 – 1.43) 3 (123, 202-203) 
Customer service occupations 721 1.39§ (0.82 – 2.38) 2 (78, 198) 
Elementary agricultural occupations 911 0.67 (0.29 – 1.52) 2 (117, 202) 
Elementary construction occupations 912 0.76 (0.35 – 1.65) 2 (117, 200) 
Elementary personal service occupations 922 1.35 (0.31 – 5.83) 2 (117, 202) 
SOR = summary odds ratio for minor group occupation ever held  95%CI = 95% confidence interval 
SOR
§
 = summary odds ratio for longest held occupation (when ever held occupation was not available) 
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Conclusion 
This is the first meta-analysis on occupational groups which is based on a large total 
number of cases and controls. Although sufficient power exists to detect associations, 
no statistically significant associations for any job title were found.  
 
Despite the high number of studies and therefore large case control base, there are 
some limitations in the study. Some occupations were associated with a slightly 
increased risk, although not statistically significant. These small excess risks could be 
due to an unknown or known but unmeasured confounding factor. Publication bias 
was tested for in this meta analysis; however other types of bias could exist, such as 
selection bias or an incomplete search for publications. Pooling individual risk 
estimates into one summary odds ratio is also limiting, as heterogeneity of exposures 
is not taken into account. For example, subjects with the same job title might be 
exposed to different agents in different countries. In the pooling process, we assume 
the same job title will equate to the same type, duration and intensity of exposures. 
Some occupations with a previously identified increased risk, such as farmers and 
mechanics also showed an increased risk in the meta analysis. However metal workers 
were shown to have a decreased risk associated with the disease, in contrast to 
previous studies. This is perhaps due to the associations being a result of early studies 
which may not be representative of recent working conditions. 
 
The results suggested moderately increased and decreased risks associated for some 
occupations however none was statistically significant, despite the large sample size 
of this meta-analysis, therefore prostate cancer is most likely not an occupational 
disease. 
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CHAPTER 7 
IS 8q24 ASSOCIATED WITH PROSTATE 
CANCER? 
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After exclusion of subjects with missing data, 277 cases and 282 controls remained. 
There were no significant differences for age (Pcases=0.50, Pcontrols=0.50) and family 
history of prostate cancer (Pcases=0.95, Pcontrols=0.38). The mean age at baseline of 
cases was 63 years, which was higher than the mean age of the sub cohort (60 years). 
Only 4.13% of the combined sample had positive family history of prostate cancer. 
There was strong evidence for linkage disequilibrium between allele -10 of DG8S737 
and the A allele of the SNP (χ2=61.2, P<0.001). No deviations from Hardy Weinberg 
equilibrium were detected in controls for the frequency of alleles and genotypes for 
the microsatellite marker DG8S737 and the SNP rs1447295 (P=0.14).  
 
The main results for the genotypic and allelic associations are presented in Table 7.1. 
The DG8S737-8 allele was unexpectedly associated with a statistically significant 
decreased risk for prostate cancer (OR, 0.62; 95%CI, 0.40 – 0.96; P = 0.03). The 
increased frequency of the -10 allele among cases suggested an increased risk of 
disease, however it was not statistically significant (OR, 1.50; 95% CI, 0.88 – 2.55). 
The results of all alleles can be found in the appendix. The SNP analysis suggested an 
increase in the crude OR with the presence of allele A, (OR, 1.38; 95%CI, 0.94 – 
2.20), although this was also not statistically significant (P = 0.10). This remained the 
case for either one or two copies of allele A (OR, 1.40; P = 0.14 and OR, 1.54; P = 
0.48 respectively). The results were not considerably different after multivariable 
adjustment which could suggest an assumption of Mendelian randomisation can be 
made in this context (204). No influence was observed for TNM stage (data not 
shown). 
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Table 7.1 Crude and Multivariable adjusted odds ratios for rs1447295 and DG8S737 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted for age, alcohol intake from wine, body mass index (BMI), energy intake, family history of prostate cancer and level of education
 Alleles Cases (n) Controls (n) OR (95% CI) P Adjusted OR (95% CI) P 
rs1447295        
Allelic Association Allele A absent 318 346 1  1  
 Allele A present 142 114 1.38 (0.94 – 2.02) 0.10 1.39 (0.94 – 2.04) 0.10 
        
Genotypic Association C/C 224 196 1  1  
 A/C 53 64 1.40 (0.90 – 2.18) 0.14 1.41 (0.90 – 2.21) 0.14 
 A/A 4 7 1.54 (0.46 – 5.09) 0.48 1.56 (0.46 – 5.34) 0.48 
        
DG8S737        
Allelic Association Allele -8 absent 417 394 1  1  
 Allele -8 present 43 66 0.61 (0.39 – 0.94) 0.03 0.62 (0.40 – 0.96) 0.03 
        
 Allele -10 absent 417 430 1  1  
 Allele -10 present 43 30 1.50 (0.89 – 2.53) 0.13 1.50 (0.88 – 2.55) 0.13 
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Conclusion 
This analysis provided an interestingly significant decreased risk associated with 
allele -8 of the microsatellite marker. This is unlikely to be a result of population 
structure, due to the matching of cases and controls, the absence of apparent outliers 
and the relative genetic homogeneity of the Dutch population (205-206). The 
apparent protective effect is in contrast with the Amundadottir study (146). In the 
latter analysis, the associations of the -8 allele and the A allele of rs1447295 were 
detected in all of the Caucasian populations studied, however, they were not 
replicated in African American men. Since this population is more genetically 
diverse, Amundadottir et al concluded that the variant responsible for conferring the 
increased prostate cancer risk must be the DG8S737 -8 allele itself or be extremely 
close to it.  
 
However, the results of this analysis and those of Suuriniemi et al do not detect an 
association, which indicate that the allele itself may not be directly responsible for 
conferring increased prostate cancer risk (147). It is possible that DG8S737 and 
rs1447295 are tightly linked markers flanking the actual causative variant and that 
there may be potentially more than one high risk haplotype present in the Caucasian 
population. Wang et al observed a stronger association with the 8/A haplotype and 
familial prostate cancer, whereas the 10/A haplotype was most strongly associated 
with aggressive prostate cancer, which supports the Suuriniemi study (207). Future 
studies comparing more detailed haplotypes in this region could help to narrow this 
interval and enable identification of the actual causative variant. 
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8.1 General discussion 
This case control study was a novel approach for investigating prostate cancer, due to the 
categorization of groups. Instead of the traditional case control study design of prostate 
cancer cases versus healthy controls from the population, the associations at varying risk 
of the disease were investigated by comparing cancer cases, elevated PSA cases, hospital 
controls and healthy population controls. By analyzing between and within group 
differences, the use of PSA as a marker for prostate cancer could be assessed, and also 
whether there is a difference between the use of hospital based controls and the traditional 
population based controls. For each chapter, the same case control strategy was used for 
comparison (see Figure 8.1), however not all tables were presented. All additional analyses 
can be found in appendices 4 – 8. The effect of the variable of interest remained consistent 
when either prostate cancer cases or high PSA cases were used. It can therefore be 
concluded that for the factors studied in this thesis, the use of high PSA cases in 
epidemiological studies on prostate cancer could be useful, especially when prostate 
cancer cases are difficult to recruit. This also serves as further evidence for the use of PSA 
as marker for prostate cancer. The same was true for hospital based controls and 
population based controls. These groups were combined for final analyses to increase 
statistical power. 
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Figure 8.1 Case Control Comparisons 
Reported associations: 
 
 
 
 
 
 
Appendix associations: 
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Little is known about the carcinogenesis of prostate cancer; age, family history and 
ethnicity are the only well established lifestyle risk factors associated with the disease 
(208-209). The risk of disease increases after the age of 55 years. It is also up to 60% 
higher in African American men compared to white men. A first degree relative increases 
the risk up to threefold and can increase with more relatives. These risk factors are not 
modifiable; therefore further epidemiological studies are still required in order to prevent 
the disease and to gain more insight into its pathogenesis. An obvious factor under 
investigation is obesity (see chapters four and five), which translates to diet, physical 
activity and body size. A Western diet usually involves high intake of fat and calories. 
Studies on prostate cancer incidence and a diet of high saturated fat report elevated risks 
(210). Previous studies have been unable to show substantial association between obesity 
and prostate cancer (211). Some studies have reported a reduced risk of prostate cancer 
associated with physical activity, however others report the opposite. The difficulties of 
measuring this exposure accurately at different life periods have been previously discussed 
in chapter four. Occupation has also been studied, specifically occupational exposures, and 
although there is some strong evidence for association with the farming, mining, metal and 
rubber industries, no definitive conclusions have been drawn. This is probably due to small 
sample sizes for each occupational group (see chapter six). A number of epidemiological 
studies have suggested sunlight deprivation increases incidence of prostate cancer and a 
high level of cumulative UV exposure has a protective effect against the disease. This has 
also been previously discussed in chapter three. 
 
The advent of genome wide association studies (GWAS) have brought to light a number of 
loci which may harbour prostate cancer susceptibility genes. However the relative 
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importance of variants located within them is questionable. Hereditary prostate cancer is 
known to be caused by a number of genes interacting with environmental factors. It is 
believed that interaction among the genes themselves may also be involved. Genome wide 
association studies have detected different loci and different genetic variants; however 
these only explain a small increase in prostate cancer risk. The different genes are also 
likely to be associated with different population frequencies in different ethnic groups. 
More recently, the variant allele -8 (22 repeats) of the microsatellite DG8S737 has been 
extensively studied, along with additional variants in the 8q24 region (160). Despite the 
promising results, this region has no known protein encoding genes. The closest cancer 
related gene to the region is C-MYC which has been associated with prostate cancer risk. It 
has been hypothesized that other genes involved in testosterone response might also play a 
role, such as genes in the polyamine pathway (152). Further work is being carried out on 
genes involved in the polyamine biosynthesis pathway and prostate cancer, using the data 
from BiPAS. Tagging SNPs were identified for the following genes: ornithine 
decarboxylase (ODC), S-adenosylmethionine decarboxylase (SAMDC), spermidine 
synthase (SDS), aspartate transaminase (GOT2), aminoacyclase (ACY1) and ornithine 
aminotransferase (OAT). Genotyping is being performed using Taqman SNP Genotyping 
Assays (Applied Biosystems, CA) for the markers. 
 
The data from BiPAS have contributed to collaborations with the Prostate Cancer 
Association Group to Investigate Cancer Associated Alterations in the Genome 
(PRACTICAL) consortium. DNA samples for prostate cancer cases and hospital based 
controls were sent to the consortium for a follow up of a previous genome wide association 
study, which led to a paper in Nature Genetics (161). A further international collaboration 
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was achieved with researchers from Maastricht University and New York University, with 
the analysis of the genetic data in chapter seven, which resulted in a publication in the 
European Journal of Human Genetics (212). 
 
8.2 Summary and implication of findings  
Chapter three investigated the association of ultraviolet radiation exposure and prostate 
cancer using results from the Birmingham Prostatic Neoplasms Association Study. A 
statistically significant increased risk of prostate cancer was observed with lower exposure 
to sunlight during early adulthood. A statistically significant protective effect for higher 
sun exposure was also observed in early adulthood. The results show that instead of 
analysing chronic exposures over time, acute exposures may be more important in prostate 
disease. It is biologically plausible that exposure to vitamin D in early life can contribute 
to a reduced risk. Exposure to high levels of the hormonal form of vitamin D causes 
alterations on the cellular composition of the prostate in rats (213). The normal ratio of 
epithelial cells to stromal cells in rodents is 5:1 (214). However when exposed to high 
levels of the vitamin, the prostate gland is mostly composed of stromal cells. 
Carcinogenesis is a type of cancer specifically arising from epithelial cells, therefore a 
reduction in the epithelial cell population will cause a reduction in prostate cancer risk. 
Future studies should take this into account, and gather information from participants 
regarding exposures in younger life, especially in UVR studies, as more time is generally 
spent outdoors in this life period compared to later years.  
 
Chapter four examined the association of physical activity and prostate cancer in BiPAS. 
A consistent reduced risk of prostate cancer was observed for men who ever cycled in all 
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analyses. Conversely, ever having played competitive sports was associated with increased 
risk of prostate cancer among all comparison groups, including for both localized and 
advanced tumours and when adjusted for testosterone levels. In summary, high levels of 
low intensity activity were generally found to have an increased risk and participants who 
had ever taken part in high intensity activity generally had a decreased risk. In this context, 
the results were consistent with previous studies and warrant further studies on different 
intensities of exercise.  
 
Chapter five studied the effect of different measures of body size on the risk of prostate 
cancer. A protective effect was observed for waist circumference of over 37cm. A 
decreased risk was associated with overweight men (BMI 25.0 – 29.9) and an increased 
association was observed in obese men (BMI of 30.0 or over). No significant associations 
were detected for adult weight change. Interestingly, a highly significant increased risk 
was associated with a BMI classified as obese at age 20; however this effect seems to 
disappear with age. Very few previous studies have examined body size in early life; the 
main limitation of such studies is the small number of obese subjects at a young age. The 
data available on early adulthood obesity suggest it is inversely associated with advanced 
prostate cancer but not with localized cancer. Further research into the complex association 
is required to fully elucidate the biological action of obesity on prostate carcinogenesis.  
 
Chapter six was a large meta analysis of 7, 762 cases and 20, 634 controls investigating the 
association between occupational groups and prostate cancer incidence. Despite the large 
case control base, we were unable to detect any statistically significant associations. 
Increased risks were observed in farmers and mechanics, which are consistent with 
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previous literature, however the results were not statistically significant. In future studies, 
more detail on exposures should be taken into account rather than job title or industry. In 
particular, type of exposures and the duration would be most interesting, better methods 
for assessing such factors need to be developed.  
 
Chapter seven was a replication study of a whole genome wide association study on 
markers on chromosome 8q24. Allele -8 of microsatellite DG8S737 and allele A of single 
nucleotide polymorphism rs1447295 were investigated in a nested case control study from 
a Dutch population. The effect estimate for rs1447295-A allele was in the same direction 
as previous studies however it was not statistically significant. Interestingly a statistically 
significant decreased risk was detected for DG8S737–8 allele, in contrast with previous 
studies. It is more likely that DG8S737 and rs1447295 are tightly linked markers flanking 
the actual causative variant and that there may be potentially more than one high risk 
haplotype present in the Caucasian population. Future studies should try to compare more 
detailed haplotypes in this locus among populations in order to further narrow this interval 
and assisting with identification of the causative variant. 
 
8.3 Limitations of study 
Self administered questionnaires are one the cheapest methods of collecting information in 
research; however a major limitation of them is that they are limited to literate populations. 
In BiPAS, the questionnaires were largely completed by the subjects; however some were 
completed by a family member acting as an interpreter. Another disadvantage is the 
researcher has little control over the quality of data collected. In the questionnaire, closed 
ended questions were used where possible to reduce the bias arising from interpretation 
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bias. The study was piloted with a small number of patients and some questions were 
adapted to allow ease of completion and data entry. The main changes were adapting open 
questions to closed questions, such as in the case of UVR exposure. Patients were 
originally asked to recall the number of hours per day they spent in the sun; this was 
subsequently changed to options of a range of hours. All questions were worded in simple 
language to avoid ambiguity or inference of a preferred answer. The questions order was 
also adapted to a logical sequence.  
 
Although some parts of the questionnaire were validated, such as the UVR sections and 
anthropometry questions, some sections were not, which is another limitation of the study. 
Validity is defined as the extent to which an instrument measures what it intends to 
measure. This can only be evaluated when there is a reference procedure or gold standard. 
It is usually difficult to carry out, expensive and sometimes impossible. Also validity in 
one population may not guarantee validity in another. 
 
8.4 Prostate cancer: current status and future research  
8.4.1 Research on environmental exposures  
Risk factors for prostate cancer have been extensively studied in the past yet few definitive 
causal associations have been identified. A popular risk factor under study is obesity due to 
its prevalence in the western world. However fat distributions and alternative 
measurements to BMI are yet to be investigated fully. Within this theme body size, 
physical activity and diet are also common factors under study. All of these factors form 
part of the body‟s natural energy balance, suggesting an imbalance of any or all of these 
factors is important in disease progression. For prostate cancer, higher levels of physical 
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activity have been shown to reduce mortality (215). The population attributable risks 
(PAR) associated with risk factors investigated are quite high. Friedenreich and colleagues 
calculated gender specific PARs for a number of cancer sites associated with physical 
activity (83). They calculated approximately 14% or 52, 464 new cases of prostate cancer 
could be prevented if sufficient levels of physical activity were achieved by all European 
men. A study by Aronson et al detected strong associations for four environmental 
exposures (metallic dust, liquid fuel combustion products, lubricating oils and greases and 
polyaromatic hydrocarbons from coal) (195). When all four exposures were combined, 
they were estimated to cause 12% of prostate cancer in the study population. Such high 
PARs represent an important public health issue. Few studies have evaluated the time 
course of risk factors, defining when a risk factor has a real impact on disease will better 
inform clinical interventions. Understanding when a factor impacts on progression is 
particularly important in a disease such as prostate cancer which occurs in later in life. In 
prostate cancer studies, measures at time of recruitment are often used for analysis, 
whereas in fact when time course of exposures are used, a more accurate insight could be 
gained. Such analyses allow preventative measures to be focused to allow behaviour 
change which could reduce risk or even prevent recurrence. It also provides insight to 
when treatments would be most beneficial. Early life exposures, such as the ones 
investigated in this thesis are important. Advice could be offered to family members of 
affected men to allow behaviour change in offspring and reduce risk. 
 
8.4.2 Research on genetics  
Genome wide association studies on various types of cancers first appeared in 
representative journals in 2005. Since then, a number of common DNA sequence 
differences have been shown to influence genetic susceptibility for over 40 different 
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common diseases. The current standard of over 1, 000 subjects for case and control groups 
provide much more power to detect small effect sizes and identify new unsuspected 
candidate genes (216). However this ability has identified multiple genomic regions with 
no known protein-coding genes, as in the case of 8q24 and prostate cancer. Despite the 
limitations, collaborative GWAS are considered to be an essential strategy for identifying 
genetic susceptibility for major human diseases. A number of GWAS have been successful 
at identifying variants associated with prostate cancer, some of the regions include 3p12, 
3q21, 8q24, 11q13, 17q24, 19q13 and 22q13.2 (217). An interesting study by Al Olama et 
al in 2009 reported many of the variants mentioned above are localized to blocks in high 
linkage disequilibrium with 8q24 (218). It is fair to say that more positive hits have been 
found for prostate cancer than any other type of cancer. This supports the hypothesis that 
prostate cancer is caused by a number of common variants with small effects (219). The 
variants detected have little effect on severity of disease, suggesting that they have more 
influence on tumour initiation than progression. This is discussed in more detail in chapter 
seven. Also, the correlation of these variants with non genetic factors is unknown, due to 
the large sample sizes needed to investigate such effects. In a study by Lindstrom et al, 39 
SNPs identified by GWAS were examined for gene environment interactions with known 
or proposed risk factors for prostate cancer. No statistically significant association were 
detected for interactions with family history of prostate cancer, BMI, smoking and alcohol 
consumption (220). There is a large amount of evidence of the genetic basis for the 
disease; however it has proved to be extremely difficult to pinpoint specific inherited 
susceptibility genes. As previously mentioned, it is believed that a number of genes could 
be interacting together, possibly even with environmental factors to cause the disease. 
Future candidate gene studies should take into account the effects of multiple genes instead 
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of concentrating on single genes, and their interaction with environmental factors. In order 
to study such small effects, larger sample sizes would be required. The results of this thesis 
show the traditional prostate cancer cases and population based controls could be 
supplemented with high PSA cases and hospital based controls to improve on power. More 
sophisticated analysis techniques are still required to study such large sample sizes and to 
model the complex genetic pathways. Collaborative efforts could also achieve the larger 
sample sizes, as shown in the worldwide consortiums such as the International Consortium 
for Prostate Cancer Genetics (ICPCG), Prostate Cancer Association Group to Investigate 
Cancer Associated Alterations in the Genome (PRACTICAL) and the Breast and Prostate 
Cancer Cohort Consortium (BPC3) (162, 221-222).  
 
Prostate cancers can also arise from somatic epigenetic alterations (223). In normal cell 
DNA, an asymmetric methylation of cytosine bases occurs in the nucleotide sequence 
CpG. Somatic changes in DNA methylation at these CpG islands are associated with gene 
silencing, often affecting activity of tumour suppressor genes (224). Chromatin protein 
marks work alongside DNA methylation to regulate gene activity. This process is also 
altered in cancer cells. The role of GSTP1 in prostate cancer has been extensively studied, 
particularly its activity after methylation. Hypermethylation of the gene is consistently 
detected in over 90% of prostate cancers (225). Over the next few years, more research in 
DNA methylation and chromatin protein marks will provide better insight in prostate 
cancer phentotypes, providing more opportunities for biomarker discovery and targeted 
treatment options. 
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8.4.3 Future use of PSA in testing 
The long latency period of prostate cancer makes it an excellent candidate for a testing 
programme for detection. The digital rectal examination (DRE) and PSA testing are 
routinely performed worldwide as a means of diagnosing prostate cancer, despite the 
controversy surrounding its effectiveness. The DRE was introduced in the USA in the 
1970s and PSA blood testing was approved by the Food and Drug Administration (FDA) 
in 1986. The two combined caused a huge improvement in the treatment and overall 
survival rates for prostate cancer patients. Although the DRE is the most efficient at 
detecting large prostate tumours, they are often advanced and may have metastasized. 
Guidelines for the use of PSA exist to enable efficient screening. The National 
Comprehensive Cancer Network (NCCN) guidelines for the USA state high risk patients 
include men of African American origin or a family history of prostate cancer (226). High 
risk men with a baseline PSA ≥ 1.0 ng/mL are recommended to have a follow up PSA test 
and DRE one year later. If after a year the PSA result is still ≥ 1.0 ng/mL, annual PSA 
testing and DREs are recommended. If an abnormal result is detected on the DRE at any 
stage, patients should be referred for biopsy and further tests. The NCCN guidelines also 
take into account PSA velocity. The NICE clinical guidelines used in the UK stratify men 
with localised prostate cancer into three groups (see Table 8.1). Clinicians treating men in 
the low risk group are advised to use watchful waiting and active surveillance (227). 
Intermediate groups should be offered radical prostatectomy or radical radiotherapy. Men 
in the high risk category are offered systemic treatment such as adjuvant hormonal therapy 
combined with radiotherapy. The PSA values used in the UK are much higher than the 
NCCN guideline, which is likely to be a reflection of the different healthcare systems. 
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Table 8.1 Risk stratification for men with localised prostate cancer 
 
Risk PSA ng/ml  Gleason Score  Clinical Stage 
Low  <10 And ≤6 And T1 – T2a 
Intermediate 10 – 20 Or 7 Or T2b – T2c 
High >20 Or 8 – 10 Or T3 – T4 
  
Taken from the National Institute for Health and Clinical Excellence (2008) Prostate 
cancer treatment and diagnosis. (58). London: National Institute for Health and Clinical 
Excellence. 
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Although PSA has some clear advantages as a marker, it also has some limitations. For 
example, a PSA test alone cannot differentiate between lethal and non lethal prostate 
cancer. Another disadvantage is no clear benefit for treatment; a patient will receive a 
cancer diagnosis that they would not have otherwise had due to screening, but they often 
do not require or benefit from treatment. Patients that are treated could suffer from adverse 
effects of unnecessary treatment. A recent study by Strope and Andriole proposed two 
opposing mechanisms were occurring in prostate cancer diagnosis; although PSA 
screening was detecting higher numbers of localized tumours, pathologists were less likely 
to grade cancers as well differentiated and therefore tumours were being assigned to higher 
Gleason scores (228). Side effects of radiation therapy include diarrhoea, urinary 
frequency, dysuria and skin changes. Long term effects include urinary incontinence and 
sexual dysfunction. Side effects of hormonal therapy include impotence, decreased libido 
and weight gain. The main risk associated with active surveillance as a treatment option is 
anxiety. However this choice is still a better overall option to reduce overtreatment. Etzioni 
et al describe the widespread use of PSA testing as one of the greatest uncontrolled 
experiments in modern medical history (229). Despite the lack of substantial evidence that 
PSA testing is beneficial, it is routinely used in the USA and is used widely in many other 
countries. The study reported PSA testing is likely to explain half or more of mortality 
reduction in the USA since the early 1990s, and therefore a testing programme is 
beneficial to prostate cancer control (229). 
 
Two recent clinical trials were carried out to resolve controversies regarding PSA testing. 
The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) was set up in 
the USA to assess the difference in mortality from testing for the specified diseases (230). 
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The study reported that higher levels of testing make little difference to mortality from 
prostate cancer. The European Randomized Study of Screening for Prostate Cancer 
(ERSPC) compared testing versus no testing and reported that prostate cancer mortality 
was reduced in the tested group (25). This study used a PSA level of 3.0 ng/ml as an 
indicator for biopsy. After further investigation, it was reported that 80% of men between 
the ages of 55 and 74 years have a PSA lower than this cut off value and therefore do not 
receive biopsies, which could lead to tumours in this group being missed. However taking 
biopsies of the whole study population would identify seven times more cancers than those 
who were actually at risk of dying from the disease. The researchers therefore concluded 
that although cut off values in a testing programme could miss cancers, the overall benefits 
of outweigh the risks of over diagnosis and over treatment. Although testing for the disease 
has been shown to reduce mortality, the poor diagnostic performance of PSA contributes 
to the risk of over diagnosis and over treatment. PSA testing could be improved by using a 
combination of different biomarkers. A number of urinary markers are currently being 
developed; one promising test is the PCA3 test. A review by Ploussard and de la Taille 
showed a vast improvement of prostate cancer detection by using a combination of PSA 
and PCA3 (231). PCA3 is a prostate specific gene and is known to be over expressed in 
prostate cancer (232). It is a non-coding RNA and though the exact function is unknown, 
one potential mechanism is in gene regulation, in a similar way to PCGEM1, another 
prostate specific gene which is expressed in the androgen receptor. A number of molecular 
techniques have consistently reported PCA3 outperforms serum PSA in cancer diagnosis. 
Since PSA is not specific to prostate cancer, elevated levels could be due to benign 
prostatic hyperplasia or other prostatic conditions. However if PSA is used in conjunction 
with PCA3, the accuracy of diagnosis could be vastly improved (232). 
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The main burden to public health is the costs associated with treatment. Any strategy to 
reduce prevalence of the disease or delay the need for biopsy and/or treatment will 
therefore reduce the number of men at risk for adverse symptoms associated with 
treatment. An accurate testing programme to reduce the burden would be advantageous. 
As discussed above, PSA testing cannot distinguish between aggressive and non 
aggressive disease and cannot solve problems associated with over treatment and over 
diagnosis. However the use of a combination of different markers could be implemented in 
a detection programme, where the risks and benefits associated with testing were clearly 
explained to the population. Some limitations of PSA testing have been previously 
mentioned, such as overdiagnosis and overtreatment. A number of other risks exist for 
PSA testing and the DRE itself. The PLCO study reported harmful effects of phlebotomy 
for PSA testing include dizziness, bruising and fainting (230). The most frequently 
reported harmful side effect is anxiety, especially following an elevated result which could 
turn out to be a false positive (233-234). Complications associated with DRE include 
discomfort and sometimes bleeding (226).  
 
Better methods for detection and treatment of early stage tumours are required. The current 
research is aimed at developing new biomarkers to complement PSA and compensate for 
its limitations as a prostate cancer biomarker. Since prostate cancer is a slow growing 
tumour which can be asymptomatic for a number of years, not all men would benefit from 
early detection. The American Cancer Society Early Detection Guidelines for Prostate 
Cancer recommend testing should be limited to men with at least a 10-year life 
expectancy. Men with serious co-morbidities which affect life expectancy, such as severe 
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chronic pulmonary obstructive disease end stage renal disease and life limiting cancer, are 
unlikely to benefit from screening as are men of advanced age. 
 
8.4.4 Future use of PSA in research 
As previously discussed, the use of high PSA cases could be advantageous in case control 
studies. When considering results for chapters 3-5, similar results were detected for both 
prostate cancer cases and high PSA cases, therefore it can be inferred that the high PSA 
case groups could be combined with case groups to increase statistical power. Another 
potential use for PSA would be as a surrogate endpoint for prostate cancer. Changes in 
PSA level could be used to measure how well a treatment works. A clinical trial by 
Petrylak and colleagues noted changes in the PSA level of patients were reflective of 
outcomes of the trial (235). For men in the treatment arm of the study, serum PSA level 
decreased by 30% in the first three months of entering the study. The risk of death in this 
group of men was also reduced by 50%. More studies on the use of PSA as an endpoint are 
required to validate these findings. PSA testing is a useful tool for the analysis of severity 
of disease. With the widespread use of screening, a much higher number of patients with 
early localized disease are identified. PSA levels can be used to categorize cases into 
severity of tumours for studies on disease progression. 
 
8.4.5 Future studies on prostate cancer 
With the four distinct groups of patients within BiPAS, the effect of different exposures on 
disease progression was analysed, which help to pinpoint the effect of certain factors. 
Demographic differences of all groups were reported in each chapter. Prostate cancer 
patients were older than both control groups and had a significantly higher percentage of 
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family history of prostate cancer compared to population controls (but not hospital 
controls). For the factors investigated in this thesis, there was little difference in 
associations to prostate cancer patients or high PSA cases. The results for population 
controls and hospital based controls were also mostly consistent. The two categories within 
the case control groups were combined for all chapters to give more statistical power. The 
strengths and weaknesses of different types of control groups have rarely been evaluated 
(236-238).  It is generally believed that population controls are the gold standard for a 
control base, as they normally arise from the same primary base as cases, which is a 
methodological advantage. However, this can be a challenge in some studies as there is not 
always a suitable resource from which to draw such controls. With this study, we were 
able to show similar associations for hospital based controls, therefore in future case 
control studies; benign prostatic hyperplasia or patients with similar prostatic diseases 
could be used as an effective control group. A study on occupational risk factors by 
Aronson et al in 1996 also pooled hospital and population based controls after testing for 
heterogeneity between the groups. They did not detect conflicting results for either groups 
and therefore advocate the idea of combining the groups for more statistical power.  
 
Epidemiological studies on lifestyle factors continue to report conflicting results for 
exposures, suggesting a highly complex disease process. Therefore study designs need to 
be refined in order to investigate the effect on different stages of cancer as well as different 
types of exposure. In addition, more research into biological mechanisms of the known 
variants and their interaction with other pathways is required in order to converge the 
knowledge of genetic and environmental causes of prostate cancer.  
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We are still in the infancy of analysis and follow up of GWAS, therefore statistical 
methods need to be refined to complement the emerging high throughput techniques. The 
new phase of next generation sequencing and consortium collaborations for both genetic 
and environmental studies will yield many more promising tools for the diagnosis and 
prognosis of urological cancers. 
 
8.5 Concluding advice 
8.5.1 Advice to prostate cancer patients 
The main findings of this thesis can be split into lifestyle factors and genetic 
predisposition; however it may not be appropriate to advise cancer patients of all such 
findings. The main adverse consequence of awareness of a genetic predisposition for a 
disease is anxiety. However, knowledge of genetic information can prompt beneficial 
actions or avoidance of harmful ones. Although no risk factor is established to reverse 
disease progression, patients should be made aware of plausible protective risk factors 
such as dietary intake of vitamin D and a sufficient level of physical activity, although it 
should be clear that these are not guaranteed to treat the cancer. For the risk factors 
investigated in this thesis, many of the exposures have an effect in early adulthood. Once 
these risks are fully established, they should also be reported to the general public to 
promote healthy behaviours for prostate cancer prevention. 
 
8.5.2 Advice to clinicians 
The American Cancer Society Early Detection Guidelines for Prostate Cancer advise a set 
of core information should be provided to patients before testing. Clinicians are advised to 
point out that prostate cancer is an important concern for men and that testing by PSA tests 
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and DREs can detect tumours earlier. Patients should also be told however that there is no 
established evidence that prostate cancer testing can reduce the risk of dying from the 
disease and there is no guaranteed benefit from treatment. The side effects of all treatments 
should be discussed. It should be made clear that there is a possibility for false positive and 
false negative results. Finally, the side effects and complications of biopsy should also be 
discussed (226). In conclusion, there is a great deal of controversy surrounding the use of 
current detection methods. Clinicians are also advised not to test asymptomatic men over 
the age of 75 or men with serious co-morbidities, which results in a life expectancy of less 
than 10 years. 
 
For men in high risk groups for cancer, advice on modifiable lifestyle factors should be 
provided. Physical activity is widely recognized as an important component of cancer 
prevention programmes. Current guidelines from the US department of Health and Human 
Services and the World Cancer Research Fund recommend 30-60 minutes of moderate 
intensity activity for at least five days a week. Although the exact details on the optimum 
type, dose and intensity of activity are not known, this guideline is a useful reference 
standard. The protective effect of UVR could also be discussed; however clinicians should 
be cautious due to the very strong association of sunlight to skin cancers. Despite the 
significant findings in this thesis, when put into perspective with all other literature in this 
area, more firm recommendations cannot be given to clinicians. 
 
8.5.3 Advice to researchers 
One of the main findings of the novel study design of BiPAS is the similar associations for 
the cases and controls groups. This design could be used in future epidemiological studies 
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to either increase statistical power if the effect of factors is similar, or to look at differences 
at different stages of disease if they are not similar. Another interesting feature was the 
inclusion of testosterone summary scores. With this information, it was possible to exclude 
the effects of testosterone for the associations observed. For some of the factors under 
investigation, exposure in early adulthood was important. Future studies should record data 
for different life periods where possible, especially for the period of between 20 years and 
30 years of age. Further studies on physical activity are required with more detail on 
activity types and specific duration. In studies examining obesity, different measures of 
obesity are important. Although BMI is quite reliable as a measure for obesity, it does not 
take into account different fat distributions. For this thesis, a pictogram was used which 
proved to be an effective tool for this. For future studies on occupation, new methods to 
assess exposure type and duration need to be developed. Finally, more replication studies 
are required to elucidate the role of genetic variants identified by GWAS. Where the 
variant is not the actual causative factor, gene environment interactions and more detailed 
haplotype analysis should be applied. 
 
8.6 Conclusion 
Despite the extensive research on prostate cancer, the complexity of the disease means it 
remains difficult to pinpoint causal factors. Multiple genetic variants have been implicated 
and few environmental factors have been fully established. We are yet discover a 
recognized causal factor, as in the case of smoking and lung cancer or the BRCA1 gene and 
breast cancer. It could be argued that such a factor does not exist for prostate cancer. 
Although this thesis was unable to establish definitive causal factors, it does add to the 
current knowledge by highlighting the importance of environmental exposures in early 
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adulthood. The answers are more likely to lie in the more complex gene-environment or 
even gene-gene interactions. Future studies on prostate cancer, and indeed other complex 
cancers and chronic diseases should concentrate on these effects. The traditional case 
control design could also be modified by the inclusion of different types of cases and 
controls, as shown by this thesis.  
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Birmingham Prostatic Neoplasms Association Study (BiPAS) 
 
Chief Investigator:  Professor Maurice Zeegers 
          The University of Birmingham 
Name of your doctor:   
    
 
We would like to invite you to take part in a clinical research study. 
 
Taking part in the study is entirely voluntary. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully. Talk to others about the study 
if you wish and please ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you wish to take part.  
 
The following information sheet is in two parts: 
Part 1 tells you the purpose of this study and what will happen if you take part. 
Part 2 gives you more detailed information about the conduct of the study.   
 
Part 1 – Purpose and your role in the study 
 
1. What is the purpose of the study? 
Prostate cancer is an important health problem. It is the most common cancer in the 
UK. However, the cause of prostate cancer is still not known. In this research we aim 
to identify lifestyle or genetic causes of this disease. With this knowledge we hope to 
be able to find clues for the prevention or cure of prostate cancer. 
 
2. Why have I been chosen? 
You have been referred to a prostate or flow clinic based on a suspicion of a prostate 
abnormality. We are hoping to collect information on patients before a formal 
diagnosis is made. We intend to study at least 2000 patients over the next 2 years.  
 
3. Do I have to take part? 
No. it is up to you to decide whether or not to take part and you do not have to 
decide straight away. If you do agree, you will be given this information sheet to 
keep and asked to sign a consent form. You are still free to withdraw at any time and 
without giving a reason. A decision to withdraw at any time or a decision not to take 
part, will not affect the standard of care you receive or your relationship with your 
doctor.  
 
4. What will happen to me if I take part? 
If you agree to take part and have signed a consent form, the study will run alongside 
your standard treatment. The study will be conducted over 5 years however; your 
actual involvement will take approximately one hour of your time. When you come 
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to the clinic, our research nurse (this will change after one year) will talk to you 
about the study and will ask you to fill in a questionnaire. The questions will be on 
your background, medical history and lifestyle. We would need you to give us about 
45 minutes of your time to fill in this questionnaire. We will also ask you to give one 
extra tube of blood in addition to the blood that you would normally give. In addition 
we will ask you permission to look through your medical notes.  
 
5. What do I have to do? 
Other than your normal treatment, we would need you to complete our questionnaire 
and let us have a sample of your blood. Blood will be drawn from a vein usually 
inside the elbow or from the back of the hand. The site is first cleaned with an 
antiseptic, a tourniquet is placed around the upper arm to temporarily restrict blood 
flow and a sterile needle is inserted into a vein. Blood is collected in an air tight vial 
or syringe.  
 
6. What will happen to the blood samples taken as part of this study? 
The blood samples that will be collected as part of the research study will be stored 
centrally at a laboratory at The University of Birmingham. The blood sample will be 
used to investigate potential prostate cancer genes. In addition we would also like to 
store your DNA and later use the samples donated as part of this study for future 
research, although such research projects have not yet been planned and could occur 
many years in the future. These future research projects may involve studies of your 
genes and DNA. By giving your consent for your blood to be stored you will be 
offering your samples as a gift.  
 
The blood and DNA samples will be stored under strict security and are given a 
code, so that the researchers receiving the samples do not know your name or any 
other personal details. Researchers who wish to use the samples that are stored will 
only be given access to the samples after their research has been approved by an 
Independent Research Ethics Committee who makes sure that the research is in the 
interest of the patients and is carried out safely.  
 
7. What are the possible disadvantages and risks of taking part? 
There are no foreseeable risks in taking part. This study will run alongside your 
routine treatment and follow up; it will not influence this process. 
 
8. What are the possible benefits of taking part? 
There is no intended immediate clinical benefit from taking part in this study. 
However, the information obtained from this study may result in changes in the 
future prevention, 
diagnosis, treatment and follow up of patients with prostate cancer or benign prostate 
hypertrophy. These changes may also benefit you. 
 
9. What happens when the research study stops? 
When the study stops your routine treatment and follow up will continue in the 
normal way, although it may incorporate new discoveries or information generated 
by this study. 
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10. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. More detailed information 
regarding this is given in part 2 (please refer to question 15). However if you have 
any problems concerning the study, then please do not hesitate to contact the local 
investigator (01214721311) or the Chief Investigator, Professor Zeegers 
(01214146721).  
 
11. Will my taking part in the study be kept confidential? 
Yes. All information which is collected about you during the course of the research 
will be kept strictly confidential. The details are included in Part 2.  
 
12. Contact Details about the study 
If you have any concerns or other questions about this study or the way it has been 
carried out, you should contact the urologist listed below: 
 
Contact Details: 
Urologist:                               Telephone:  
 
This completes Part 1 of the information sheet. If the information in Part 1 has 
interested you and you are considering participation, please continue to read 
the additional information in Part 2 before making any decision. 
 
Part 2 – Information about the study 
13. What if relevant information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the disease that is being studied. If this happens, your research doctor 
will tell you about it and discuss whether you want to or should continue in the 
study. If you decide not to carry on, your urologist will make arrangements for your 
care to continue. If you decide to continue in the study you will be asked to sign an 
updated consent form. 
 
Also, on receiving new information, your research doctor might consider it to be in 
your best interest to withdraw you from the study. He/she will explain the reasons 
and arrange for your care to continue. If the study is stopped for any other reason, 
you will be told why and your continuing care will be arranged. 
 
14. What will happen if I don’t want to carry on with the study? 
As mentioned in Part 1 of this form your participation in this study is entirely 
voluntary and you are free to withdraw from it at any time. If you withdraw from the 
study, we will destroy all you identifiable samples, but we may still need to use the 
data collected up to your withdrawal. With your permission we would like to collect 
follow up information about you from the NHS Central Register (NHSCR). 
 
15. What if there is a problem? 
If you have a concern about any aspect of the study; you should ask to speak to the 
researchers who will do their best to answer your question. If you remain unhappy 
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and wish to complain formally, you can do this through the NHS Complaints 
Procedure. Details can be obtained from the hospital.  
 
In the event that something does go wrong and you are harmed during the research 
study there are no special compensation arrangements. If you are harmed and this is 
due to someone‟s negligence then you may have grounds for a legal action for 
compensation against the research sponsor (University of Birmingham) but you may 
have to pay your legal costs. The normal National Health Service complaints 
mechanisms will still be available to you.  
 
16. Will my taking part in this study be kept confidential? 
All information, which is collected about you during the course of the research, will 
be kept strictly confidential. If you agree to take part in this study we will need you 
to sign a consent form. You will be given a copy of the consent form and this 
information sheet to keep.  
 
We would like to collect some contact details from you including your current 
address and telephone number. We would like to collect these details so that we 
contact you again in the future. Your contact details will be kept strictly confidential 
and only members of the BiPAS research team would be allowed access to them.  
 
Information on all patients entered into this study will be sent to the BiPAS Study 
Office which is located at the University of Birmingham where it will be retained in 
secure storage and handled according to the 1998 Data Protection Act. No personally 
identifiable information will be released from the BiPAS study office. Limited 
clinical information may be passed on to researchers within the UK. It would not be 
possible to identify any patient from this information and any information provided 
will be handled according to the normal standard of medical confidentiality and data 
protection. With your consent we will also be informing your GP of your 
participation in the study.  
 
17. What will happen to the samples I give? 
The blood samples that will be collected as part of this research study will be stored 
centrally at a laboratory at The University of Birmingham. The blood samples will 
be used to investigate prostate specific antigen (PSA) levels and potential prostate 
cancer genes. In addition, we would also like to store your DNA and later use the 
samples donated as part of the study for future research, although such research 
projects have not yet been planned and could occur for many years in the future. 
These future research projects may involve studies of your genes and DNA. By 
giving your consent for your blood to be stored you will be offering your samples as 
a gift. 
 
The blood and DNA samples will be stored under strict security and are given a 
code, so that researchers receiving the samples do not know your name or any other 
personal details. Researchers who wish to use the samples that are stored will only 
be given access to the samples after their research has been approved by an 
Independent Research Ethics Committee who makes sure that the research is in the 
interest of the patients and is carried out safely.  
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18. Will any genetic tests be done? 
Participants who have been recruited from hospitals will be tested for specific genes 
which have been linked to possible increased risk of prostate cancer. The samples 
will be fully anonymised and the results from these tests are not expected to be 
meaningful and available to individuals at this stage. The research may inform future 
testing programmes which would make information available later through the NHS. 
Samples and information may be retained for future genetic studies in which case 
additional consent will be sought from the participants or the study will be presented 
to an ethics committee for consideration.  
 
19. What will happen to the results of the research study? 
Important results from the study will be published as they become available, which 
may be during the course of the study or after the study has finished, and this could 
possibly take several years. We intend that any results will be published in peer 
reviewed journals or will be presented at meetings involved with this field of cancer 
research, and these publications will be available upon request from your specialist 
doctor. You will not be identified in any report or publication.  
 
20. Who is organising and funding the research? 
The research is being organised by The Departments of Public Health and 
Epidemiology, Primary Care and General Practice, Institute of Biomedical Research 
and the Cancer Research UK Institute for Cancer Studies at The University of 
Birmingham in collaboration with the Department of Urology at The Queen 
Elizabeth Hospital, Birmingham. The research is funded by Cancer Research UK. 
The doctors conducting this study are not being paid for including and looking after 
you within this study.  
 
21. Who has reviewed this study? 
This study has been reviewed by the Multi-centre Research Ethics Committee and by 
scientific experts at Cancer Research UK.  
 
Should you wish to participate in this study you will be given a copy of this patient 
information sheet and a signed consent form to keep. Thank you for taking the time 
to read this sheet and should you require further information please do not hesitate to 
contact us. 
 
Yours sincerely, 
Urologist. 
 
 
 
 
 
 
 
 
 
  
 172 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2: Participant consent form 
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Birmingham Prostatic Neoplasms Association Study (BiPAS) 
 
Centre Name:  
Study Number:  
Patient Identification Number: 
 
Name of Researcher:  
 
1. I confirm that I have read and understood the information sheets version 1.1 of the 
above study and have had the opportunity to ask questions.              
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected. 
 
3. I understand that my medical notes may be looked at by members of the BiPAS 
research team and regulatory authority representatives, but understand that strict 
confidentiality will be maintained. I give permission for these individuals to have 
access to my records. 
 
4. I agree for blood to be taken, stored and used for current and future biological 
research projects which WILL receive appropriate scientific and ethical approval.  
 
5. I agree to my GP being informed of my participation in the study. 
 
6. I agree for my contact details to be stored and used to contact me about aspects of 
the study either by telephone or post. 
 
7. I agree to take part in the above Birmingham Prostate Cancer Association Study 
(BiPAS). 
 
__________________                   _____________                    ______________  
Name of patient                             Date                                       Signature 
 
__________________                   _____________                    ______________ 
Name of person taking consent      Date                                       Signature 
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Appendix 3: Questionnaire 
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THE BIRMINGHAM PROSTATIC NEOPLASMS ASSOCIATION 
STUDY 
 
Patient Identifier:         1 
First 3 letters from surname followed by first 2 letters of forename followed by [site identified] and number 
eg:  John Smith = SMIJO[site identifier]001 
 
Date of Birth: // 
Patient/Hospital number: // 
Hospital:   
Clinic:  
Date of Interview:  // 
Will the interview take place with the support of a translator?    Yes  No  
Name of Translator:  …………………………………………………………. 
INTRODUCTION 
 
In order to provide better health care for prostate cancer patients, we hope to 
discover more about how prostate cancer is related to people‟s circumstances. In 
order to do this we are asking a range of people to answer these questions including 
some people with prostate problems and others with no such problems. 
 
The questions that you will be asked will include questions about your lifestyle, your 
behaviours, your health and the help and support you receive from the people around 
you. 
 
There may be some questions that you think are unusual.  The questions are not 
used to test you in any way and the responses you give will not be used to make 
any judgements about you.  There are no right or wrong answers.  All of your 
responses will be treated as strictly confidential and will be used only for medical 
research. 
 
Some of the questions will ask for personal information.  If you feel that any of the 
questions are too personal, do not answer them.  However, by answering these 
questions, you will help us to discover links between lifestyle and health. 
 
There is no time limit, so if you want a little time to think about any of the questions 
please do so.  Try to answer every question, even if the answer is „I can‟t remember‟ 
or „I don‟t know‟. 
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GENERAL INFORMATION   
 
CONTACT DETAILS: 
 
What is your postal address: 
 
House Number and Street
 ……………………………………………………………….. 
 
Area   
 ……………………………………………………………….. 
 
Location (Town/City) 
 ……………………………………………………………….. 
 
Postcode (if known)  ………………………………. 
 
 
What is your home telephone number?   / 
 
MARITAL STATUS 
 
What is your current marital status?  (tick appropriate box) 
 
Single     Married/living with partner     Widowed     Separated     Divorced  
ETHNIC ORIGIN 
To which of these groups do you consider you belong to ? (tick appropriate box) 
 
White  Black, Caribbean   Black, other   Chinese   
Pakistani  Indian        Bangladeshi   Other    
      „Other‟ specify  ……………….. 
 Mixed  (specify)……………… If „white‟ please specify origin eg. Irish etc 
 
EDUCATION AND QUALIFICATIONS 
 
How old were you when you left school?   
 
Do you have any of the following qualifications? (Tick all applicable) 
 
School Leaving Certificate  CSE   
GCE “O” Level or GCSE Technical College Exams / City and Guilds  
Completed Apprenticeship Higher National Diploma (HND)   
“A” Level, Highers  Matriculation (University entry exam)   
Trade Certificates  Teaching Diploma, NHC  
Secretarial College Exam University Degree  
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PAST HISTORY OF CANCER  
 
 
Have you ever been diagnosed as suffering from any of the following cancers? 
 
If YES, please give date of diagnosis: 
 
Year 
Prostate                No   Yes    
Kidney                  No   Yes    
Bladder                 No   Yes   
Liver                    No   Yes    
Melanoma    No   Yes    
Non-melanoma Skin Cancer  No   Yes    
Lung                 No   Yes    
Colorectal/Bowel cancer               No   Yes    
Upper GI (Stomach/pancreas)     No   Yes    
Haematological (e.g. Leukemia)  No   Yes    
Other  ……………………………..No   Yes    
 
 
HAVE YOU HAD A VASECTOMY? 
 
Yes    Date……………..        No  Please turn over 
 
Have you had a reversal of a vasectomy? 
 
Yes       Date………       No   
 
If you have had a reversal of a vasectomy have you subsequently had children? 
Yes       Details            No      
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OCCUPATION HISTORY 
 
SECTION 5: OCCUPATIONAL HISTORY 
 
In this section we would like you to tell us about your most recent job and all of your previous jobs that you have had for one year or more. 
 
We have allowed enough sections for up to 6 jobs.  If you have had more than 6 jobs, complete all sections of this part of the questionnaire and 
then continue on a separate piece of paper.  THE FIRST LINE HAS BEEN FILLED IN AND USED AS AN EXAMPLE. 
 
Job Title 
Time period that you 
worked there Description of 
Activities 
Name of 
Organisation 
Location 
(Town/City) 
Type of Business 
Mainly 
indoor 
activity 
Mainly 
outdoor 
activity 
Shift 
work 
From (y) To (y) Please tick one 
EXAMPLE: 
DRIVER 
1972 1996 HGV DRIVER 
JO BLOGGS 
BUILDERS 
BIRMINGHAM 
BUILDING  
CONTRACTORS 
  YES 
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DIETARY BEHAVIOURS  
 
 
The questions in this section ask about your normal diet during the last year 
 
Please indicate how often on average, during the past year, you have eaten each of the food types that 
are listed below 
 
 
Average Use Last Year 
Never or 
less than 
once per 
month 
1-3 per 
month 
Once a 
week 
2-4 
per 
week 
5-6 
per 
week 
At least 
once per 
day 
STAPLE FOODS       
Bread ………………………………… □ □ □ □ □ □ 
Potatoes………………………………. □ □ □ □ □ □ 
Pasta…………………………………………… 
(eg. Macaroni, Spaghetti) 
□ □ □ □ □ □ 
Rice ……………………………………………… □ □ □ □ □ □ 
Noodles………………………………………… □ □ □ □ □ □ 
Wheat ……………………………………………. 
(eg. Whole grain bread) 
□ □ □ □ □ □ 
Cereal…………………………………………….. 
(eg. Oats, bran, corn) 
□ □ □ □ □ □ 
       
MEAT       
Meat (no organs)……………………………….. 
(eg. Pork, Steak, Beef, Lamb) 
□ □ □ □ □ □ 
Organ Meat……………………………………… 
(eg. Liver, Heart, Kidney) 
□ □ □ □ □ □ 
Chicken………………………………………….. □ □ □ □ □ □ 
Other Poultry……………………………………. 
(eg. Goose, Duck) 
□ □ □ □ □ □ 
       
FISH       
Dark Fleshed Fish……………………………… 
(eg. Mackerel, Salmon, Anchovies, Sardines, 
Trout, Tuna, Herring) 
□ □ □ □ □ □ 
White fleshed fish ………………………………. 
(eg.  Cod, Haddock, Hake, Halibut, Plaice, 
Seabass, Skate, Sole) 
□ □ □ □ □ □ 
Seafood………………………………………… 
(eg. Prawn, Crab, Lobster, Cockles, Winkles, 
Squid, Octopus, Mussels) 
□ □ □ □ □ □ 
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DIETARY BEHAVIOURS  
 
 
Average Use Last Year 
Never or 
less than 
once per 
month 
1-3 
per 
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per 
week 
At least 
once per 
day 
VEGETABLES        
Fruit Vegetables……………………… 
(eg. Tomato, Cucumber, Aubergine) 
□ □ □ □ □ □ 
Flower vegetables………………………… 
(eg. Broccoli, Cauliflower)  
□ □ □ □ □ □ 
Leafy vegetables…………………………… 
(eg. Spinach, Cabbage, Lettuce) 
□ □ □ □ □ □ 
Stem vegetables…………………………… 
(eg. Asparagus, Celery, Fennel) 
□ □ □ □ □ □ 
Mushrooms………………………………… □ □ □ □ □ □ 
Bulbs………………………………………… 
(eg. Onion, Garlic, Leek, Shallot) 
□ □ □ □ □ □ 
Roots………………………………………… 
(eg. Beetroot, Swede, Carrot, Parsnip) 
□ □ □ □ □ □ 
FRUIT        
Citrus Fruits……………………………… 
(eg. Orange, Lemon, Lime, Grapefruit) 
□ □ □ □ □ □ 
Stone Fruits……………………………… 
(eg. Plum, Apricot, Peach, Cherry) 
□ □ □ □ □ □ 
Soft Fruits………………………………… 
(eg. Strawberry, Rasberry) 
□ □ □ □ □ □ 
Fleshy Fruits……………………………… 
(eg. Apple, Pear, Banana, Pineapple) 
□ □ □ □ □ □ 
Vine Fruits……………………………… 
(eg. Grape, Melon, Cantalope) 
□ □ □ □ □ □ 
DAIRY       
Cream……………………………………… □ □ □ □ □ □ 
Butter / Margarine………………………… □ □ □ □ □ □ 
Yogurt…………………………………...... □ □ □ □ □ □ 
Cheese …………………………………… □ □ □ □ □ □ 
Egg ……………………………………… 
 
 
□ □ □ □ □ □ 
OTHER FOODS       
       
Pulses……………………………………… 
(eg. Pea, Bean, Lentil) 
□ □ □ □ □ □ 
Nuts and Seeds…………………………… □ □ □ □ □ □ 
Soy/Tofu products…………………………. 
(eg. Soy milk, Tofu, Soya meat) 
□ □ □ □ □ □ 
Sweets and snacks………………………… 
(eg. Crisps, cakes, chocolate) 
□ □ □ □ □ □ 
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DIETARY BEHAVIOURS  
 
 
FLUID INTAKE 
 
Please indicate how often, during the past year, you have drunk one measure each of the 
types of drinks that are listed below. 
 
Measure 
Average Use Last Year 
Never or less 
than one 
measure per 
month 
1-3 per 
month 
One a 
week 
2-4 
per 
week 
5-6 
per 
week 
At least 
one per 
day 
How 
many 
per 
day? 
ALCOHOLIC DRINKS 
Wine or champagne……… 1 small   
glass 
□ □ □ □ □  
         
Fortified Wine…………… 
(eg. Port, Sherry, Cinzano) 
1 small 
glass 
□ □ □ □ □  
         
Beer……………………… 
(eg. Beer, Lager, Stout) 
1 Pint □ □ □ □ □  
         
Cider…………………… 1 Pint □ □ □ □ □  
         
Spirits……………………… 
(eg. Gin, Brandy, Rum, 
Vodka, Whisky) 
1 pub  
measure 
(25cl) 
□ □ □ □ □  
         
Liqueurs…………………… 
(eg. Tia Maria, Cointreau, 
Baileys, Grand Marnier, etc) 
1 pub  
measure 
(25cl) 
□ □ □ □ □  
HOT DRINKS 
Coffee…………… 1 cup □ □ □ □ □  
         
Tea………………………… 1 cup □ □ □ □ □  
         
Hot Chocolate…………… 1 cup □ □ □ □ □  
         
Ovaltine / Horlicks……… 1 cup □ □ □ □ □  
         
Soup…………………… 1Cup/ 
bowl 
□ □ □ □ □  
COLD  DRINKS 
Fizzy pop………………… 
(eg. Lemonade, Cola) 
 ½ pint  
glass 
□ □ □ □ □  
         
Pure fruit juice…………… 
(eg. Orange, Apple, etc) 
½ pint 
glass 
□ □ □ □ □  
         
Fruit squash or cordial ……. ½ pint 
glass 
□ □ □ □ □  
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Milk ……………………… ½ pint 
glass 
□ □ □ □ □  
        
Water …………………… ½ pint 
glass 
□ □ □ □ □  
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DIETARY BEHAVIOURS  
 
 
 
 
 
Average Use Last Year 
Never or 
less than 
once per 
month 
1-3 per 
month 
Once a 
week 
2-4 
per 
week 
5-6 
per 
week 
At least 
once per 
day 
FOODS OF INTEREST       
Fast Foods e.g. McDonalds, Fish ‘n 
Chips………………………………….. 
□ □ □ □ □ □ 
Takeaway/Pub Meal/ Restaurant 
…………………………………… 
□ □ □ □ □ □ 
Ketchup or Tomato Sauces………… □ □ □ □ □ □ 
Tomato based foods e.g. Pastas, soups 
pizzas  ………………………………… 
□ □ □ □ □ □ 
 
 
Could you kindly indicate which of the following non prescribed 
treatments/supplements you are currently taking IN ADDITION to your diet? 
 
Name   Brand   Date Started  Dose 
 
Prostabrit  ………………… ……………… …………… 
 
Saw Palmetto  ………………… ……………… …………… 
 
Selenium  ………………… ……………… …………… 
 
Vitamin E  ………………… ………………. ……………..  
 
Vitamin D  ………………… ………………. ……………..      
 
Multivitamin  …………………. ………………. ……………  
 
Other (please specify) …………………. ……………….. ……………… 
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Ultra violet light exposure risk 
 
Skin Type:  How would you describe your skins reaction to sun exposure? 
Always burns and never tans    
Usually burns and tans a little   
Burns rarely and tans gradually   
Never burns and always tans   
 
 
Adult Hair colour (Before grey):  
Red   
Auburn   
Blonde   
Brown   
Black   
 
 
Adult Eyes colour: 
Blue     Grey   
Green     Hazel   
Brown   
 
 
With regard to your jobs over the years, please say how many years you have spent 
working : 
Outdoors =        never       Indoors =  never    
 0 – 9 years     0 – 9 years   
  10 –19 years     10 –19 years   
20 – 29 years     20 – 29 years   
Over 30 years     Over 30 years   
                                                                        
Travel 
Have you ever lived abroad? 
  
 No  Yes Time lived aboard:    years  months 
     
Where did you live abroad? ………………………… 
    Was it a sunny country?   Yes  No  
Do you remember being badly sunburnt as a child (blistering or sunburn lasting more than 48 
hours)? 
 Yes  How many times?   
 No 
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Ultra violet exposure clarification 
 
 
We are interested to learn about your history of sun exposure/baking.  The 
following questions relate to the amount of time you have spent outside in the sun 
since you were a young adult. 
 
 
From Age 60+, on average how many hours per day did you spend outdoors on: 
 
 Weekdays   never          Weekends        never   
                               0 – 4 hours                                            0 – 4 hours   
                               5 – 9 hours                                            5 – 9 hours   
                               10 – 14 hours                                        10 – 14 hours`  
                            More than 15 hours                          More than 15 hours  
 
 
During middle age (40-59) 
 
 Weekdays   never           Weekends        never   
                               0 – 4 hours                                            0 – 4 hours   
                               5 – 9 hours                                            5 – 9 hours   
                               10 – 14 hours                                        10 – 14 hours  
                                More than 15 hours                      More than 15 hours  
 
 
During early adult life (20-39) 
 
 Weekdays   never           Weekends        never   
                               0 – 4 hours                                            0 – 4 hours   
                               5 – 9 hours                                            5 – 9 hours   
                               10 – 14 hours                                        10 – 14 hours  
                                More than 15 hours                      More than 15 hours  
 
On average how many weeks do you spend abroad in a hot country per year?  
 
What Sun Protection Factor (SPF) do you usually use?        
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Extent of sunbathing / Lying / Sitting in the sun at the following ages: 
 
 Frequently Occasionally Rarely Never 
60+     
40-59     
0-39     
(Participants have to answer whether they are someone who sunbathes (and how 
often) or not for each age category) 
 
 
 
 
On average, during your lifetime, how many sunbed sessions (electric) have you had 
per year?  
 
 
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PHYSICAL ACTIVITY 
 
How would you classify yourself? 
 
Type of activity 
 
 
Walking (including to school, work, shopping or a as a leisure activity) 
 
From 12 – 19 years of age (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
From 20 – 39 years of age (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
Since 40 (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
 
Cycling (including to school, work, shopping or a as a leisure activity) 
 
From 12 – 19 years of age (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
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From 20 – 39 years of age (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
Since 40 (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
Gardening 
 
From 12 – 19 years of age (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
From 20 – 39 years of age (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
Since 40 (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
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Housework (cooking, cleaning, childcare) 
 
From 12 – 19 years of age (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
From 20 – 39 years of age (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
Since 40 (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
Non-competitive sport (aerobics, skiing, etc) 
 
Please specify which sport ………………………………………….. 
 
From 12 – 19 years of age (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
From 20 – 39 years of age (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
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Since 40 (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
Competitive sport or dance  
 
Please specify which sport ………………………………………….. 
 
From 12 – 19 years of age (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
From 20 – 39 years of age (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
 
Since 40 (number of hours per week): 
Never     
0 – 4 hours per week   
5 – 9 hours per week   
10 – 14 hours per week  
More than 15 hours    
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These questions are about the time you spend sitting while at work, at home and 
during leisure time.  This may include time spent sitting at a desk, visiting friends, 
reading, or sitting or lying down to watch television. 
 
During an average week, how much time do you usually spend sitting on a weekday? 
 
Never    
0 – 4 hours per day  
5 – 9 hours per day  
10 – 14 hours per day  
All day   
 
During an average week, how much time do you usually spend sitting at the 
weekend? 
 
Never    
0 – 4 hours per day  
5 – 9 hours per day  
10 – 14 hours per day  
All day   
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 TOBACCO 
 
 
 
Have you ever regularly smoked cigarettes for at least a year?  By regularly we 
mean: at least 1 cigarette per day OR at least 5 cigarettes per week OR at least 1 
pack per month. 
 
Yes  
No      
Don‟t know      
 
 
At what age did you start to smoke regularly (in years)?    
 
Do you still smoke regularly? 
 
Yes  
No                                                           At what age did you stop   
Don‟t know      
 
 
On average, how many cigarettes do/did you smoke per day?  
 
What was the maximum number you ever smoked per day if different from above?  
 
 
For how long did you smoke this many?     months   or     years 
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Body Dimensions 
 
 
Please answer the following questions using either metric (cm, kg) or imperial (feet, 
inches, stones, pounds) measurements 
 
What is your current height (in bare 
feet)? 
feet inches Or 
cm 
 
What is your current weight (in light 
clothing)? 
stone pounds Or 
kg 
How much did you weigh at age 20? stone pounds Or 
kg 
How much did you weigh at age 30? stone pounds Or 
kg 
How much did you weigh at age 40? stone pounds Or 
kg 
 
What is your current waist size? 
inches Or 
cm 
 
 
 
 
Have you ever taken supplements to lose weight?  Yes  No  
 
If „yes‟ please specify……………………………………………………………… 
 
Have you ever taken supplements to gain weight/muscle? Yes  No  
 
If „yes‟ please specify………………………………………………………………… 
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Body Dimensions 
 
 
 
Body size in different periods of life (pictogram): please mark how you think you 
looked at different ages: 
 
 
 
 
 
 
 
 
 
 
 
At around age 20               
 
At around age 30               
 
At around age 40               
 
 
                     Now                 
 
 
 
  
 195 
FAMILY HISTORY 
 
 
1.  Have 3 or more first-degree relatives (e.g. father, brother, son) had prostate cancer?  
Yes   No   Don‟t Know   
 
2.  Has there been prostate cancer in 3 successive generations on either your maternal or 
paternal side? 
Yes   No   Don‟t Know  
 
3.  Have at least 2 relatives been affected by prostate cancer at either 55 years or younger? 
Yes                       No                     Don‟t Know      
 
 
 
In this section we would like you to tell us about your PARENTS. Please fill in the table 
below using CAPITAL LETTERS and completing ONE section for EACH parent. 
 
Relation Year of Birth 
Have they 
ever had 
cancer? 
If Yes, which type  
of cancer? 
Age at which 
cancer was 
diagnosed 
(if known) Yes No 
FATHER 
     
MOTHER 
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 FAMILY HISTORY 
 
 
COULD YOU PLEASE TELL US THE NUMBER OF SIBLINGS YOU HAVE? 
 
Please ONLY include siblings which are you are related to by blood. You DO NOT need to 
tell us about any adopted or step-relations. 
 
BROTHERS          SISTERS     
 
 
SIBLING’S MEDICAL HISTORY 
 
We would now like you to provide some more information about your brothers and sisters 
including any medical history of cancer.  You DO NOT need to tell us about any adopted 
or step-relations. 
 
 
Gender 
(Please tick) Year of Birth 
Have they ever 
had cancer? 
(Please tick) 
If Yes, which 
type of cancer? 
Age at which 
cancer was 
diagnosed 
(if known)  Male Female Yes No 
1        
2 
       
3 
   
  
  
4 
   
  
  
5 
       
6 
   
  
  
 
If you have more than 6 siblings, complete all 6 sections of this part of the questionnaire and 
then continue on a separate piece of paper. 
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 FAMILY HISTORY 
 
 
COULD YOU PLEASE TELL US THE NUMBER OF CHILDREN YOU HAVE? 
 
You DO NOT need to tell us about any adopted or step-relations. 
 
SONS     DAUGHTERS     
 
 
CHILDREN’S MEDICAL HISTORY 
 
We would now like you to provide some more information about your children including 
any medical history of cancer.  You DO NOT need to tell us about any adopted or step-
relations. 
 
 
Gender 
(Please tick) Year of Birth 
Have they ever 
had cancer? 
(Please tick) 
If Yes, which 
type of cancer? 
Age at which 
cancer was 
diagnosed 
(if known)  Male Female Yes No 
1        
2 
       
3 
   
  
  
4 
   
  
  
5 
       
6 
   
  
  
 
If you have more than 6 children, complete all 6 sections of this part of the questionnaire and 
then continue on a separate piece of paper. 
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TESTOSTERONE QUESTIONS 
 
We would like to obtain more information about the link between testosterone and prostate 
disease.   
 
1. Do you have a decrease in libido (sex drive)? 
Yes No  
2. Do you have a lack of energy? 
Yes No  
3. Do you have a decrease in strength and/or endurance? 
Yes No  
4. Have you lost height? 
Yes No  
5. Have you noticed a decreased "enjoyment of life" 
Yes No  
6. Are you sad and/or grumpy? 
Yes No  
7. Are your erections less strong? 
Yes No  
8. Have you noticed a recent deterioration in your ability to play sports? 
Yes No  
9. Are you falling asleep after dinner? 
Yes No  
10. Has there been a recent deterioration in your work performance? 
Yes No  
 
 
Finally, in this study we are asking participants to give blood, however, in the future we may 
be using saliva samples for analysis. 
 
Could you kindly indicate if you were asked in the future for research purposes which sample 
you would prefer to provide. 
 
   Blood  Saliva      Don‟t care  
 
Thank you for taking the time to complete this questionnaire. 
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Table 3.4: Odds Ratios and 95% Confidence intervals for UVR exposure comparing hospital controls and combined case group - 
Results from The Birmingham Prostatic Neoplasms Association Study 
 Hospital Controls  
N  
Combined Cases 
 N 
Non Adjusted  
OR 
Adjusted 
 OR* Adjusted 95%CI 
p value or p 
trend§  
Usual reaction to sunlight       
Always/easily burns 59 232 1 1   
Rarely/never burns 118 390 0.84 0.89* 0.62 - 1.29 0.54 
No of times sunburnt as a child       
1 13 47 1 1   
≥ 2 154 548 0.98 1.06* 0.55 - 2.04 0.87 
Ever lived abroad in a sunny country       
No 136 455 1 1   
Yes 30 127 1.27 1.20* 0.76 - 1.89 0.44 
Time spent outside       
Early adulthood (20-39 years)       
High 2 26 1 1   
Medium 30 90 0.87 1.06
**
 0.63 - 1.76  
Low 104 360 3.77 3.38
**
 0.79 - 14.49 0.26§ 
Middle age (40-60 years)       
High 10 38 1 1   
Medium 34 124 1.01 1.00
**
 0.62 - 1.61  
Low 85 310 1.05 0.79
**
 0.37 - 1.70 0.83§ 
Late adulthood (60+ years)       
High 5 13 1 1   
Medium 3 17 2.02 2.61
**
 0.55 - 12.42  
Low 5 14 0.93 1.09
**
 0.21 - 5.76 0.41§ 
Life course       
High 6 30 1 1   
Medium 13 38 0.73 0.57
**
 0.27 - 1.20  
Low 55 220 1.26 1.59
**
 0.59 - 4.24 0.17§ 
Sunbathing in life course       
High 23 118 1 1   
Medium 40 160 1.34 1.48
**
 0.90 - 2.42  
Low 58 173 1.77 2.31
**
 1.24 - 4.32 0.03§ 
*Adjusted for age of diagnosis, ethnicity and family history of prostate cancer **Adjusted for age of diagnosis, ethnicity, skin type and hair colour § p trend  
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Table 3.5: Odds Ratios and 95% Confidence intervals for UVR exposure comparing population controls and combined case group - 
Results from The Birmingham Prostatic Neoplasms Association Study 
 Population Controls  
N 
Combined Cases 
N 
Non Adjusted  
OR 
Adjusted 
 OR* Adjusted 95%CI 
p value or p 
trend§  
Usual reaction to sunlight       
Always/easily burns 50 232 1 1   
Rarely/never burns 120 390 0.7 0.74* 0.51 - 1.07 0.11 
No of times sunburnt as a child       
1 16 47 1 1   
≥ 2 145 548 1.29 1.35 0.72 - 2.51 0.35 
Ever lived abroad in a sunny country       
No 140 455 1 1   
Yes 27 127 1.45 1.37* 0.86 - 2.18 0.18 
Time spent outside       
Early adulthood (20-39 years)       
High 2 26 1 1   
Medium 24 90 1.35 1.29
**
 0.78 - 2.13  
Low 132 360 4.67 4.69
**
 1.11 - 19.80 0.08
§
 
Middle age (40-60 years)       
High 10 38 1 1   
Medium 45 124 0.87 0.87
**
 0.57 - 1.32  
Low 100 310 1.2 1.14
**
 0.55 - 2.40 0.72
§
 
Late adulthood (60+ years)       
High 1 13 1 1   
Medium 2 17 2.43 4.30
**
 0.45 - 41.46  
Low 4 14 3.71 7.45
**
 0.92 - 60.08 0.14
§
 
Life course       
High 6 30 1 1   
Medium 10 38 1.13 1.09
**
 0.51 - 2.32  
Low 65 220 1.48 1.54
**
 0.62 - 3.82 0.65
§
 
Sunbathing in life course       
High 34 118 1 1   
Medium 49 160 0.58 0.62
**
 0.36 - 1.05  
Low 30 173 0.61 0.62
**
 0.34 - 1.15 0.18
§
 
*Adjusted for age of diagnosis, ethnicity and family history of prostate cancer **Adjusted for age of diagnosis, ethnicity, skin type and hair colour § p trend   
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Table 3.6: Odds Ratios and 95% Confidence intervals for UVR exposure comparing combined controls and high PSA case group - 
Results from The Birmingham Prostatic Neoplasms Association Study 
*Adjusted for age of diagnosis, ethnicity and family history of prostate cancer **Adjusted for age of diagnosis, ethnicity, skin type and hair colour § p trend 
 Combined Controls  
N 
High PSA Cases 
N 
Non Adjusted  
OR 
Adjusted 
 OR* Adjusted 95%CI 
p value or p 
trend§  
Usual reaction to sunlight       
Always/easily burns 109 135 1 1   
Rarely/never burns 238 193 0.65 0.65* 0.47 - 0.90 0.01 
No of times sunburnt as a child       
1 29 26 1 1   
≥ 2 299 290 1.08 1.18* 0.67 - 2.07 0.57 
Ever lived abroad in a sunny country       
No 276 235 1 1   
Yes 57 78 1.61 1.61* 1.10 - 2.36 0.02 
Time spent outside       
Early adulthood (20-39 years)       
High 4 12 1 1   
Medium 54 44 0.95 0.94
**
 0.60 - 1.47  
Low 236 201 3.5 3.71
**
 1.20 - 11.46 0.07
§
 
Middle age (40-60 years)        
High 20 17 1 1   
Medium 79 61 0.79 0.79
**
 0.53 - 1.18  
Low 185 180 0.87 0.88
**
 0.44 - 1.77 0.5
§
 
Late adulthood (60+ years)       
High 6 4 1 1   
Medium 5 5 - 1.68
**
 0.31 - 9.20  
Low 9 9 0.69 0.89
**
 0.16 - 4.92 0.76
§
 
Life course       
High 12 15 1 1   
Medium 23 16 0.72 0.65
**
 0.31 - 1.36  
Low 120 117 1.29 1.55
**
 0.68 - 3.53 0.26
§
 
Sunbathing in life course       
High 57 69 1 1   
Medium 89 77 0.75 0.82
**
 0.53 - 1.27  
Low 88 102 1.05 1.21
**
 0.74 - 1.99 0.29
§
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Table 3.7 Odds Ratios and 95% Confidence intervals for UVR after stratification for severity of disease - Results from The Birmingham 
Prostatic Neoplasms Association Study 
§ Adjusted for age at diagnosis, ethnicity, family history of prostate cancer, skin type and hair colour 
* Adjusted for age at diagnosis, ethnicity and family history of prostate cancer   Localized = Gleason < 7 Advanced = Gleason ≥ 10 
 
 
Localized n (%) Advanced n (%) OR Adjusted OR Adjusted 95%CI p trend 
Usual reaction to sunlight    
Always/easilyburns 47 (36.4) 50 (30.7) 
    Rarely/never burns 82 (63.6) 113 (69.3) 1.3 1.36* 0.82 - 2.28 0.24 
Number of times severely sunburnt as a 
child                                                                1 14 (11.8) 7 (4.5) 
    ≥ 2 105 (88.25) 150 (95.5) 2.85 2.51* 0.94 - 6.69 0.07 
Ever lived abroad in a sunny country      No 102 (87.2) 117 (78) 
    Yes 15 (12.8) 33 (22) 1.92 1.50* 0.74 - 3.05 0.26 
Time spent outside 
      Early adulthood (20-39 years)                High 5 (5) 9 (7.6) 
    Medium 19 (19) 26 (22) 1.25 1.34
§
 0.65 - 2.73 
 Low 76 (76) 83 (70.4) 1.65 1.35
§
 0.43 - 4.20 0.67 
Middleage adulthood (40 - 59)               High 9 (9.3) 12 (10.3) 
    Medium 23 (23.7) 39 (33.6) 1.7 1.80
§
 0.94 - 3.46 
 Low 65 (67) 65 (56.1) 1.33 1.11
§
 0.42 - 2.93 0.21 
Life course                                                High 6 (9.7) 9 (11.8) 
    Medium 6 (9.7) 15 (19.7) 2.4 2.68
§
 0.97 - 7.43 
 Low 50 (80.6) 52 (68.5) 1.44 1.39
§
 0.43 - 4.52 0.16 
Sunbathing in life course                        High 21 (22.3) 28 (26.2) 
    Medium 41 (43.6) 41 (38.3) 0.84 0.70
§
 0.36 - 1.39 
 Low 32 (34.1) 38 (35.5) 1.12 1.03
§
 0.46 - 2.33 0.48 
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Table 4.5: Odds Ratios and 95% Confidence intervals for physical activity comparing hospital controls and combined case group (aged 
40+ years)  - Results from The Birmingham Prostatic Neoplasms Association Study 
 
 Hospital Controls Combined Cases Non Adjusted Adjusted Adjusted p value or 
 N N OR OR* 95%CI p trend 
Walking hours per week       
Low (Never – 4) 100 387 1 1   
Medium (5-9) 41 140 0.88 0.88 0.54 – 1.43  
High (≥10) 19 52 0.71 0.96 0.46 – 2.01 0.67§ 
Cycling hours per week       
Never 86 356 1 1   
Ever 52 158 0.73 0.76 0.48 – 1.21 0.25 
Gardening hours per week       
Low (Never – 4) 134 501 1 1   
Medium (5-9) 18 57 0.85 0.99 0.50 – 1.97  
High (≥10) 3 9 0.80 0.49 0.12 – 1.98 0.61§ 
Housework hours per week       
Low (Never – 4) 129 505 1 1   
Medium (5-9) 9 27 0.77 0.71 0.27 – 1.88  
High (≥10) 5 8 0.41 0.51 0.15 – 1.73 0.45§ 
Social Sport hours per week       
Never 83 307 1 1   
Ever 60 190 0.56 0.73 0.47 – 1.13 0.16 
Competitive Sport hours per week       
Never 105 301 1 1   
Ever 37 202 1.90 1.81 1.15 – 2.86 0.01 
 
* Adjusted for age at diagnosis, ethnicity, family history of prostate cancer, education, ever smoker and BMI  § P trend   
Combined cases = prostate cancer cases + high PSA cases 
 
 
 
  
 206 
 
Table 4.6: Odds Ratios and 95% Confidence intervals for physical activity comparing population controls and combined case group 
(aged 40+ years) - Results from The Birmingham Prostatic Neoplasms Association Study 
 
 Population Controls Combined Cases Non Adjusted Adjusted Adjusted p value or  
 N N OR OR* 95%CI p trend§ 
Walking hours per week       
Low (Never – 4) 125 387 1 1   
Medium (5-9) 39 140 1.16 1.35 0.85 – 2.14  
High (≥10) 8 52 2.10 2.43 1.09 – 5.44 0.06§ 
Cycling hours per week       
Never 117 356 1 1   
Ever 49 158 1.06 1.02 0.67 – 1.55 0.92 
Gardening hours per week       
Low (Never – 4) 158 501 1 1   
Medium (5-9) 14 57 1.28 1.57 0.79 – 3.08 0.20 
High (≥10) 0 9     
Housework hours per week       
Low (Never – 4) 162 505 1 1   
Medium (5-9) 10 27 0.87 0.94 0.37 – 2.38 0.90 
High (≥10) 0 8     
Social Sport hours per week       
Never 108 307 1 1   
Ever 54 190 1.24 1.23 0.81 – 1.85 0.34 
Competitive Sport hours per week       
Never 99 301 1 1   
Ever 67 202 0.99 1.03 0.70 – 1.53 0.87 
 
* Adjusted for age at diagnosis, ethnicity, family history of prostate cancer, education, ever smoker and BMI  § P trend  
Combined cases = prostate cancer cases + high PSA cases 
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Table 4.7: Odds Ratios and 95% Confidence intervals for physical activity comparing high PSA cases and combined control group 
(aged 40+ years)  - Results from The Birmingham Prostatic Neoplasms Association Study 
 
 Combined Controls High PSA Cases Non Adjusted Adjusted Adjusted p value or 
 N N OR OR* 95%CI p trend 
Walking hours per week       
Low (Never – 4) 225 214 1 1   
Medium (5-9) 80 71 0.93 1.10 0.72 – 1.67  
High (≥10) 27 29 1.13 1.75 0.91 – 3.36 0.24§ 
Cycling hours per week       
Never 203 188 1 1   
Ever 101 93 0.99 0.97 0.66 – 1.43 0.87 
Gardening hours per week       
Low (Never – 4) 292 274 1 1   
Medium (5-9) 32 29 0.97 1.31 0.72 – 2.41  
High (≥10) 3 6 2.13 1.90 0.42 – 8.51 0.49§ 
Housework hours per week       
Low (Never – 4) 291 273 1 1   
Medium (5-9) 19 16 0.90 0.99 0.43 – 2.29  
High (≥10) 5 7 1.49 2.03 0.61 – 6.79 0.52§ 
Social Sport hours per week       
Never 191 156 1 1   
Ever 114 115 1.24 1.15 0.97 – 1.69 0.46 
Competitive Sport hours per week       
Never 204 168 1 1   
Ever 104 102 1.19 1.15 0.78 – 1.67 0.48 
 
*Adjusted for age at diagnosis, ethnicity, family history of prostate cancer, education, ever smoker and BMI § P trend 
Combined controls = population controls + hospital controls 
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Table 4.8: Odds Ratios and 95% Confidence intervals for physical activity comparing combined cases and combined control group 
(aged 12 - 29 years)  - Results from The Birmingham Prostatic Neoplasms Association Study 
 
 Combined Controls Combined Cases Non Adjusted Adjusted Adjusted p value or 
 N N OR OR* 95%CI p trend 
Walking hours per week       
Low (Never – 4) 195 312 1 1   
Medium (5-9) 100 164 1.03 1.13 0.80 - 1.61  
High (≥10) 36 75 1.3 1.71 1.02 - 2.85 0.12§ 
Cycling hours per week       
Never 65 112 1 1   
Ever 257 424 0.96 0.87 0.59 - 1.30 0.5 
Gardening hours per week       
Low (Never – 4) 321 511 1 1   
Medium (5-9) 4 18 2.83 2.22 0.73 - 6.82  
High (≥10) 2 9 2.83 2.71 0.55 - 13.43 0.18§ 
Housework hours per week       
Low (Never – 4) 317 530 1 1   
Medium (5-9) 4 4 0.45 0.47 0.10 - 2.20 0.33 
High (≥10)       
Social Sport hours per week 142 266 1 1   
Never 159 221 0.74 0.74 0.53 - 1.03 0.07 
Ever       
Competitive Sport hours per week 120 190 1 1   
Never 186 305 1.04 1.12 0.81 - 1.56 0.49 
Ever 104 102 1.19 1.15 0.78 – 1.67 0.48 
 
* Adjusted for age at diagnosis, ethnicity, family history of prostate cancer, education, ever smoker and BMI  § P trend   
Combined cases = prostate cancer cases + high PSA cases 
Combined controls = hospital controls + population controls 
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Table 4.9: Odds Ratios and 95% Confidence intervals for physical activity comparing combined cases and combined control group 
(aged 20 - 39 years)  - Results from The Birmingham Prostatic Neoplasms Association Study 
 
 Combined Controls Combined Cases Non Adjusted Adjusted Adjusted p value or 
 N N OR OR* 95%CI p trend 
Walking hours per week       
Low (Never – 4) 182 315 1 1   
Medium (5-9) 105 172 0.95 1.11 0.78 - 1.57  
High (≥10) 39 68 1.01 1.53 0.91 - 2.56 0.27§ 
Cycling hours per week       
Never 173 297 1 1   
Ever 134 220 0.96 0.86 0.63 - 1.18 0.36 
Gardening hours per week       
Low (Never – 4) 307 491 1 1   
Medium (5-9) 17 48 1.88 1.62 0.35 - 7.45 0.11 
High (≥10)       
Housework hours per week 301 494 1 1   
Low (Never – 4) 12 24 1.42 2.61 0.54 - 12.76 0.44 
Medium (5-9)       
High (≥10) 148 271 1 1   
Social Sport hours per week 154 213 0.76 0.68 0.49 - 0.95 0.02 
Never       
Ever 141 215 1 1   
Competitive Sport hours per week 167 279 1.1 1.2 0.87 - 1.65 0.26 
Never 186 305 1.04 1.12 0.81 - 1.56 0.49 
Ever 104 102 1.19 1.15 0.78 – 1.67 0.48 
* Adjusted for age at diagnosis, ethnicity, family history of prostate cancer, education, ever smoker and BMI  § P trend   
Combined cases = prostate cancer cases + high PSA cases 
Combined controls = hospital controls + population controls 
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Table 5.6: Odds Ratios and 95% Confidence intervals for obesity comparing hospital controls and combined case group - Results from 
The Birmingham Prostatic Neoplasms Association Study 
 
 Hospital Controls n (%) Combined cases n (%) Crude OR Adjusted OR* Adjusted 95%CI p value/p trend 
Waist Circumference       
<34.0 41 (24.7) 363 (53.5) 1 1    
34.1 - 37.0 50 (30.1) 128 (18.9) 0.29 0.34 0.21 - 0.55  
≥37.1 75 (45.2) 188 (27.6) 0.28 0.32 0.21 - 0.50 0.96
§
 
BMI       
18.5 - 24.99 49 (28.0) 163 (23.6) 1 1     
25.0 - 29.99 78(44.6) 228 (33.0) 0.88 0.9 0.59 - 1.36   
≥30.0 48 (27.4) 299 (43.4) 1.87 1.49 0.94 - 2.35 0.84
§
 
Body size age 20       
18.5 - 24.99 124 (74.7) 416 (72.3) 1 1     
25.0 - 29.99 42 (25.3) 150 (26.1) 1.06 1.05 0.70 - 1.56 0.81 
≥30.0 0 9 (1.6)         
Body size age 30       
18.5 - 24.99 78 (46.7) 272 (47.6) 1 1     
25.0 - 29.99 87 (52.1) 289 (50.5) 0.95 0.94 0.66 - 1.33 0.78 
≥30.0 2 (1.2) 11 (1.9) 1.58 1.56 0.33 - 7.31 0.73 
Body size age 40             
18.5 - 24.99 38 (22.8) 155 (26.8) 1 1     
25.0 - 29.99 116 (69.5) 382 (66.3) 0.81 0.79 0.53 - 1.19 0.31 
≥30.0 13 (7.7) 39 (66.9) 0.74 0.71 0.34 - 1.47 0.27 
Body size current       
18.5 - 24.99 22 (13.1) 75 (13.0) 1 1     
25.0 - 29.99 105 (62.5) 363 (62.8) 1.01 1 0.59 - 1.69 0.99 
≥30.0 41 (24.7) 140 (24.2) 1 0.99 0.55 - 1.78 0.97 
* Adjusted for age at diagnosis, ethnicity & family history of prostate cancer  § P trend   
Combined cases = prostate cancer cases + high PSA cases 
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Table 5.7: Odds Ratios and 95% Confidence intervals for obesity comparing population controls and combined case group - Results 
from The Birmingham Prostatic Neoplasms Association Study 
 Population Controls n (%) Combined cases n (%) Crude OR Adjusted OR* Adjusted 95%CI p value/p trend 
Waist Circumference       
<34.0 41 (24.7) 363 (53.5) 1 1     
34.1 - 37.0 50 (30.1) 128 (18.9) 0.29 0.34 0.21 - 0.55   
≥37.1 75 (45.2) 188 (27.6) 0.28 0.32 0.21 - 0.50   
BMI             
18.5 - 24.99 49 (28.0) 163 (23.6) 1 1     
25.0 - 29.99 78(44.6) 228 (33.0) 0.88 0.9 0.59 - 1.36   
≥30.0 48 (27.4) 299 (43.4) 1.87 1.49 0.94 - 2.35 0.05§ 
Body size age 20             
18.5 - 24.99 116 (67.1) 416 (72.3) 1 1     
25.0 - 29.99 56 (32.4) 150 (26.1) 0.75 0.75 0.59 - 1.69 0.99 
≥30.0 1 (0.5) 9 (1.6) 2.51 2.65 0.35 - 19.95 0.34 
Body size age 30             
18.5 - 24.99 78 (45.1) 272 (47.6) 1 1     
25.0 - 29.99 91 (52.6) 289 (50.5) 0.91 0.91 0.64 - 1.29 0.6 
≥30.0 4 (2.3) 11 (1.9) 0.79 0.86 0.27 - 2.75 0.8 
Body size age 40             
18.5 - 24.99 39 (22.5) 155 (26.8) 1 1     
25.0 - 29.99 126 (72.8) 382 (66.3) 0.76 0.79 0.53 - 1.19 0.26 
≥30.0 8 (4.7) 39 (66.9) 1.23 1.37 0.59 - 3.17 0.46 
Body size current             
18.5 - 24.99 22 (12.9) 75 (13.0) 1 1     
25.0 - 29.99 104 (61.2) 363 (62.8) 1.02 1.13 0.66 - 1.92 0.66 
≥30.0 44 (25.9) 140 (24.2) 0.93 1.01 0.56 - 1.81 0.98 
* Adjusted for age at diagnosis, ethnicity & family history of prostate cancer  § P trend   
Combined cases = prostate cancer cases + high PSA cases 
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Table 5.8: Odds Ratios and 95% Confidence intervals for obesity comparing high PSA cases and combined control group - Results from 
The Birmingham Prostatic Neoplasms Association Study 
 Combined Controls n (%) High PSA cases n (%) Crude OR Adjusted OR* Adjusted 95%CI p value/p trend 
Waist Circumference       
<34.0 147 (40.8) 205 (55.0) 1 1     
34.1 - 37.0 85 (23.6) 71 (19.0) 0.6 0.68 0.46 - 1.02   
≥37.1 128 (35.6) 97 (26.0) 0.54 0.63 0.44 - 0.91 0.03§ 
BMI            
18.5 - 24.99 93 (24.9) 86 (22.7) 1 1     
25.0 - 29.99 141 (37.7) 131 (34.6) 1 0.99 0.98-1.45   
≥30.0 140 (37.4) 162 (42.7) 1.25 1.02 0.68 - 1.52 0.99§ 
Body size age 20            
18.5 - 24.99 240 (70.8) 220 (72.1) 1 1     
25.0 - 29.99 98 (28.9) 82 (26.9) 0.91 0.86 0.61 - 1.22 0.41 
≥30.0 1 (0.3) 3 (1.0) 3.27 3.07 0.29 - 32.01 0.35 
Body size age 30            
18.5 - 24.99 156 (45.9) 147 (48.4) 1 1     
25.0 - 29.99 178 (52.4) 150 (49.3) 0.89 0.88 0.64 - 1.20 0.41 
≥30.0 6 (1.7) 7 (2.3) 1.24 1.15 0.37 - 3.34 0.81 
Body size age 40            
18.5 - 24.99 77 (22.6) 92 (30.1) 1 1     
25.0 - 29.99 242 (71.2) 188 (61.4) 0.65 0.63 0.44 - 0.90 0.01 
≥30.0 21 (6.2) 26 (8.5) 1.04 0.92 0.47 - 1.80 0.81 
Body size current            
18.5 - 24.99 44 (13.0) 46 (15.0) 1 1     
25.0 - 29.99 209 (61.8) 197 (64.4) 0.9 0.86 0.54 - 1.36 0.52 
≥30.0 85 (25.2) 63 (20.6) 0.71 0.66 0.39 - 1.13 0.13 
* Adjusted for age at diagnosis, ethnicity & family history of prostate cancer  § P trend   
Combined controls = hospital controls + population controls 
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Appendix 7: Additional analyses for Chapter 7 
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Table 7.2 Additional analysis for DG8S737 alleles 
 
* Adjusted for age, alcohol intake from wine, body mass index (BMI), energy intake, family history of prostate cancer and level of education 
ALLELES REPEAT NUMBERS CASES (n) CONTROLS (n) CRUDE ODDS RATIO (95%CI) P ODDS RATIO* (95%CI) P 
Allele -14 absent   371 361 1   1   
Allele -14 present 19 89 99 0.89 (0.63 – 1.25) 0.5 0.90 (0.64 – 1.27) 0.56 
Allele -12 absent   453 452 1   1   
Allele -12 present 20 7 8 0.76 (0.24 – 2.35) 0.63 0.75 (0.24 – 2.36) 0.62 
Allele -10 absent   417 430 1   1   
Allele -10 present 21 43 30 1.50 (0.89 – 2.53) 0.13 1.50 (0.88 – 2.55) 0.13 
Allele -8 absent   417 394 1   1   
Allele -8 present 22 43 66 0.61 (0.39 – 0.94) 0.03 0.62 (0.40 – 0.96) 0.03 
Allele -6 absent   390 374 1   1   
Allele -6 present 23 70 86 0.91 (0.63 – 1.31) 0.62 0.91 (0.63 – 1.32) 0.63 
Allele -4 absent   444 449 1   1   
Allele -4 present 24 16 11 1.69 (0.74 – 3.87) 0.21 1.47 (0.63 – 3.43) 0.37 
Allele -2 absent   416 408 1   1   
Allele -2 present 25 44 52 0.78 (0.50 -1.22) 0.28 0.79 (0.50 – 1.24) 0.31 
Allele 0 absent   400 392 1   1   
Allele 0 present 26 60 68 0.82 (0.55 – 1.22) 0.33 0.84 (0.56 – 1.25) 0.39 
Allele 2 absent   422 406 1   1   
Allele 2 present 27 38 54 0.76 (0.48 – 1.20) 0.24 0.75 (0.47 – 1.20) 0.24 
Allele 4 absent   435 431 1   1   
Allele 4 present 28 25 29 0.79 (0.43 – 1.42) 0.43 0.78 (0.43 – 1.41) 0.41 
Allele 6 absent   434 436 1   1   
Allele 6 present 29 26 24 1.15 (0.63 – 2.11) 0.66 1.06 (0.57 – 1.97) 0.85 
Allele 8 absent   457 453 1   1   
Allele 8 present 30 3 7 0.68 (0.17 – 2.70) 0.58 0.63 (0.16 – 2.56) 0.52 
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